Use of pharmaceutical composition comprising compound having bis(azanylylidene) sulfonyl structure for treating anemia-related diseases
By developing PKR agonists containing diazasubunit sulfonyl structure, the problems of high complication risks and economic burdens in existing treatment methods have been solved, and the effect of increasing the concentration of ATP and hemoglobin in red blood cells has been achieved, which is anemia-related diseases. New treatment options are provided.
Patent Information
- Application Number
- PCT/CN2024/095232
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
Existing treatments for anemia-related diseases, such as hematopoietic stem cell transplantation, gene therapy and recombinant fusion protein therapy, have problems with high risk of surgical complications and high economic burden, and are deficient in beta-thalassemia, sickle-type anemia and pyruvate kinase The treatment effect of diseases such as diseases is limited.
A compound containing the diazazosulfonyl structure was developed as a pyruvate kinase (PKR) agonist, which improves the energy state of red blood cells by activating PKR in red blood cells, increasing ATP concentration and reducing 2,3-DPG concentrations. and functions.
This compound has shown significant effects on improving hemoglobin content and ATP concentration in in vitro and in vivo experiments, and has potential application value in the treatment of β-thalassemia, sickle cell anemia, pyruvate kinase deficiency and myelodysplastic syndrome.
Smart Images

Figure PCTCN2024095232-FTAPPB-I100001 
Figure PCTCN2024095232-FTAPPB-I100002 
Figure PCTCN2024095232-FTAPPB-I100003
Abstract
Description
Use of a pharmaceutical composition containing a diazapyridylsulfonyl structure compound in treating anemia-related diseases Technical Field
[0001] The present invention belongs to the field of medical technology, and particularly relates to use of a pharmaceutical composition containing a diazainylsulfonyl structure compound in treating anemia-related diseases. Background Art
[0002] Under normal physiological conditions, the human body carries and delivers oxygen to tissues and organs through the hemoglobin in mature red blood cells. Glycolysis plays an important role in maintaining the lifespan, morphology, and function of red blood cells (RBCs).
[0003] β-thalassemia is an autosomal recessive genetic disorder. Due to point mutations or deletions in the β-chain gene, β-chain synthesis is partially or completely inhibited, resulting in an imbalance in the ratio of α-chain to β-chain. α-chains aggregate near the cell membrane to form insoluble hemichromatin, which reduces the total amount of oxygen carried by RBCs. Simultaneously, free heme and iron increase, leading to increased levels of reactive oxygen species (ROS), which oxidize cell membrane proteins and lipids, causing cell lysis and premature apoptosis, and inhibiting RBC differentiation and maturation. Consequently, RBCs in patients with β-thalassemia consume more ATP, a key factor in shortened RBC lifespan and increased hemolysis (Int J Mol Sci 22, 7229(2021)). The clinical manifestations of β-thalassemia vary, ranging from asymptomatic, non-transfusion-dependent β-thalassemia (NTDT) to transfusion-dependent β-thalassemia (TDT), primarily related to the degree of β-chain deficiency. TDT patients produce almost no HbA and typically develop anemia after HbF is converted to HbA. It is estimated that approximately 5% of the world's population has at least one β-thalassemia gene variant. There are approximately 300,000 people with β-thalassemia worldwide, distributed along the Mediterranean coast and throughout Southeast Asia (N Engl J Med 371, 1908-1916 (2014)). In my country, the primary prevalence is in the area south of the Yangtze River. A 2017 meta-analysis showed that the prevalence of β-thalassemia in mainland China is 2.21% (Sci Rep 7, 920 (2017)).
[0004] Sickle cell anemia (SCD) is an autosomal dominant hemoglobinopathy characterized by the substitution of valine for glutamic acid at position 6 of the β-peptide chain, which predisposes hemoglobin S (HbS) to aggregation upon deoxygenation, forming sickle-shaped red blood cells. Clinical manifestations include chronic hemolytic anemia, chronic ischemic damage to organs and tissues, splenic infarction, susceptibility to infection, and vaso-occlusive crises (VOCs) (Lancet 376, 2018-2031 (2010)). SCD mutations are found worldwide, including in African Americans (approximately 7%-10%), sub-Saharan Africa (30%), Mediterranean countries (particularly Greece), the Middle East (0.2%-27%), and India (13%) (J Neonatal Screen 4, 31 (2018)). Overall, the global prevalence of SCD is estimated to be approximately 300 million people (Engl J Med 375, 435–442 (2016)). In patients with β-thalassemia and SCD, an imbalance in the α- / non-α-chain ratio leads to ineffective erythropoiesis (IE), triggering apoptosis of erythroid precursors, leading to anemia and splenomegaly. Simultaneously, hepcidin production is reduced, resulting in systemic iron overload. IE is the primary pathogenesis and pathological feature of β-thalassemia. In the bone marrow of patients with β-thalassemia, the content of erythroid precursors is approximately six times that of normal individuals, and the apoptosis rate is approximately four times that of normal individuals (Int J Mol Sci 22, 7229(2021)). Furthermore, the lifespan of circulating erythrocytes in SCD patients is shortened, and late erythroblast death also occurs in the body.
[0005] Pyruvate kinase deficiency (PKD) is a hereditary functional deficiency of an enzyme involved in the glycolysis of red blood cells, resulting in non-spherocytic hemolytic anemia. All of the above are autosomal recessive genetic disorders, causing decreased hemoglobin (Hb), altered oxygen-carrying function, shortened red blood cell lifespan, and congenital anemia.
[0006] Myelodysplastic syndrome (MDS) is a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells, characterized by abnormal differentiation and development of myeloid cells, manifested as ineffective hematopoiesis, progressive cytopenia, and hematopoietic failure. Among them, the main symptom of patients with low-risk myelodysplastic syndrome (LR-MDS) is anemia, characterized by abnormal hematopoietic function and transformation to high-risk acute myeloid leukemia (AML).
[0007] Hematopoietic stem cell (HSC) transplantation is currently the only curative treatment for anemia-related conditions such as β-thalassemia, sickle cell anemia (SCD), pyruvate kinase deficiency (PKD), and low-risk myelodysplastic syndrome (LR-MDS). However, limited by donor availability, post-transplant immunosuppression, and relatively high treatment costs, this therapy is only suitable for a small proportion of patients. Supportive care includes blood transfusions, folic acid supplementation, splenectomy, and iron chelation to reduce iron overload. Currently, research is underway to improve IE caused by an imbalance in the α- / non-α-chain ratio, with therapies currently under investigation including gene therapy, protein therapy, and small molecule compounds.
[0008] In terms of gene therapy, 22 patients with TDT were reported in 2018 using autologous HSCs encoding the T87Q variant Lenti Globin BB305 vector, with significant clinical benefits, but no complete cure (N Engl J Med 378, 1479-1493 (2018)). In addition, based on CRISPR-Cas9 technology, CTX001 was used to inhibit BCL11A to induce HbF, which can reduce the number of blood transfusions in patients with severe SCD (N Engl J Med 384, 252-260 (2021)).
[0009] The recombinant fusion protein Luspatercept (ACE-536) was approved in 2019 for the treatment of adult patients with TDT. Luspatercept can bind to the transforming growth factor (TGFβ) superfamily ligand, inhibit the SMAD2 / 3 pathway, promote RBC maturation, and reduce the number of blood transfusions in patients (J Cell Mol Med 24, 6162-6177 (2020)). Crizanlizumab, an FDA-approved monoclonal antibody targeting P-selectin, is used to reduce the frequency of VOCs by reducing the interaction between endothelial cells and circulating blood cells, but it cannot change HbS aggregation (J Pain Res 14, 849-856 (2021)).
[0010] Despite the availability of multiple treatment options, hematopoietic stem cell transplantation, gene therapy, recombinant fusion protein therapy, and blood transfusion combined with iron chelation therapy generally carry the risk of surgical complications, a high economic burden, and impacts on patients' quality of life, leaving a significant unmet need. In comparison, small molecule drug therapy offers unique clinical advantages.
[0011] Among small molecule compounds, the Janus kinase 2 inhibitor Ruxolitinib can improve IE and reduce splenomegaly in a mouse model of β-thalassemia (Blood 131, 263-265 (2018)). Bitopertin (RO-4917838) is an orally available, potent, and highly selective inhibitor of glycine transporter 1 that can improve anemia and hemolysis in patients with β-thalassemia and increase RBC survival in vivo (Br J Haematol 194, 474-477 (2021)). VIT-2763, an orally active small molecule iron transporter inhibitor, blocks iron efflux by inhibiting hepcidin binding to iron transporter (J Clin Invest 130, 491-506 (2020)). Inducing sustained HbF production can alleviate clinical symptoms in patients with β-chain abnormalities. For example, hydroxyurea (HU), used clinically for the treatment of SCD, can stimulate HbF production and reduce HbS aggregation, but HU can inhibit bone marrow function. IMR-687, a phosphodiesterase (PDE9) inhibitor, increases intracellular cGMP levels and stimulates HbF production by inhibiting PDE9, and has significant efficacy in preclinical models of SCD (Haematologica 105, 623-631 (2020)).
[0012] Pyruvate kinase (PK) is a key enzyme in glycolysis, catalyzing the conversion of phosphoenolpyruvate to enolpyruvate and producing adenosine triphosphate (ATP). Efficient ATP production maintains red blood cell function and membrane integrity, as well as the energy required to clear excess globin chains. When ATP supply fails to meet the metabolic demands of thalassemia red blood cells, premature cell death occurs, ultimately leading to ineffective erythropoiesis and hemolysis. Therefore, stimulating PKR to increase ATP in red blood cells is expected to play a positive role in the treatment of patients with hemoglobinopathies such as PKR-deficient β-thalassemia, sickle cell anemia (SCD), pyruvate kinase deficiency (PKD), and low-risk myelodysplastic syndrome (LR-MDS).
[0013] Currently, research papers on small molecule drugs targeting PKR have been published one after another, but compared with other popular targets, its research is still relatively small, mainly as follows:
[0014] Mitapivat (AG-348), an oral small molecule allosteric agonist, has shown efficacy and safety in clinical trials in patients with PKR deficiency (N Engl J Med 381, 933-944 (2019)). Mitapivat was approved for marketing by the U.S. FDA in February 2022 for the treatment of anemia in adults with PK deficiency. Phase III clinical studies are currently underway for thalassemia and sickle cell anemia. The completed Phase II clinical study showed good efficacy. At week 12, 92.3% of patients achieved an increase in HGB of 1.0 g / dL, with an average increase of 1.34 g / dL, and improved hemolysis and erythropoiesis markers. Studies have shown that LR-MDS patients have glycolytic dysfunction and acquired PK deficiency. PK activation can increase red blood cell energy and solve the problem of ineffective erythropoiesis. The second-generation compound AG-946 is in Phase II clinical research on anemia symptoms in LR-MDS patients.
[0015] FORMA Therapeutics Inc disclosed a pyrrolopyrrole compound as a PKR agonist in WO2018175474 and WO2020061255.
[0016] Global Blood Therapeutics Inc disclosed a pyrrolidinopyrazole compound as a pyruvate kinase activator in WO2021202796.
[0017] Agios Pharmaceuticals Inc. disclosed azetidine arylsulfonamide derivative compounds as pyruvate kinase regulators in WO2012083246, WO2011002817, WO2012092442, WO2014139325, etc.
[0018] Summary of the Invention
[0019] The applicant of the present invention previously provided a novel compound containing a diazasulfonyl structure in international application PCT / CN2022 / 140731 (international filing date December 21, 2022). The entire contents of the prior international application PCT / CN2022 / 140731 are hereby incorporated into the present invention as a part thereof.
[0020] Based on the novel compounds provided in PCT / CN2022 / 140731, the present inventors conducted further extended research and provided new applications of pharmaceutical compositions containing the novel compounds in the treatment and prevention of anemia-related diseases.
[0021] Although the prior International Application No. PCT / CN2022 / 140731 is incorporated herein by reference in its entirety, for the sake of clarity and completeness, the present invention further describes the novel compounds in detail through the structural descriptions below and the preparation and characterization of the specific examples that follow. The compounds of the general formula and the compounds of the specific examples described in the International Application No. PCT / CN2022 / 140731 are referred to herein as "compounds of the present invention."
[0022] As confirmed by the biological activity test of this application, the compound of the present invention has good agonist activity on PKR in in vitro enzymatic tests, and can also significantly activate PKR activity in red blood cells of healthy people and patients with β-thalassemia in ex vivo tests, and significantly increase the concentration of biomarker ATP and reduce the concentration of 2,3-DPG. The same pharmacodynamic effect was further observed in in vivo tests in wild-type mice. In addition, in anemic mouse models, hemoglobin content, ATP concentration, and 2,3-DPG concentration can also be increased, and oral absorption is good in rats, mice, and dogs. Therefore, it is expected that the compound of the present invention has important development value and application potential in the treatment or prevention of anemia-related diseases such as β-thalassemia, sickle cell anemia (SCD), pyruvate kinase deficiency (PKD), and myelodysplastic syndrome (MDS).
[0023] Thus, in a first aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient for use as a PKR agonist.
[0024] In a second aspect, the present invention provides a pharmaceutical composition for preventing or treating anemia-related diseases, comprising a compound of the present invention and a pharmaceutically acceptable excipient.
[0025] In a third aspect, the present invention provides use of a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient in the preparation of a medicament for preventing or treating anemia-related diseases.
[0026] In a fourth aspect, the present invention provides a method for preventing or treating anemia-related diseases, comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient.
[0027] In particular, the anemia-related diseases mentioned above include pyruvate kinase deficiency (PKD), myelodysplastic syndrome (MDS), hemoglobinopathy, sickle cell anemia (SCD), β-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia or anemia of chronic disease; preferably, the anemia-related disease is pyruvate kinase deficiency (PKD), myelodysplastic syndrome (MDS), sickle cell anemia (SCD) or β-thalassemia, and the myelodysplastic syndrome (MDS) may further be low-risk myelodysplastic syndrome (LR-MDS).
[0028] Detailed description of the invention:
[0029] In one embodiment, the compound of the present invention according to the first, second, third and fourth aspects of the present invention is selected from the compound of formula I or an isomer, pharmaceutically acceptable salt or solvate thereof:
[0030] in:
[0031] R 1 、R 2 and R 3 independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b 、-SR b 、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f or-C(O)OR g, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused cyclic group is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -R a 、-OR b 、-SR b 、-NO2、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f and -C(O)OR g ;
[0032] Or, R 1 and R 2 、R 1 and R 3 or R 2 and R 3 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, -(C5-C8)spirocyclyl, a 5- to 8-membered spiroheterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, or a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S;
[0033] R 4 -NH2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b 、-SR b 、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f 、-C(O)OR g or -NR c (CR h R i ) t -R a , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused cyclic group is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -R a 、-OR b 、-SR b 、-NO2、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f and -C(O)OR g ;
[0034] t is 0, 1, 2, or 3;
[0035] R a 、R b 、R c 、R d 、R e 、R f 、R g 、R h and R i is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclyl is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -OH, -SH, -NO, -NH, alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclyl. -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H, -C(O)OH, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, and 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N, and S, or wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused cyclic group is optionally substituted with one or more substituents selected from -S(O)2OH, -S(O)OH, -NHS(O)2OH, or -NHS(O)OH; or, R a 、R b 、R c 、R d 、R e 、R f 、R g 、R h and R i is independently at each occurrence -S(O)2OH, -S(O)OH, -NHS(O)2OH or -NHS(O)OH;
[0036] Alternatively, any two selected from R a 、R b 、R c 、R d 、R e 、R f 、R g 、R h and R i The groups together with the atoms to which they are attached may optionally be combined to form a group optionally substituted by one or more R a Substituted C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, (C3-C8)cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S.
[0037] In some embodiments, the compounds of the present invention described in the first, second, third and fourth aspects of the present invention are selected from the specific isomeric compounds of formula I above, having formula I-1 or I-2,
[0038] In some embodiments, in the compounds of the aforementioned formula I, formula I-1 or I-2 of the present invention, R 1 and R 2 You can further make the following independent choices:
[0039] In one embodiment,
[0040] R 1 and R 2 independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b or -NR c R d , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused cyclic group is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ;
[0041] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S;
[0042] R a 、R b 、R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14aryl, a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic group, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of: =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl and a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S.
[0043] In another embodiment,
[0044] R 1 and R 2 independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl group, a 5-8 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, N and S, a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b or -NR c R d , wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ;
[0045] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S;
[0046] R a 、R b 、R c and R dis independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, C6-C8 aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered fused cyclyl containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclyl is optionally substituted with one or more substituents selected from the group consisting of =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl and a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S.
[0047] In another embodiment,
[0048] R 1 and R 2 independently -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6) straight chain alkyl, -(C1-C6) branched chain alkyl, -(C3-C6) cycloalkyl, a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl group, a 7-14 membered bicyclic or tricyclic fused ring group containing 0-4 heteroatoms independently selected from O, N and S, -OR b or -NR c R d , wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of: -F, -Cl, -Br, -CN, -R a 、-OR b 、-NR c R d ;
[0049] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S;
[0050] R a 、R b 、R c and R dis independently at each occurrence -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2 and -(C1-C6)alkyl.
[0051] In another embodiment,
[0052] R 1 and R 2 independently -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6) straight chain alkyl, -(C1-C6) branched chain alkyl, -(C3-C6) cycloalkyl or a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from the following: -F, -Cl, -Br, -CN, -R a 、-OR b 、-NR c R d ;
[0053] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S;
[0054] R a 、R b 、R c and R d is independently at each occurrence -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2, and -(C1-C6)alkyl.
[0055] In another embodiment,
[0056] R 2 is -H, -F, -Cl or -Br;
[0057] R 1 -H, -F, -Cl, -Br, -OH, -NH2, -(CH2) q CH3, -(CH2) q OH, -CH(OH)(CH2) q CH3, -C(OH)((CH2) q CH3)2、 -(CH2) q NH2, -(CH2) q NH(CH2) q CH3, -(CH2) q N((CH2) q CH3)2, 3-6 membered heterocycloalkyl containing 1 N atom, -(C1-C6)alkyl substituted by 3-6 membered heterocycloalkyl containing 1 N atom;
[0058] q is independently 0, 1, 2, 3, or 4 at each occurrence;
[0059] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a dioxane ring, or a 2,3-dihydrobenzofuran ring; or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, tetrahydrofuran, tetrahydropyran, morpholine, dioxane, a 2,3-dihydrobenzofuran ring, or tetrahydro-2H-pyran.
[0060] In another embodiment,
[0061] R 2 is -H, -F, -Cl or -Br;
[0062] R 1 -H, -F, -Cl, -Br, -OH, -NH2,
[0063] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form
[0064] In another embodiment,
[0065] R 2 is -H, -F, -Cl or -Br;
[0066] R 1 -H, -F, -Cl, -Br, -OH, -NH2, -CH3, -CH(OH)CH3, -(CH2) q CH3, -(CH2) q OH, -CH(OH)(CH2) q CH3, -C(OH)((CH2) q CH3)2, -C(OH)(CH2) q CH3)(CH3),-C(OH)(CH3)2, -CH2F, -CHF2, -(CH2) q CH2F, -(CH2) q CHF2, -CH2Cl, -CHCl2, -(CH2) q CH2Cl, -(CH2) q CHCl2, -(CH2) q NH2, -NHCH3, -NH(CH2) q CH3, -(CH2) q NHCH3, -(CH2) q NH(CH2) q CH3, -N(CH3)2, -N((CH2) q CH3)2, -(CH2) q N(CH3)((CH2) q CH3), -(CH2) q N(CH3)2, -(CH2) q N((CH2) q CH3)2, 3-6 membered heterocycloalkyl containing 1 N atom, -(C1-C6)alkyl substituted by 3-6 membered heterocycloalkyl containing 1 N atom;
[0067] q is 1, 2, 3, or 4 independently at each occurrence;
[0068] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a dioxane ring, a 2,3-dihydrobenzofuran ring, or a tetrahydro-2H-pyran ring.
[0069] In another embodiment,
[0070] R 2 is -H, -F, -Cl or -Br;
[0071] R 1 -H, -F, -Cl, -Br, -OH, -NH2,
[0072] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form
[0073] In some embodiments, in the compounds of the aforementioned formula I, formula I-1 or I-2 of the present invention, R 1 and R 2 Independently make any combination of the above choices, R 3 You can further make the following independent choices:
[0074] In one embodiment,
[0075] R 3 is -H, halogen, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or 7-14 membered fused cyclic radical containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl or fused cyclic radical is optionally substituted with one or more substituents selected from the group consisting of: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ;
[0076] R a 、R b 、R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14aryl, a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic group, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of: =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl and a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S.
[0077] In another embodiment,
[0078] R 3 is -H, halogen, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered bicyclic or tricyclic fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ;
[0079] R a 、R b 、R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, C6-C8 aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered fused cyclyl containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclyl is optionally substituted with one or more substituents selected from the group consisting of =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl and a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S.
[0080] In another embodiment,
[0081] R 3is -H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, C6-C8aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered bicyclic fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, aryl, heteroaryl or fused cyclic group is optionally substituted by one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -R a AND-OR b ;
[0082] R a and R b is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2, and -(C1-C6)alkyl.
[0083] In another embodiment,
[0084] R 3 is -H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, pyridinyl, phenyl, benzothiazolyl, benzomorpholinyl or benzopyrrolidinyl, wherein pyridinyl, phenyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, piperazinyl, piperazinyl substituted with any number of halogens or -(C1-C6)alkyl.
[0085] In another embodiment,
[0086] R 3 -H, -F, -Cl, -Br, -CH3, -CH2CH3, pyridyl,
[0087] In another embodiment,
[0088] R 3 is -H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, pyridyl, phenyl, naphthyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl or Among them, pyridyl, phenyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl, Optionally substituted with one or more substituents selected from: -F, -Cl, -Br, -CN, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -(C1-C6)haloalkyl, -(C3-C6)halocycloalkyl, -O-(C1-C6)haloalkyl, -O-(C3-C6)halocycloalkyl, pyrazolyl, pyrazolyl substituted with any number of halogen or -(C1-C6)alkyl, piperazinyl, piperazinyl substituted with any number of halogen or -(C1-C6)alkyl;
[0089] ring is a 3-6 membered saturated or unsaturated heterocyclic group linked via a N atom, and the heterocyclic group optionally contains 1-2 heteroatoms independently selected from O, N and S in addition to the N atom.
[0090] In another embodiment,
[0091] R 3 -H, -F, -Cl, -Br, -CH3, -CH2CH3,
[0092] In some embodiments, in the compounds of the aforementioned formula I, formula I-1 or I-2 of the present invention, R 1 、R 2 and R 3 Independently make any combination of the above choices, R 4 You can further choose:
[0093] In the first type of implementation:
[0094] R 4 for
[0095] X is a chemical bond, -(CR h R i ) t -、-NR c (CR h R i ) t -or-O-; where R c 、R h 、R i and t is optionally as defined anywhere in the present invention;
[0096] represents a single bond or a double bond;
[0097] Y 1 is N, C or CH;
[0098] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0099] Each R j independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H or -C(O)OH, wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, The aryl, heteroaryl or fused cyclic group is optionally substituted by one or more substituents selected from the group consisting of -H, =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H, -C(O)OH, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl or a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from: -S(O)2OH, -S(O)OH, -NHS(O)2OH or -NHS(O)OH; or each R j Independently, they may be -O-(C3-C6)cycloalkyl, -S(O)2OH, -S(O)OH, -NHS(O)2OH or -NHS(O)OH;
[0100] m is selected from 0, 1, 2, 3, 4, 5 or 6;
[0101] n is 0, 1 or 2.
[0102] In some embodiments of the first class,
[0103] R 4 for
[0104] X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-;
[0105] represents a single bond or a double bond;
[0106] Y 1 is N, C or CH;
[0107] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0108] Each R j are independently -H, halogen, -OH, -NH2, -CN, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C1-C6)alkyl or -(C1-C6)alkoxy substituted with any number of halogens, oxazolyl, thiazolyl, and triazolyl;
[0109] m is selected from 0, 1, 2, 3, 4, 5 or 6;
[0110] n is 0, 1 or 2.
[0111] In some embodiments of the first class,
[0112] R 4 for
[0113] X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-;
[0114] represents a single bond or a double bond;
[0115] Y 1 is N, C or CH;
[0116] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0117] Each R jEach is independently -H, halogen, -OH, -NH2, -CN, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -(C1-C6)alkoxy, -O-(C3-C6)cycloalkyl, -(C1-C6)alkyl substituted with any number of halogen, -(C1-C6)alkoxy substituted with any number of halogen, -(C3-C6)cycloalkyl substituted with any number of halogen, -O-(C3-C6)cycloalkyl substituted with any number of halogen, oxazolyl, thiazolyl and triazolyl;
[0118] m is selected from 0, 1, 2, 3, 4, 5 or 6;
[0119] n is 0, 1 or 2.
[0120] In a second embodiment,
[0121] R 4 for
[0122] X is a chemical bond, -(CR h R i ) t -、-NR c (CR h R i ) t -or-O-; where R c 、R h 、R i and t is optionally as defined anywhere in the present invention;
[0123] represents a single bond or a double bond;
[0124] Y 1 is N, C or CH;
[0125] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0126] Each R j independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic radical containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H or -C(O)OH, wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic The aryl, aryl, heteroaryl or fused cyclic group is optionally substituted by one or more substituents selected from the group consisting of: =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H, -C(O)OH, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl or a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from: -S(O)2OH, -S(O)OH, -NHS(O)2OH or -NHS(O)OH; or each R j Independently, ═O, —S(O)2OH, —S(O)OH, —NHS(O)2OH, or —NHS(O)OH;
[0127] m and p are independently selected from 0, 1, 2, 3, 4, 5 or 6;
[0128] n is 0, 1, or 2;
[0129] Ring A is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, a 5- to 14-membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7- to 14-membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S.
[0130] In some embodiments of the second class,
[0131] R 4 for
[0132] X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-;
[0133] represents a single bond or a double bond;
[0134] Y 1 is N, C or CH;
[0135] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0136] Each R j are independently -H, halogen, -OH, -NH2, -CN, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C1-C6)alkyl or -(C1-C6)alkoxy substituted with any number of halogens, oxazolyl, thiazolyl or triazolyl;
[0137] m and p are independently selected from 0, 1, 2, 3, 4, 5 or 6;
[0138] n is 0, 1, or 2;
[0139] Ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxane, piperazine, pyrazine or triazine.
[0140] In some embodiments of the second class,
[0141] R 4 for
[0142] X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-;
[0143] represents a single bond or a double bond;
[0144] Y 1 is N, C or CH;
[0145] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0146] Each R j Each is independently -H, halogen, -OH, -NH2, -CN, =O, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C1-C6)alkyl substituted with any number of halogens, -(C1-C6)alkoxy substituted with any number of halogens, oxazolyl, thiazolyl or triazolyl;
[0147] m and p are independently selected from 0, 1, 2, 3, 4, 5 or 6;
[0148] n is 0, 1, or 2;
[0149] Ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxacyclohexane, piperazine, pyrazine, triazine, 4,5-dihydro-1H-imidazole or 1,3-dioxolane.
[0150] In other specific embodiments, R 4 You can further choose
[0151] In other specific embodiments, R 4 You can further choose
[0152] As one of the preferred embodiments, in some embodiments, the compound of the present invention described in the first aspect, second aspect, third aspect and fourth aspect of the present invention is selected from the compound represented by Formula I, Formula I-1 or I-2 or its isomer, pharmaceutically acceptable salt or solvate:
[0153] in,
[0154] R 1 and R 2 independently -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6) straight chain alkyl, -(C1-C6) branched chain alkyl, -(C3-C6) cycloalkyl or a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from the following: -F, -Cl, -Br, -CN, -R a 、-OR b 、-NR c R d ;
[0155] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S;
[0156] R 3-H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -(C6-C8)aryl, or a 7-14 membered bicyclic fused ring group containing 0-4 heteroatoms independently selected from O, N, and S, wherein each alkyl, cycloalkyl, aryl, or fused ring group is optionally substituted by one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -R a AND-OR b ;
[0157] R a 、R b 、R c and R d is independently at each occurrence -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2, and -(C1-C6)alkyl;
[0158] R 4 for
[0159] X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-;
[0160] represents a single bond or a double bond;
[0161] Y 1 is N, C or CH;
[0162] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all N at the same time;
[0163] Each R j are independently -H, halogen, -OH, -NH2, -CN, -(C1-C6)alkyl, -O-(C1-C6)alkyl, -(C1-C6)alkyl substituted with any number of halogens, -O-(C1-C6)alkyl substituted with any number of halogens, oxazolyl, thiazolyl or triazolyl; or, each R j It can also be further independently selected from =O, -(C3-C6)cycloalkyl, -O-(C3-C6)cycloalkyl, -(C3-C6)cycloalkyl substituted with any number of halogens, -O-(C3-C6)cycloalkyl substituted with any number of halogens;
[0164] m and p are independently 0, 1, 2, 3, 4, 5 or 6;
[0165] n is 0, 1, or 2;
[0166] Ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxacyclohexane, piperazine, pyrazine or triazine; or, Ring A is 4,5-dihydro-1H-imidazole or 1,3-dioxolane.
[0167] As a second preferred embodiment, in some embodiments, the compound of the present invention described in the first, second, third and fourth aspects of the present invention is selected from the compound represented by Formula I, Formula I-1 or I-2 or its isomers, pharmaceutically acceptable salts or solvates:
[0168] in,
[0169] R 2 is -H, -F, -Cl or -Br;
[0170] R 1 -H, -F, -Cl, -Br, -OH, -NH2, -(CH2) q CH3, -(CH2) q OH, -CH(OH)(CH2) q CH3, -C(OH)((CH2) q CH3)2、 -(CH2) q NH2, -(CH2) q NH(CH2) q CH3, -(CH2) q N((CH2) q CH3)2, a 3-6 membered heterocycloalkyl group containing one N atom, or a -(C1-C6)alkyl group substituted by a 3-6 membered heterocycloalkyl group containing one N atom; or, R 1 for -CH2F, -CHF2, -(CH2) q CH2F, -(CH2) q CHF2, -CH2Cl, -CHCl2, -(CH2) q CH2Cl or -(CH2) q CHCl2;
[0171] q is independently 0, 1, 2, 3, or 4 at each occurrence;
[0172] Or, R 1 and R 2Together with the atoms to which they are attached, they may optionally combine to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a dioxane ring, or a 2,3-dihydrobenzofuran ring; or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form tetrahydro-2H-pyran or oxetane.
[0173] R 3 R is -H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, pyridinyl, phenyl, benzothiazolyl, benzomorpholinyl or benzopyrrolidinyl, wherein pyridinyl, phenyl, benzothiazolyl, benzomorpholinyl or benzopyrrolidinyl is optionally substituted with one or more substituents selected from -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, piperazinyl, piperazinyl substituted with any number of halogens or -(C1-C6)alkyl; or, R 3 for Among them is a 3-6 membered saturated or unsaturated N-containing heterocyclic group connected via a N atom, wherein the heterocyclic group optionally contains 1-2 heteroatoms independently selected from O, N and S in addition to the N atom, and Optionally substituted with one or more substituents selected from the group consisting of: -F, -Cl, -Br, -CN, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -(C1-C6)haloalkyl, -(C3-C6)halocycloalkyl, -O-(C1-C6)haloalkyl, -O-(C3-C6)halocycloalkyl, pyrazolyl, pyrazolyl substituted with any number of halogen or -(C1-C6)alkyl, piperazinyl, piperazinyl substituted with any number of halogen or -(C1-C6)alkyl.
[0174] R 4 for
[0175] X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-;
[0176] represents a single bond or a double bond;
[0177] Y 1 is N, C or CH;
[0178] Y 2 and Y 3 Each independently represents N, CH2 or CH, Y2 and Y 3 Not all N at the same time;
[0179] Each R j are independently -H, halogen, -OH, -NH2, -CN, -(C1-C6)alkyl, -O-(C1-C6)alkyl, -(C1-C6)alkyl substituted with any number of halogens, -O-(C1-C6)alkyl substituted with any number of halogens, oxazole, thiazole and triazole; or, each R j It can also be further independently selected from =O, (C3-C6) cycloalkyl, -O-(C3-C6) cycloalkyl, -(C3-C6) cycloalkyl substituted with any number of halogens, or -O-(C3-C6) cycloalkyl substituted with any number of halogens;
[0180] m and p are independently 0, 1, 2, 3, 4, 5 or 6;
[0181] n is 0, 1, or 2;
[0182] Ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxacyclohexane, piperazine, pyrazine or triazine; or, Ring A is 4,5-dihydro-1H-imidazole or 1,3-dioxolane.
[0183] As a third preferred embodiment, in some embodiments, the compound of the present invention described in the first, second, third and fourth aspects of the present invention is selected from the compound represented by Formula I, Formula I-1 or I-2 or its isomers, pharmaceutically acceptable salts or solvates:
[0184] in,
[0185] R 2 is -H, -F, -Cl or -Br;
[0186] R 1 -H, -F, -Cl, -Br, -OH, -NH2, Or, R 1 for
[0187] Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form
[0188] R 3-H, -F, -Cl, -Br, -CH3, -CH2CH3, pyridyl, or R 3 for
[0189] R 4 for or R 4 for
[0190] Preferably, the compounds of the present invention described in the first, second, third and fourth aspects of the present invention are selected from the compounds shown in the following table or their isomers, pharmaceutically acceptable salts or solvates:
[0191] Preferably, the compound of the present invention used in the first, second, third and fourth aspects of the present invention is selected from the compounds shown in the following table or their isomers, pharmaceutically acceptable salts or solvates:
[0192] Preferably, the compounds of the present invention described in the first, second, third and fourth aspects of the present invention are selected from the compounds shown in the following table or their isomers, pharmaceutically acceptable salts or solvates:
[0193] In another embodiment, the compound of the present invention according to the first, second, third and fourth aspects of the present invention is selected from the compound of the following formula II or its isomers, pharmaceutically acceptable salts or solvates:
[0194] In Formula II:
[0195] R 3 and R 4 For example, any corresponding R in the compound of formula Ⅰ, Ⅰ-1 or Ⅰ-2 3 and R 4 the definitions involved;
[0196] Each R jindependently -H, halogen, -OH, -NH2, -CN, =O, -NO2, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH or -NHS( O)OH, -C(O)H, or -C(O)OH, wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused cyclic radical is optionally substituted with one or more substituents selected from the group consisting of -H, =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH, or -NHS(O)OH, -C(O)H, -C(O)OH, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N, and S, a C6-C 14 aryl or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S;
[0197] m is independently selected from 0, 1, 2, 3, 4, 5 or 6;
[0198] v is 0 or 1;
[0199] Ring B is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, a 5- to 14-membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7- to 14-membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S.
[0200] In other specific embodiments,
[0201] Each R jare independently -H, halogen, -OH, -NH2, -CN, =O, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C1-C6)alkyl substituted with any number of halogens, -(C1-C6)alkoxy substituted with any number of halogens, oxazolyl, thiazolyl, and triazolyl;
[0202] Ring B is (C3-C8) cycloalkyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, a 5- to 14-membered heteroaryl group containing 1 to 4 heteroatoms independently selected from O, N and S, or a 7- to 14-membered bicyclic or tricyclic fused ring group containing 0 to 4 heteroatoms independently selected from O, N and S.
[0203] In other specific embodiments,
[0204] Ring B is a 3-7 membered oxacycloalkyl group or an 8-10 membered azabicyclic fused heteroaryl group. Alternatively, Ring B is oxepane, oxhexane, tetrahydrofuran, oxetane, oxirane, 1H-indole or isoindoline.
[0205] In other specific embodiments,
[0206] Ring B is
[0207] Preferably, the compounds of the present invention described in the first, second, third and fourth aspects of the present invention are selected from the compounds shown in the following table or their isomers, pharmaceutically acceptable salts or solvates:
[0208] In another embodiment, the compound of the present invention described in the first, second, third and fourth aspects of the present invention is selected from the deuterated compound of the aforementioned formula I or II or its isomer, pharmaceutically acceptable salt or solvate:
[0209] Among them, R 1 、R 2 、R 3 、R 4 、R j , m, v and ring B are the same as any corresponding R in the aforementioned compound of formula I or II 1 、R 2 、R 3 、R 4 、R j , m, v and ring B involved in the definition;
[0210] In the compound of formula I or II, at least one H is substituted by D.
[0211] In other specific embodiments,
[0212] The structure of the compound of formula I or II Any one or more H in is replaced by D, or R 4 Any one or more H in is replaced by D. Alternatively, the structure of the compound of formula I or II All H in are replaced by D.
[0213] In other specific embodiments,
[0214] R 1 、R 2 or R 3 When H is selected, it is independently optionally substituted with D.
[0215] Preferably, the compounds of the present invention described in the first, second, third and fourth aspects of the present invention are selected from the compounds shown in the following table or their isomers, pharmaceutically acceptable salts or solvates:
[0216] In one embodiment, the content of the compound of the present invention in the pharmaceutical composition described in the first aspect, second aspect, third aspect and fourth aspect of the present invention is 0.05 mg to 1000 mg, and in particular, the content of the compound of the present invention in the unit dose of the pharmaceutical composition is 0.05 mg to 1000 mg, wherein the unit dose refers to the minimum measurement unit specification product of the pharmaceutical composition or the drug prepared from the pharmaceutical composition.
[0217] In some embodiments, the pharmaceutical composition comprising the compounds of the present invention can be presented in any pharmaceutically acceptable dosage form and route of administration. Acceptable dosage forms include, but are not limited to, tablets, capsules, granules, pills, pastes, powders, tinctures, films, patches, coatings, implants, injections, lozenges, drops, sprays, aerosols, atomized inhalers, gels, suppositories, ointments, etc. Acceptable routes of administration include, but are not limited to, oral, intravenous, rectal, parenteral, topical, transdermal, ophthalmic, nasal, buccal, or pulmonary (inhalation) administration, etc.
[0218] In the present invention, when a later technical solution further defines a previous technical solution, it may only further define some of the technical features. In this case, the undefined technical features may be optionally defined in the previous technical solution or anywhere in the present invention.
[0219] definition
[0220] Unless stated otherwise, the following terms used in the specification and claims have the following meanings.
[0221] "Alkyl" refers to an aliphatic hydrocarbon group, including a saturated hydrocarbon group, which may be substituted or unsubstituted. The alkyl portion may be a straight-chain or branched chain alkyl group. For example, -(C1-C6)alkyl or -(C1-C3)alkyl. -(C1-C6)alkyl refers to an alkyl group having 1 to 6 carbon atoms, such as 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, and the like. The alkyl group may be unsubstituted or substituted with one or more substituents, including but not limited to alkyl, alkoxy, cyano, hydroxyl, carbonyl, carboxyl, aryl, heteroaryl, amine, halogen, sulfonyl, sulfinyl, phosphonyl, and the like.
[0222] "Alkenyl" refers to an unsaturated hydrocarbon group containing a carbon-carbon double bond in its structure, which may be substituted or unsubstituted. The alkenyl portion may be a straight-chain alkenyl or a branched alkenyl. For example, -(C2-C6)alkenyl or -(C2-C4)alkenyl. -(C2-C6)alkenyl refers to an alkenyl group having 2 to 6 carbon atoms, such as 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms. Non-limiting examples of alkenyl groups include ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, n-hexenyl, and the like. The alkenyl group may be unsubstituted or substituted with one or more substituents, including but not limited to alkyl, alkoxy, cyano, hydroxyl, carbonyl, carboxyl, aryl, heteroaryl, amine, halogen, sulfonyl, sulfinyl, phosphonyl, and the like.
[0223] "Alkynyl" refers to an unsaturated hydrocarbon group containing a carbon-carbon triple bond in its structure, which may be substituted or unsubstituted. The alkynyl moiety may be a straight-chain alkynyl or a branched alkynyl. For example, -(C2-C6)alkynyl or -(C2-C4)alkynyl. -(C2-C6)alkynyl refers to an alkynyl group having 2 to 6 carbon atoms, such as alkynyl groups having 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms. Non-limiting examples of alkynyl groups include ethynyl, n-propynyl, isopropynyl, n-butynyl, isobutynyl, n-hexynyl, and the like. The alkynyl group may be unsubstituted or substituted with one or more substituents, including but not limited to alkyl, alkoxy, cyano, hydroxyl, carbonyl, carboxyl, aryl, heteroaryl, amine, halogen, sulfonyl, sulfinyl, phosphonyl, and the like.
[0224] "Ring" refers to any covalently closed structure, including for example carbocyclic ring (for example aryl, cycloalkyl or cycloalkenyl), heterocyclic group (for example heteroaryl, heterocycloalkyl or heterocycloalkenyl), aromatic group (such as aryl or heteroaryl), non-aromatic group (such as cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl), which can be substituted or unsubstituted. Ring can be optionally substituted, can be monocyclic or polycyclic. Typical polycyclic rings generally include bicyclic and tricyclic rings. The ring of the application usually has 3-20 ring atoms, for example 3 ring atoms, 4 ring atoms, 5 ring atoms, 6 ring atoms, 7 ring atoms, 8 ring atoms, 9 ring atoms, 10 ring atoms, 11 ring atoms, 12 ring atoms, 13 ring atoms, 14 ring atoms, 15 ring atoms, 16 ring atoms, 17 ring atoms, 18 ring atoms, 19 ring atoms or 20 ring atoms.
[0225] "Membered" refers to the number of atoms that make up the ring. Typical five-membered rings include cyclopentyl, pyrrole, imidazole, thiazole, furan, and thiophene. Typical six-membered rings include cyclohexyl, cyclohexenyl, pyridine, pyran, pyrazine, thiopyran, pyridazine, pyrimidine, and benzene. A ring containing heteroatoms among its backbone atoms is considered a heterocycle.
[0226] "Heteroatom" refers to an atom other than carbon or hydrogen. One or more heteroatoms in the heterocycle of the present application may be independently selected from O, S, N, Si and P, but is not limited thereto.
[0227] "Aryl" refers to a cyclic group with a conjugated π electron system, including aryl groups whose skeleton atoms constituting the ring are all carbon atoms and heteroaryl groups whose skeleton atoms constituting the ring contain heteroatoms. "Aryl" preferably refers to a monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group with a conjugated π electron system, preferably having 6 to 10 atoms, such as phenyl and naphthyl, which may be substituted or unsubstituted. More preferably, phenyl. "Heteroaryl" preferably refers to a heteroaromatic system comprising 1 to 4 (e.g., 1, 2, 3, or 4) heteroatoms, 5 to 14 ring atoms (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14), wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen, which may be substituted or unsubstituted. The heteroaryl group is preferably 5-10 membered and contains 1-3 heteroatoms; more preferably 5-membered or 6-membered and contains 1-2 heteroatoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyranyl, thiopyranyl, pyrimidinyl, thiadiazole, pyrazinyl, triazinyl, etc., preferably imidazolyl, thiazolyl, pyrazolyl or pyrimidinyl, thiazolyl; more preferably, pyrazolyl, such as 1H-pyrazol-4-yl or thiazolyl. The heteroaryl ring may be fused to an aryl, heterocycloalkyl, cycloalkyl ring, or another heteroaryl group to form a fused heteroaryl. The fused heteroaryl group is preferably an 8-10 membered fused heteroaryl group, including but not limited to: indolyl such as 1H-indol-5-yl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl such as 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl, or 1H-benzo[d]imidazolyl such as 1H-benzo[d]imidazol-6-yl.
[0228] "Non-aromatic group" refers to a cyclic group that does not have a conjugated π electron system and is not aromatic. It is generally also called an alicyclic group, including cycloalkyl and cycloalkenyl groups whose skeletal atoms constituting the ring are all carbon atoms and heterocycloalkyl and heterocycloalkenyl groups whose skeletal atoms constituting the ring contain heteroatoms.
[0229] "Fused" refers to rings that share adjacent pairs of carbon atoms and are typically bi- or tri-ring fused.
[0230] “Fused cyclic group” includes “fused non-aromatic group”, “fused aromatic group”, “fused non-aromatic group” includes “fused cycloalkyl group”, “fused heterocycloalkyl group”, “fused cycloalkenyl group” and “fused heterocycloalkenyl group”, and “fused aromatic group” includes “fused aryl group” and “fused heteroaryl group”, all of which may be substituted or unsubstituted.
[0231] "Cycloalkyl" refers to a saturated cyclic hydrocarbon substituent containing 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl and tricyclic alkyl, which contains 3 to 20 carbon atoms that can form a ring, preferably 3 to 10 carbon atoms (i.e., 3-10 membered cycloalkyl, also referred to as -(C3-C10 ) cycloalkyl), for example 3 to 8, 3 to 7, 3 to 6, 5 to 6 carbon atoms. Preferably, the cycloalkyl is selected from the monovalent cycloalkyl derived from the following rings:
[0232] Preferred are cyclopropyl, cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane. The cycloalkyl group may be substituted or unsubstituted.
[0233] It should be understood that when a cycloalkyl group is connected to two groups according to the structure or context, the cycloalkyl group is a divalent group, i.e., there are two connection sites. In this case, it can also be referred to as a cycloalkylene group. Examples of preferred cycloalkylene groups include, but are not limited to, monocyclic structures such as cyclopropylene, cyclobutylene, cyclopentylene (e.g., cyclopentyl-1,2-diyl, cyclopentyl-1,3-diyl), cyclohexylene (e.g., cyclohexyl-1,2-diyl, cyclohexyl-1,3-diyl, cyclohexyl-1,4-diyl), cycloheptanylene, or cyclooctanylene.
[0234] "Heterocycloalkyl" and "cycloheteroalkyl" are used interchangeably to refer to saturated non-aromatic monocyclic, fused, bridged, and spirocyclic rings containing one or more (e.g., 1, 2, 3, or 4) heteroatoms. The heteroatoms may be N, O, S, or SO2. Preferably N, O and / or S. Heterocycloalkyl can be a 3- to 10-membered (e.g., 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-membered, i.e., containing 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms) monocyclic, bicyclic or tricyclic group. Typical heterocycloalkyl groups include, but are not limited to, monovalent groups derived from the following rings:
[0235] These heterocycloalkyl groups can also be represented by commonly understood structural formulas, for example:
[0236] It should be understood that when a heterocycloalkyl group is connected to two groups according to the structure or context, the heterocycloalkyl group is a divalent group, i.e., it has two attachment sites. In this case, it can also be referred to as a heterocycloalkylene group. Examples of heterocycloalkylene groups include, but are not limited to, divalent groups formed from the above groups, such as:
[0237] "Cycloalkenyl" refers to a cyclic hydrocarbon substituent containing one to three rings, which contains one or more double bonds but none of which has a completely conjugated π electron system and is non-aromatic, including monocyclic alkenyl, bicyclic alkenyl and tricyclic alkenyl, and contains 3 to 20 carbon atoms that can form a ring, preferably 3 to 10 carbon atoms (i.e., 3-10 membered cycloalkenyl, also known as -(C3-C 10) cycloalkenyl), for example 3 to 8, 3 to 7, 3 to 6, 5 to 6 carbon atoms. Preferably, the cycloalkenyl is selected from the monovalent cycloalkenyl derived from the following rings:
[0238] Preferred are cyclopropenyl, cyclopentenyl and cyclohexenyl. Cycloalkenyl groups may be substituted or unsubstituted. It should be understood that when, according to the structure or context, a cycloalkenyl group is connected to two groups, the cycloalkenyl group is a divalent group, i.e., has two attachment sites. In this case, it may also be referred to as a cycloalkenylene group.
[0239] "Heterocycloalkenyl" refers to an unsaturated, non-aromatic, monocyclic, fused, bridged, or spirocyclic ring containing one or more (e.g., 1, 2, 3, or 4) heteroatoms. The heteroatoms may be N, O, S, or SO2. Preferably N, O and / or S. The heterocycloalkenyl group may be a 3- to 10-membered (e.g., 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-membered, i.e., containing 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms) monocyclic, bicyclic or tricyclic group. Typical heterocycloalkenyl groups include, but are not limited to, monovalent groups derived from the following rings:
[0240] These heterocyclic alkenyl groups can also be represented by commonly understood structural formulas, for example: It should be understood that when, according to the structure or context, a heterocycloalkenyl group is connected to two groups, the heterocycloalkenyl group is a divalent group, i.e., has two connection points. In this case, it can also be referred to as a heterocycloalkenylene group.
[0241] "Oxo" refers to the replacement of a hydrogen on a carbon with =0.
[0242] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.
[0243] "Haloalkyl" refers to an alkyl group in which at least one hydrogen atom is replaced by a halogen atom, such as CF3.
[0244] "Substituted" means that one or more hydrogen atoms, preferably up to 5 (e.g., 1, 2, 3, 4, 5), more preferably 1 to 3 hydrogen atoms, in a group can be replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group having free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
[0245] "Inhibitor" refers to a substance that reduces enzyme activity.
[0246] "Agonist" refers to a substance that increases enzyme activity.
[0247] "Optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes that the event or circumstance occurs or does not occur.
[0248] The term "substituted or unsubstituted" as used herein refers to any group that is monosubstituted or polysubstituted by a specified substituent to the extent that such monosubstituted or polysubstituted (including multiple substitutions in the same moiety) is chemically permitted, and each substituent may be located at any available position on the group and may be attached via any available atom on the substituent. "Any available position" refers to any position on the group that is chemically accessible by methods known in the art or the methods taught by the present invention and that does not produce an excessively unstable molecule. When there are two or more substituents on any group, each substituent is defined independently of any other substituent and may therefore be the same or different.
[0249] "Stereoisomers" as used herein refer to compounds of the present invention that, when they contain one or more asymmetric centers, can exist as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures, and single diastereomers. Compounds of the present invention may have asymmetric centers, which may result in the existence of two optical isomers. The scope of the present invention includes all possible optical isomers and their mixtures. If a compound of the present invention contains an olefinic double bond, the scope of the present invention includes both cis-isomers and trans-isomers, unless otherwise specified. Compounds of the present invention may exist as tautomers (a type of functional group isomers) that have different points of hydrogen attachment due to one or more double bond shifts, for example, a ketone and its enol form are keto-enol tautomers. Each tautomer and their mixtures are within the scope of the present invention. All enantiomers of the compounds, including diastereomers, racemates, mesomorphs, cis-trans isomers, tautomers, geometric isomers, epimers, and mixtures thereof, are within the scope of the present invention.
[0250] The term "compounds of the present invention" used in the present invention is intended to cover compounds of the general formula (I) and (II) as defined in the present invention or any preferred or specific embodiment thereof (including compounds of formula (I-1), (I-2) and example compounds), their stereoisomers, pharmaceutically acceptable salts, tautomers or solvates.
[0251] The term "pharmaceutically acceptable" as used herein refers to molecular entities and compositions that are approved or approvable by relevant agencies in various countries, or listed in generally recognized pharmacopoeias for use in animals, and more particularly humans, or that do not produce adverse, allergic or other untoward reactions when administered in appropriate amounts to animals, such as humans.
[0252] The term "pharmaceutically acceptable salt" used in the present invention refers to a salt of the compound of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Specifically, such salts are non-toxic and can be inorganic acid addition salts or organic acid addition salts and base addition salts.
[0253] As used herein, the term "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from a disease (e.g., a disease described herein) (referred to as a patient) or normal individuals. "Non-human animals" herein include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock, and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0254] The "pharmaceutical composition" described in the present invention refers to a composition comprising one or more compounds of Formula (I), Formula (I-1), Formula (I-2) or Formula (II) or their stereoisomers, tautomers, pharmaceutically acceptable salts or solvates and a carrier or excipient generally accepted in the art for delivering biologically active compounds to an organism (e.g., a human).
[0255] The term "drug combination" as used in the present invention means that the compounds of the present invention can be combined with other active agents to achieve the purpose of the present invention. The other active agents may be one or more additional compounds of the present invention, or may be a second or additional (e.g., a third) compound that is compatible with the compounds of the present invention, i.e., does not adversely affect each other, or has complementary activities, such as Luspatercept (ACE-536), Ruxolitinib, Bitopertin (RO-4917838), Hydroxyurea, IMR-687, Mitapivat (AG-348), etc. Such active agents are suitably combined in an effective amount to achieve the intended purpose. The other active agents may be co-administered with the compounds of the present invention in a single pharmaceutical composition, or administered separately from the compounds of the present invention in different discrete units, and when administered separately, they may be administered simultaneously or sequentially. The sequential administration may be close or distant in time.
[0256] It should be understood that when selecting the various groups in the compound structure of the present invention, the groups that are connected, coordinated or influenced by each other should be selected accordingly under the premise of complying with the chemical valence rules.
[0257] "Prevention" in the present invention refers to avoiding, alleviating, or reducing the risk of the occurrence and development of a disease; "treatment" refers to the use of artificial intervention to eliminate, hinder, alleviate, weaken, limit, inhibit or curb the symptoms of a disease or the development, process or progression of disease symptoms.
[0258] According to the contents of the present invention, in accordance with common technical knowledge and means in this field, without departing from the above basic technical ideas of the present invention, other various forms of modifications, replacements or changes can be made. DETAILED DESCRIPTION
[0259] To further illustrate the present invention, the compounds of the present invention, their preparation methods and applications are described in detail below with reference to the examples.
[0260] The following abbreviations or terms have the following meanings:
[0261] Grubb's 2 refers to Grubbs second generation catalyst
[0262] DMF stands for N,N-dimethylformamide;
[0263] DMSO indicates dimethyl sulfoxide;
[0264] HATU represents 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate;
[0265] DIPEA stands for N,N-diisopropylethylamine;
[0266] Pd2(dba)3 represents tris(dibenzylideneacetone)dipalladium;
[0267] Xantphos represents 4,5-bisdiphenylphosphino-9,9-dimethylxanthene;
[0268] -Cbz represents a benzyloxycarbonyl protecting group;
[0269] -Boc represents a tert-butyloxycarbonyl protecting group;
[0270] -Fmoc represents a 9-fluorenylmethoxycarbonyl protecting group;
[0271] -PMB represents a p-methoxybenzyl protecting group;
[0272] -Bn represents a benzyl protecting group;
[0273] -Trt represents a trityl protecting group;
[0274] -Tos represents a p-toluenesulfonyl protecting group;
[0275] -Pht represents a phthaloyl protecting group;
[0276] -Alloc represents an allyloxycarbonyl protecting group;
[0277] Tris buffer means tris(hydroxymethyl)aminomethane buffer.
[0278] -TBS represents tert-butyldimethylsilyl;
[0279] -TBDPS represents tert-butyldiphenylsilyl.
[0280] The present invention also provides a method for synthesizing the compound of the present invention. The method of the present invention is mainly based on the preparation method reported in chemical literature or uses commercially available chemical reagents as starting materials for related synthesis.
[0281] method:
[0282] In the above reaction formula, “R A "refer to where R 4 As defined herein wherever it appears; "R C "refer to where R 1 、R 2 、R 3 、R j , m, v and Ring B are as defined in the present invention at any place; "R B " refers to R protected by a protecting group C , R B After removing the protecting group, it becomes R C , the protecting groups include but are not limited to -TBS or -TBDPS.
[0283] The following steps involve compound ZR A 、Compound ZR B , wherein "Z" is capable of undergoing condensation reaction with amino groups to convert R A or R B Connect The condensation reaction is preferably a condensation reaction between sulfonyl chloride and amino group or a condensation reaction between carboxyl group and amino group. "Z" can be independently selected in different compounds and includes but is not limited to -Cl, -F, -Br, -OH, and compound ZR A Preferably Cl-R A , compound ZR B Preferably OH-R B .
[0284] Step 1:
[0285] Compound A is dissolved in tetrahydrofuran solution, and then triethylamine and compound ZR are added A The reaction was carried out at 25° C. After the reaction was completed, the mixture was extracted with ethyl acetate three times, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and then separated and purified by chromatography to obtain compound B.
[0286] Step 2:
[0287] Compound B is dissolved in trifluoroacetic acid, and the reaction is carried out at 60° C. After the reaction is completed, the product is concentrated to dryness and then separated and purified by a chromatography column to obtain compound C.
[0288] Step 3:
[0289] Compound C was dissolved in DMF solution, and then compound ZR was added in sequence. B , HATU and DIPEA were subjected to condensation reaction at 25°C. After the reaction was completed, the reaction solution was poured into water and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and then separated and purified by chromatography to obtain compound D.
[0290] Step 4:
[0291] Compound D is dissolved in tetrahydrofuran solution, and then tetrabutylammonium fluoride is added to perform a deprotection reaction to finally obtain compound E.
[0292] Example 1: Preparation of (S)-1-(1'-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1) The synthesis steps are as follows:
[0293] Step 1: Preparation of 7-bromo-2,3-dihydro-[1,4]dioxo[2,3-b]pyridine (Compound 1A)
[0294] 5-Bromopyridine-2,3-diol (13.0 g, 68.4 mmol) was dissolved in DMF (130 mL), followed by the addition of 1,2-dibromoethane (19.3 g, 102.6 mmol) and potassium carbonate (28.3 g, 205 mmol). The reaction system was stirred at 100°C overnight. After the reaction was complete, the reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 1A.
[0295] MS (ESI) m / z 216.0 (M+H) +
[0296] Step 2: Preparation of 7-(benzylthio)-2,3-dihydro-[1,4]dioxo[2,3-b]pyridine (Compound 1B)
[0297] Under argon protection, 7-bromo-2,3-dihydro-[1,4]dioxo[2,3-b]pyridine (1.0 g, 4.6 mmol) was dissolved in 1,4-dioxane solution (20 mL), followed by the addition of benzylmercaptan (570 mg, 4.6 mmol), Pd2(dba)3 (240 mg, 0.23 mmol), Xantphos (270 mg, 0.46 mmol), and DIPEA (1190 mg, 9.3 mmol). The reaction system was stirred at 80°C overnight. After the reaction was complete, the reaction solution was concentrated to dryness under reduced pressure, and the residue was separated and purified by silica gel column to obtain compound 1B.
[0298] MS (ESI) m / z 260.1 (M+H) + .
[0299] Step 3: Preparation of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride (Compound 1C)
[0300] 7-(Benzylthio)-2,3-dihydro-[1,4]dioxo[2,3-b]pyridine (800 mg, 3 mmol) and dichlorohydantoin (820 mg, 6 mmol) were dissolved in a mixture of acetonitrile (30 mL), acetic acid (0.75 mL), and water (0.5 mL). The reaction system was stirred at 25°C overnight. After completion of the reaction, the reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 1C.
[0301] MS (ESI) m / z 236.0 (M+H) + .
[0302] Step 4: Preparation of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid (Compound 1D)
[0303] (S)-3-Hydroxy-2-phenylpropionic acid (900 mg, 5.4 mmol) and 4-dimethylaminopyridine (1.32 g, 10.8 mmol) were dissolved in dichloromethane (10 mL), and tert-butyldiphenylsilyl chloride (1.64 g, 6 mmol) was added. The reaction system was stirred at 25°C overnight. After the reaction was complete, the reaction solution was concentrated to dryness, and the crude product was separated and purified on a C-18 column to obtain compound 1D.
[0304] MS (ESI) m / z 405.2 (M+H) + .
[0305] Step 5: Preparation of benzyl 3-methyleneazetidine-1-carboxylate (Compound 1E)
[0306] Benzyl 3-oxoazetidine-1-carboxylate (86.6 g, 268 mmol) and methyltriphenylphosphonium bromide (50 g, 243.5 mmol) were dissolved in tetrahydrofuran (500 mL), followed by the addition of potassium tert-butoxide (40.9 g, 365.5 mmol). The mixture was stirred at 25°C overnight. After the reaction was complete, the reaction solution was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain Compound 1E.
[0307] MS (ESI) m / z 204.1 (M+H) +
[0308] Step 6: Preparation of 1-benzyl 1'-(tert-butyl) 2H,2'H-[3,3'-diazetidinylidene]-1,1'(4H,4'H)-dicarboxylate (Compound 1F)
[0309] Benzyl 3-methyleneazetidine-1-carboxylate (39 g, 191.9 mmol) and tert-butyl 3-methyleneazetidine-1-carboxylate (32.47 g, 191.9 mmol) were dissolved in dichloroethane (2000 mL), followed by the addition of Grubb's 2 (16.29 g, 19.19 mmol). The mixture was stirred at 50°C for 48 hours. After the reaction was complete, the reaction solution was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain Compound 1F.
[0310] MS (ESI) m / z 345.2 (M+H) +
[0311] Step 7: Preparation of benzyl 1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate (Compound 1G)
[0312] 1-Benzyl 1'-(tert-butyl) 2H,2'H-[3,3'-diazetidinylidene]-1,1'(4H,4'H)-dicarboxylate (3.2 g, 9.29 mmol) was dissolved in ethyl acetate (32 mL), followed by the addition of p-toluenesulfonic acid (1.6 g, 9.29 mmol). The reaction system was stirred at 50°C for 6 hours. After completion of the reaction, the reaction solution was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain compound 1G.
[0313] MS (ESI) m / z 245.1 (M+H) +
[0314] Step 8: Preparation of benzyl 1'-((2,3-dihydro-[1,4]dioxo[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate (Compound 1H)
[0315] Benzyl 1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate (100 mg, 0.41 mmol) and triethylamine (82.5 mg, 0.82 mmol) were dissolved in tetrahydrofuran (4 mL), followed by the addition of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride (96.5 mg, 0.41 mmol). The mixture was stirred at 25°C for 2 hours. After completion of the reaction, the reaction solution was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain compound 1H.
[0316] MS (ESI) m / z 444.1 (M+H) +
[0317] Step 9: Preparation of 7-((1',4'-dihydro-2H,2'-H-[3,3'-diazetidinylidene]-1(4H)-ylsulfonyl)-2,3-dihydro-[1,4]dioxo[2.3-b]pyridine) (Compound II)
[0318] Benzyl 1'-((2,3-dihydro-[1,4]dioxo[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate (120 mg, 0.27 mmol) was dissolved in trifluoroacetic acid (5 mL), and the reaction system was stirred at 60°C overnight. After the reaction was complete, the reaction solution was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain compound 1I.
[0319] MS (ESI) m / z 310.1 (M+H) +
[0320] Step 10: Preparation of (S)-3-((tert-butyldiphenylsilyl)oxy)-1-(1'-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 1J)
[0321] (S)-3-((tert-Butyldiphenylsilyl)oxy)-2-phenylpropanoic acid (80 mg, 0.2 mmol) and 7-((1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidenediazetidinylidene]-1(4H)-ylsulfonyl)-2,3-dihydro-[1.4]dioxo[2.3-b]pyridine) (61 mg, 0.2 mmol) were dissolved in DMF (5 mL). HATU (112 mg, 0.3 mmol) and DIPEA (77 mg, 0.6 mmol) were added, and the reaction system was stirred at 25°C for 3 hours. After the reaction was complete, the reaction solution was concentrated to dryness and compound 1J was prepared by reverse-phase high-pressure liquid chromatography.
[0322] MS (ESI) m / z 695.3 (M+H) +
[0323] Step 11: Preparation of (S)-1-(1'-((2,3-dihydro-[1,4]dioxo[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1)
[0324] (S)-3-((tert-Butyldiphenylsilyl)oxy)-1-(1'-((2,3-dihydro-[1,4]dioxo[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (50 mg, 0.087 mmol) was dissolved in tetrahydrofuran (5 mL), and then tetrabutylammonium fluoride (45.5 mg, 0.17 mmol) was added. The reaction system was stirred at 25°C for 3 hours. After the reaction was complete, the reaction solution was concentrated to dryness and compound 1 of Example 1 was prepared by reverse phase high pressure liquid chromatography.
[0325] MS (ESI) m / z 458.2 (M+H) +
[0326] 1 H NMR(400MHz,DMSO-d6)δ8.23(s,1H),7.71(s,1H),7.51-7.20(m,5H),4.87(s,1H),4.80-4.7 2(m,1H),4.60(s,2H),4.50-4.30(m,8H),4.30-4.20(m,1H),3.96(s,1H),3.75-3.55(m,2H).
[0327] Example 2: Preparation of (S)-1-(1'-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 2):
[0328] In step 8 of Example 1, 2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 2 of Example 2.
[0329] MS (ESI) m / z 457.1 (M+H) + .
[0330] 1 H NMR(400MHz,DMSO-d6)δ7.35-7.20(m,7H),7.13-7.11(m,1H),4.85-4.7(m,2H) ,4.40-4.20(m,11H),3.95-3.85(m,1H),3.75-3.70(m,1H),3.50-3.40(m,1H).
[0331] Example 3: Preparation of (S)-1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 3):
[0332] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 3 of Example 3.
[0333] MS (ESI) m / z 456.1 (M+H) +
[0334] 1H NMR (400MHz, DMSO-d6) δ9.64(s,1H),8.77(s,1H),8.35-8.24(m,1H),7.90(d,J=9.4Hz,1H),7.21(d,J=14.2Hz,5 H),4.64(d,J=12.5Hz,2H),4.34-4.10(m,7H),3.81(d,J=10.0Hz,1H),3.61-3.50(m,1H),3.40(d,J=7.1Hz,1H).
[0335] Example 4: Preparation of (S)-3-hydroxy-2-phenyl-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 4):
[0336] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 4 of Example 4.
[0337] MS (ESI) m / z 400.0 (M+H) +
[0338] 1 H NMR (400MHz, DMSO-d6) δ8.76 (s, 1H), 8.11 (d, J = 11.6Hz, 1H), 7.95 (d, J = 5.3Hz, 1H), 7.71 (s, 1H), 7.28-7.19 (m, 5H), 4.68 (d, J = 13. 2Hz,1H),4.50(s,4H),4.37-4.23(m,2H),4.17(d,J=14.6Hz,1H),3.85(q,J=9.0Hz,1H),3.58(d,J=10.4Hz,1H),3.50-3.40(m,2H)
[0339] Example 5: Preparation of (S)-3-hydroxy-1-(1'-((4-methoxyphenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 5):
[0340] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride was replaced with p-methoxybenzenesulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 5 of Example 5.
[0341] MS (ESI) m / z 429.5 (M+H) +
[0342] 1 H NMR (400MHz, DMSO-d6) δ7.80-7.65(m,2H),7.20(m,7H),4.83-4.60(m,2H),4. 24(d,J=30.9Hz,7H),3.82(s,4H),3.60-3.54(m,1H),3.41(d,J=10.1Hz,1H).
[0343] Example 6: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 6):
[0344] Step 1: Preparation of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid (Compound 6A)
[0345] 3-Hydroxy-2-phenylpropionic acid (1.0 g, 6.0 mmol) and 4-dimethylaminopyridine (1.47 g, 12 mmol) were dissolved in dichloromethane (10 mL), followed by the addition of tert-butyldiphenylsilyl chloride (1.54 g, 9 mmol). The reaction system was stirred overnight at 25°C. After completion of the reaction, the reaction solution was concentrated to dryness and purified by silica gel column chromatography to obtain compound 6A.
[0346] MS (ESI) m / z 405.2 (M+H) + .
[0347] Step 2: Preparation of benzyl 1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate (Compound 6B)
[0348] Benzyl 3-(azetidin-3-ylidene)azetidine-1-carboxylate (500 mg, 2.05 mmol) and triethylamine (413 mg, 4.1 mmol) were dissolved in tetrahydrofuran (20 mL), followed by the addition of 4-(difluoromethoxy)benzenesulfonyl chloride (500 mg, 2.05 mmol). The reaction system was stirred at 25°C for 3 hours. After completion of the reaction, the reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 6B.
[0349] MS (ESI) m / z 451.1 (M+H) + .
[0350] Step 3: Preparation of 1-((4-(difluoromethoxy)phenyl)sulfonyl)-1,1',4,4'-tetrahydro-2H,2'H-3,3'-diazetidinylidene (Compound 6C)
[0351] Benzyl 1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate (750 mg, 1.66 mmol) was dissolved in trifluoroacetic acid (5 mL), and the mixture was stirred at 40°C for 16 hours. After the reaction was complete, the reaction solution was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain compound 6C.
[0352] MS (ESI) m / z 317.1 (M+H) +
[0353] Step 4: Preparation of 3-((tert-butyldiphenylsilyl)oxy)-1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 6D)
[0354] 3-((tert-Butyldiphenylsilyl)oxy)-2-phenylpropanoic acid (109 mg, 0.3 mmol) and 1-((4-(difluoromethoxy)phenyl)sulfonyl)-1,1',4,4'-tetrahydro-2H,2'H-3,3'-diazetidinylidene (85 mg, 0.3 mmol) were dissolved in DMF (5 mL). HATU (157 mg, 0.4 mmol) and DIPEA (104 mg, 0.8 mmol) were added, and the reaction system was stirred at 25°C for 3 hours. After the reaction was complete, the reaction solution was concentrated to dryness and compound 6D was prepared by reverse-phase high-pressure liquid chromatography.
[0355] MS (ESI) m / z 703.2 (M+H) +
[0356] Step 5: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'-H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 6)
[0357] 3-((tert-Butyldiphenylsilyl)oxy)-1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (100 mg, 0.14 mmol) and tetrabutylammonium fluoride (37 mg, 0.14 mmol) were dissolved in tetrahydrofuran (5 mL), and the reaction system was stirred at 25°C for 3 hours. After the reaction was complete, the reaction solution was concentrated to dryness and compound 6 of Example 6 was prepared by reverse phase high pressure liquid chromatography.
[0358] MS (ESI) m / z 465.2 (M+H) +
[0359] 1 H NMR(400MHz,DMSO-d6)δ7.91-7.88(m,2H),7.45-7.43(m,2H),7.30-7.20(m,5H),4.72-4.69(m ,1H),4.60(s,2H),4.36-4.15(m,7H),4.95-4.85(m,1H),3.65-3.60(m,1H),3.50-3.40(m,1H).
[0360] Example 7: Preparation of (S)-1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 7):
[0361] In step 4 of Example 6, (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid, and the same preparation method as in Example 6 was used to obtain Compound 7 of Example 7.
[0362] MS (ESI) m / z 465.1 (M+H) +
[0363] 1 H NMR(400MHz,DMSO-d6)δ7.91-7.88(m,2H),7.45-7.43(m,2H),7.30-7.20(m,5H),6.06(s,1H), 4.72-4.69(m,1H),4.36-4.15(m,7H),4.95-4.85(m,1H),3.65-3.60(m,1H),3.50-3.40(m,2H).
[0364] Example 8: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-hydroxy-2-phenylethane-1-one (Compound 8):
[0365] In step 4 of Example 6, 2-hydroxy-2-phenylacetic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as Example 6 was used to obtain Compound 8 of Example 8.
[0366] MS (ESI) m / z 451.1 (M+H) +
[0367] 1 H NMR (400MHz, DMSO-d6) δ8.47 (s, 1H), 7.90 (m, 2H), 7.45 (s, 2H), 7.30 (d, J = 21.5Hz, 5H), 5.85(s,1H),5.04(s,1H),4.65(d,J=13.9Hz,1H),4.52(d,J=14.1Hz,1H),4.29(s,6H).
[0368] Example 9: Preparation of (S)-3-hydroxy-2-phenyl-1-(1'-((4-(trifluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 9):
[0369] In step 8 of Example 1, 4-(trifluoromethoxy)benzenesulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 9 of Example 9.
[0370] MS (ESI) m / z 483.1 (M+H) +
[0371] 1 H NMR(400MHz, DMSO-d6)δ7.99-7.96(m,2H),7.67-7.65(d,J=0.8Hz,2H),7.30-7.22(m,5H),4.81-4 .69(m,2H),4.36-4.18(m,7H),3.90-3.86(t,J=0.8Hz,1H),3.63-3.60(m,1H),3.47-3.43(m,1H).
[0372] Example 10: Preparation of (S)-1-(1'-(4-fluorophenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 10):
[0373] In step 8 of Example 1, 4-fluorobenzenesulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 10 of Example 10.
[0374] MS (ESI) m / z 417.1 (M+H) +
[0375] 1 H NMR(400MHz, DMSO-d6)δ7.99-7.96(m,2H),7.67-7.65(d,J=0.8Hz,2H),7.30-7.22(m,5H),4.81-4 .69(m,2H),4.36-4.18(m,7H),3.90-3.86(t,J=0.8Hz,1H),3.63-3.60(m,1H),3.47-3.43(m,1H).
[0376] Example 11: Preparation of (S)-1-(1'-(3-fluoro-4-difluoromethoxyphenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 11):
[0377] In step 8 of Example 1, 3-fluoro-4-difluoromethoxybenzenesulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 11 of Example 11.
[0378] MS (ESI) m / z 483.1 (M+H) +
[0379] 1H NMR (400MHz, DMSO-d6) δ7.92-7.89(m,1H),7.89-7.62(m,2H),7.44-7.22(m,6H),4.82-4.79(m,1H),4. 72-4.69(d,J=28.0Hz,1H),4.34-4.20(m,7H),3.89-3.84(m,1H),3.64-3.58(m,1H),3.47-3.43(m,1H).
[0380] Example 12: Preparation of (S)-1-(1'-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 12):
[0381] Step 1: Preparation of tert-butyl 6-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 12B)
[0382] 6-Bromo-3,4-dihydro-2H-1,4-benzoxazine (2 g, 9.34 mmol), 4-dimethylaminopyridine (114 mg, 0.93 mmol), and triethylamine (1.42 g, 14 mmol) were dissolved in tetrahydrofuran (40 mL). Di-tert-butyl dicarbonate (2 g, 9.34 mmol) was then added, and the reaction system was stirred at 40°C for 16 hours. After the reaction was complete, the reaction solution was poured into water and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. Compound 12B was obtained by separation and purification on a silica gel column.
[0383] MS (ESI) m / z 314.0 (M+H) + .
[0384] Step 2: Preparation of tert-butyl 6-(benzylthio)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 12C)
[0385] Tert-butyl 6-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (500 mg, 1.59 mmol), benzyl mercaptan (236.8 mg, 1.91 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (92 mg, 0.16 mmol), tris(dibenzylideneacetone)dipalladium (73 mg, 0.07 mmol), and N,N-diisopropylethylamine (617 mg, 4.77 mmol) were dissolved in 1,4-dioxane (10 mL). The reaction system was stirred at 40°C for 16 hours. After the reaction was complete, the reaction solution was poured into water, and the aqueous phase was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 12C.
[0386] MS (ESI) m / z 358.1 (M+H) + .
[0387] Step 3: Preparation of tert-butyl 6-(chlorosulfonyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 12D)
[0388] Tert-butyl 6-(benzylthio)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (500 mg, 1.39 mmol) was dissolved in a mixed solvent (acetonitrile:acetic acid:water = 40:1.5:1, 25 mL). 1,3-Dichloro-5,5-dimethylhydantoin (547.6 mg, 2.78 mmol) was added with stirring at 0°C. Stirring was then performed at room temperature for 3 hours. After the reaction was complete, the reaction solution was poured into water and extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain compound 12D.
[0389] In step 8 of Example 1, tert-butyl 6-(chlorosulfonyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 12 of Example 12.
[0390] MS (ESI) m / z 456.1 (M+H) +
[0391] 1H NMR (400MHz, DMSO-d6) δ7.34-7.21(m,6H),7.0(s,1H),6.89-6.84(m,2H),6.33(s,1H),4.82-4.79(t,J=0.8Hz, 1H),4.73-4.70(d,J=1.2Hz,1H),4.38-4.21(m,10H),3.91-3.85(m,1H),3.63-3.59(m,1H),3.47-3.43(m,1H).
[0392] Example 13: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-hydroxyethane-1-one (Compound 13):
[0393] Step 1: Preparation of tert-butyl 6-(2-ethoxy-2-oxoacetyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 13A)
[0394] tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate (500 mg, 1.59 mmol) was added to dry tetrahydrofuran (10 mL). The reaction system was purged with nitrogen three times and then maintained under nitrogen. The temperature was lowered to -78°C and n-butyl lithium (122 mg, 1.91 mmol) was slowly added dropwise with stirring. After completion, the mixture was stirred at -78°C for 0.5 hours. Diethyl oxalate (256 mg, 1.75 mmol) was added dropwise to the reaction mixture. After the addition was complete, the mixture was warmed to room temperature and stirred for 1 hour. After the reaction was complete, the reaction mixture was poured into water, and the aqueous phase was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness and purified by silica gel column chromatography to obtain compound 13A.
[0395] MS (ESI) m / z 336.1 (M+H) + .
[0396] Step 2: Preparation of tert-butyl 6-(2-ethoxy-1-hydroxy-2-oxoethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 13B)
[0397] Tert-butyl 6-(2-ethoxy-2-oxoacetyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (170 mg, 0.50 mmol) was added to tetrahydrofuran (8 mL) and stirred at 0°C. Sodium borohydride (29 mg, 0.76 mmol) was then added. The mixture was then stirred at room temperature for 0.5 hours. After the reaction was complete, the reaction solution was poured into water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 13B.
[0398] MS (ESI) m / z 338.1 (M+H) + .
[0399] Step 3: Preparation of 2-(4-(tert-Butyloxycarbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-hydroxyacetic acid (Compound 13C)
[0400] Tert-butyl 6-(2-ethoxy-1-hydroxy-2-oxoethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (170 mg, crude) and lithium hydroxide hydrate (106 mg, 2.52 mmol) were added to a mixture of tetrahydrofuran (3 mL) and water (3 mL) and stirred at room temperature for 16 hours. After the reaction was complete, the reaction solution was adjusted to a pH of 4-5 with 2N hydrochloric acid solution in an ice bath, diluted with water, and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain compound 13C.
[0401] MS (ESI) m / z 310.1 (M+H) + .
[0402] In step 4 of Example 6, 2-(4-(tert-butoxycarbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-hydroxyacetic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as in Example 6 was used to obtain Compound 13 of Example 13.
[0403] MS (ESI) m / z 508.1 (M+H) +
[0404] 1H NMR (400MHz, DMSO-d6) δ7.95-7.88(d,J=8Hz,2H),7.49-7.43(d,J=8Hz,3H),6.56-6.51(m,2H),6.41-6.39(m,1H),5.76(s,1H),5.49-5.48( d,J=4Hz,1H),4.81-4.79(d,J=8Hz,1H),4.61-4.57(d,J=16Hz,1H),4.42-4.38(d,J=16Hz,1H),4.27(s,6H),4.07-4.05(m,2H),3.22(s,2H).
[0405] Example 14: Preparation of (1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)(4-phenyltetrahydro-2H-pyran-4-yl)methanone (Compound 14):
[0406] Step 1: Preparation of methyl 4-phenyltetrahydro-2H-pyran-4-carboxylate (Compound 14B)
[0407] Methyl 2-phenylacetate (2.0 g, 13.32 mmol) was dissolved in tetrahydrofuran (40.0 mL). The reaction temperature was lowered to 0°C, and sodium hydride (1.06 g, 26.64 mmol) was then slowly added portionwise. The reaction mixture was stirred at 0°C for 30 minutes, followed by the dropwise addition of 2-iodoethyl ether (3.47 g, 10.65 mmol). After the addition was complete, the reaction mixture was stirred at 0°C for 10 minutes before slowly warming to room temperature. The reaction mixture was then heated to 50°C and stirred for 18 hours. After the reaction was complete, water was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 14B was obtained by separation and purification on a silica gel column.
[0408] MS (ESI) m / z 221.1 (M+H) + .
[0409] Step 2: Preparation of 4-phenyltetrahydro-2H-pyran-4-carboxylic acid (Compound 14C)
[0410] Methyl 4-phenyltetrahydro-2H-pyran-4-carboxylate (1.0 g, 4.54 mmol) was dissolved in methanol (10.0 mL) and water (10.0 mL). Sodium hydroxide (544.8 mg, 13.62 mmol) was then added, and the reaction mixture was stirred at 50°C for 3 hours. After completion of the reaction, the pH of the reaction system was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to dryness, and the residue was purified by silica gel column chromatography to obtain compound 14C.
[0411] MS (ESI) m / z 338.1 (M+H) + .
[0412] In step 4 of Example 6, 4-phenyltetrahydro-2H-pyran-4-carboxylic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as Example 6 was used to obtain Compound 14 of Example 14.
[0413] MS (ESI) m / z 505.1 (M+H) +
[0414] 1 H NMR(400MHz,DMSO-d6)δ7.88-7.84(m,2H),7.46-7.23(m,8H),4.30-4.10(m,6H),3.97(s, 2H),3.78-3.63(m,2H),3.52(t,J=11.0Hz,2H),2.15(d,J=13.5Hz,2H),1.91-1.72(m,2H).
[0415] Example 15: Preparation of 1-(1'-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(3-methoxyphenyl)-3-(methylamino)propan-1-one (Compound 15):
[0416] Step 1: Preparation of methyl 2-(3-methoxyphenyl)acrylate (Compound 15B)
[0417] Methyl 2-(3-methoxyphenyl)acetate (2.00 g, 11.10 mmol) was added to N,N-dimethylformamide (20.0 mL), followed by potassium carbonate (3.83 g, 27.75 mmol), triformaldehyde (1.19 g, 13.32 mmol), and tetrabutylammonium iodide (410.0 mg, 1.11 mmol). The reaction mixture was incubated at 80°C for half an hour. After the reaction was complete, compound 15B was isolated and purified by silica gel column chromatography.
[0418] MS (ESI) m / z 193.1 (M+H) + .
[0419] Step 2: Preparation of methyl 2-(3-methoxyphenyl)-2-(methylamino)acetate (Compound 15C)
[0420] Methyl 2-(3-methoxyphenyl)acrylate (2.02 g, 10.5 mmol) was added to a solution of methylamine in tetrahydrofuran (20.0 mL) and reacted at room temperature for 4 hours. Compound 15C was obtained by separation and purification on a silica gel column.
[0421] MS (ESI) m / z 224.1 (M+H) + .
[0422] Step 3: Preparation of methyl 3-((tert-butoxycarbonyl)(methyl)amino)-2-(3-methoxyphenyl)propanoate (Compound 15D)
[0423] Methyl 2-(3-methoxyphenyl)-2-(methylamino)acetate (2.00 g, 8.96 mmol) and 4-dimethylaminopyridine were dissolved in dichloromethane (10.0 mL), and triethylamine (1.81 g, 17.92 mmol) and di-tert-butyl dicarbonate (1.95 g, 8.96 mmol) were added. The mixture was allowed to react at room temperature for two hours. After completion, water was added to the reaction system to quench the reaction and the pH was adjusted to 5-6 with 2N aqueous hydrochloric acid. The mixture was then extracted with ethyl acetate (20.0 mL x 3). The combined organic layers were washed with saturated sodium chloride (20.0 mL) and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to dryness, and the residue was purified by silica gel column chromatography to obtain compound 15D.
[0424] MS (ESI) m / z 324.2 (M+H) + .
[0425] Step 4: Preparation of 3-((tert-Butyloxycarbonyl)(methyl)amino)-2-(3-methoxyphenyl)propanoic acid (Compound 15E)
[0426] Methyl 3-((tert-butoxycarbonyl)(methyl)amino)-2-(3-methoxyphenyl)propanoate (669.0 mg, 2.07 mmol) was dissolved in tetrahydrofuran (5.0 mL) and water (5.0 mL), and lithium hydroxide (99.1 mg, 4.14 mmol) was added. The reaction was allowed to proceed at room temperature for 16 hours. After the reaction was complete, the organic phase was concentrated under reduced pressure to dryness, and the residue was purified by silica gel column chromatography to obtain Compound 15E.
[0427] MS (ESI) m / z 310.2 (M+H) + .
[0428] In step 8 of Example 1, 2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxin[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-((tert-butoxycarbonyl)(methyl)amino)-2-(3-methoxyphenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain Compound 15 of Example 15.
[0429] MS (ESI) m / z 500.2 (M+H) + .
[0430] 1 H NMR(400MHz,DMSO-d6)δ7.28-7.22(m,3H),7.06-7.04(m,1H),6.85-6.81(m,3H),4 .34-4.30(m,6H),4.10-3.81(m,9H),3.71(s,3H),3.15-3.04(m,1H),2.28(s,3H).
[0431] Example 16: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropane-1-one (Compound 16):
[0432] Step 1: Preparation of methyl 2-(4-fluorophenyl)-3-hydroxypropionate (Compound 16B)
[0433] Methyl 4-fluorophenylacetate (1.0 g, 5.95 mmol) and paraformaldehyde (562.5 mg, 6.24 mmol) were dissolved in dimethyl sulfoxide (40.0 mL), followed by the addition of sodium methoxide (16.1 mg, 0.30 mmol). The reaction mixture was allowed to react at room temperature for 4 hours. After the reaction was complete, water was added to the reaction system to quench the reaction. The aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to dryness under reduced pressure, and the residue was separated and purified by silica gel column chromatography to obtain compound 16B.
[0434] MS (ESI) m / z 199.1 (M+H) + .
[0435] Step 2: Preparation of 2-(4-fluorophenyl)-3-hydroxypropanoic acid (Compound 16C)
[0436] Methyl 2-(4-fluorophenyl)-3-hydroxypropanoate (600.0 mg, 3.03 mmol) was dissolved in methanol (9.0 mL) and water (6.0 mL). Sodium hydroxide (242.2 mg, 6.05 mmol) was then added, and the reaction mixture was stirred at 50°C for 3 hours. After the reaction was complete, the pH was adjusted to 2 with 1N aqueous hydrochloric acid and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The resulting white solid residue was concentrated and purified via silica gel column chromatography to yield compound 16C.
[0437] MS (ESI) m / z 185.1 (M+H) + .
[0438] In step 4 of Example 6, 2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as in Example 6 was used to obtain Compound 16 of Example 16.
[0439] MS (ESI) m / z 483.1 (M+H) + .
[0440] 1 H NMR(400MHz,DMSO-d6)δ7.91-7.89(d,J=7.7Hz,2H),7.63-7.29(m,5H),7.12-7.09(m,2H),4.85(s,1H) ),4.70(d,J=12.7Hz,1H),4.39-4.22(m,7H),3.85-3.83(m,1H),3.70-3.64(m,1H),3.51-3.41(m,1H).
[0441] Example 17: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-3-methyl-2-phenylbutan-1-one (Compound 17):
[0442] Step 1: Preparation of 3-hydroxy-3-methyl-2-phenylbutyric acid (Compound 17B)
[0443] 2-Phenylacetic acid (0.7 g, 5.14 mmol) was dissolved in tetrahydrofuran (11.0 mL). Isopropylmagnesium chloride (1.06 g, 10.28 mmol, 2 M) was added dropwise at room temperature. After the addition was complete, the reaction solution was stirred at 40°C for 1 hour. Acetone (328.5 mg, 5.66 mmol) was then added, and the reaction solution was stirred at 40°C for another 1 hour. The reaction solution was adjusted to pH 2 with 3N hydrochloric acid, and the aqueous phase was extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The resulting white solid residue was concentrated and purified on a silica gel column to obtain compound 17B.
[0444] MS (ESI) m / z 195.1 (M+H) + .
[0445] In step 4 of Example 6, 3-hydroxy-3-methyl-2-phenylbutyric acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as Example 6 was used to obtain Compound 17 of Example 17.
[0446] MS (ESI) m / z 493.2 (M+H) + .
[0447] 1 H NMR(400MHz,DMSO-d6)δ7.90-7.88(m,2H),7.63-7.19(m,8H),4.91(s,1H),4.75- 4.72(d,J=13.3Hz,1H),4.28-4.22(m,7H),3.50(s,1H),1.13(s,3H),0.98(s,3H).
[0448] Example 18: Preparation of 1-(1'-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropane-1-one (Compound 18):
[0449] In step 10 of Example 1, 3-((tert-butyloxycarbonyl)(methyl)amino)-2-(3-methoxyphenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid, and the same preparation method as in Example 1 was used to obtain Compound 18 of Example 15.
[0450] MS (ESI) m / z 475.1 (M+H) + .
[0451] 1 H NMR (400MHz, DMSO-d6) δ7.34-7.24(m,4H),7.14-7.10(m,2H),7.06(d,J=8.4Hz, 1H),4.83-4.81(m,1H),4.31-4.30(m,5H),4.00-3.85(m,8H),3.52-3.39(m,2H).
[0452] Example 19: Preparation of 1-(1'-((2,3-dihydro-[1,4]dioxolane[2,3-b]pyridin-7-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropane-1-one (Compound 19):
[0453] In step 10 of Example 1, 2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as in Example 6 was used to obtain Compound 19 of Example 19.
[0454] MS (ESI) m / z 476.1 (M+H) + .
[0455] 1 H NMR(400MHz,DMSO-d6)δ8.28(s,1H),7.66(s,1H),7.33-7.27(m,2H),7.17-7.10(m,2H),4.87-4.85(m ,1H),4.75-4.68(m,1H),4.55-4.53(m,2H),4.40-4.21(m,9H),3.85-3.80(m,1H),3.70-3.55(m,2H).
[0456] Example 20: Preparation of (S)-1-(1'-((8-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 20):
[0457] Step 1: Preparation of 7-bromo-5-fluoro-2,3-dihydrobenzo[b][1,4]dioxin (Compound 20B)
[0458] 5-Bromo-3-fluorobenzene-1,2-diol (500 mg, 2.42 mmol), 1,2-dibromoethane (680.67 mg, 3.62 mmol), and potassium carbonate (1.0 g, 7.25 mmol) were added to N,N-dimethylformamide (5 mL), and the reaction system was stirred at 100°C for 16 hours. After the reaction was complete, the reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 20B.
[0459] MS (ESI) m / z 233.0 (M+H) + .
[0460] Step 2: Preparation of 7-(benzylthio)-5-fluoro-2,3-dihydrobenzo[b][1,4]dioxin (Compound 20C)
[0461] 7-Bromo-5-fluoro-2,3-dihydrobenzo[b][1,4]dioxin (330 mg, 1.42 mmol), benzylmercaptan (175.88 mg, 1.42 mmol), N,N-diisopropylethylamine (365.35 mg, 2.83 mmol), tris(dibenzylideneacetone)dipalladium-chloroform adduct (64.84 mg, 70.81 μmol), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (81.94 mg, 141.61 μmol) were added to 1,4-dioxane (6 mL), and the reaction system was stirred at 80°C for 16 hours. After completion of the reaction, the reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 20C.
[0462] MS (ESI) m / z 277.1 (M+H) + .
[0463] Step 3: Preparation of 8-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride (Compound 20D)
[0464] 7-(Benzylthio)-5-fluoro-2,3-dihydrobenzo[b][1,4]dioxin (200 mg, 723.78 μmol) and dichlorobenzene (285.20 mg, 1.45 mmol) were added to acetonitrile (7.5 mL), acetic acid (0.19 mL), and water (0.13 mL). The reaction system was stirred at 25°C for 16 hours until the reaction was complete. The reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 20D.
[0465] MS (ESI) m / z 253.0 (M+H) + .
[0466] In step 8 of Example 1, 8-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 20 of Example 20.
[0467] MS (ESI) m / z 475.1 (M+H) + .
[0468] 1 H NMR(400MHz,DMSO-d6)δ7.31-7.15(m,7H),4.73-4.70(d,J=13.0Hz,1H),4.42 -4.30(m,12H),3.90-3.87(m,1H),3.47-3.44(m,1H),3.33-3.31(m,1H).
[0469] Example 21: Preparation of 2-amino-1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylethan-1-one (Compound 21):
[0470] In step 4 of Example 6, 2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as Example 6 was used to obtain Compound 21 of Example 21.
[0471] MS (ESI) m / z 450.1 (M+H) + .
[0472] 1H-NMR (400MHz, DMSO-d6) δ7.91-7.89(m,2H),7.45-7.43(m,3H),7.32-7.22(m,5H),4.72-4.69(d,J=10.4Hz,1H),4.37-4.19(m,8H),2.12(s,2H).
[0473] Example 22: Preparation of 2-amino-1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)ethan-1-one (Compound 22):
[0474] In step 4 of Example 6, 2-((tert-butoxycarbonyl)amino)-2-(4-fluorophenyl)acetic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid, and the same preparation method as Example 6 was used to obtain Compound 22 of Example 22.
[0475] MS (ESI) m / z 468.1 (M+H) + .
[0476] 1 H-NMR (400MHz, DMSO-d6) δ7.91-7.89(d,J=8.8Hz,2H),7.46-7.27(m,5H),7.14-7.10(m,2H),4.69(s,1H),4.40-4.22(m,8H),2.34-2.32(m,2H).
[0477] Example 23: Preparation of 2-amino-1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(3-(trifluoromethyl)phenyl)ethan-1-one (Compound 23):
[0478] In step 4 of Example 6, 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)acetic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid, and the same preparation method as Example 6 was used to obtain Compound 23 of Example 23.
[0479] MS (ESI) m / z 518.1 (M+H) + .
[0480] 1H-NMR (400MHz, DMSO-d6) δ7.92-7.90 (d, J=8.8Hz, 2H), 7.67-7.51 (m, 4H), 7.46-7.44 (d, J= 8.5Hz,2H),4.80-4.75(d,J=13.7Hz,1H),4.53-4.21(m,8H),2.33-2.27(d,J=24.7Hz,2H).
[0481] Example 24: Preparation of 1-(1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-hydroxy-2-(2-methylbenzo[d]thiazol-4-yl)ethan-1-one (Compound 24):
[0482] Step 1: Preparation of 2-methyl-4-hydroxymethylbenzo[d]thiazole (Compound 24B):
[0483] 4-Bromo-2-methyl-1,3-benzothiazole (200 mg, 876.77 μmol) and tributyltin carbinol (430 mg, 1.34 mmol) were dissolved in 1,4-dioxane (5 mL). Tetrakis(triphenylphosphine)palladium (100 mg, 86.58 μmol) was added at room temperature. The resulting mixture was stirred at 100°C under nitrogen for 16 hours. After cooling to room temperature, the reaction mixture was quenched with saturated aqueous ammonium chloride. The aqueous phase was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 24B was obtained by separation and purification on a silica gel column.
[0484] MS (ESI) m / z 180.0 (M+H) + .
[0485] Step 2: Preparation of 2-methylbenzo[d]thiazole-4-carbaldehyde (Compound 24C):
[0486] To a solution of dimethyl sulfoxide (65 mg, 831.91 μmol) in dichloromethane (3 mL) was slowly added dropwise oxalyl chloride (70 mg, 551.50 μmol) at -78°C. The resulting mixture was stirred at -78°C under nitrogen for 0.5 hours. A solution of 2-methyl-4-hydroxymethylbenzo[d]thiazole (50 mg, 278.96 μmol) in dichloromethane (2 mL) was then added at the same temperature. The resulting mixture was stirred at this temperature for 1 hour. Triethylamine (0.3 mL) was then added and the resulting mixture was stirred for a further 0.5 hour before warming to room temperature and stirring for an additional 0.5 hour. After the reaction was complete, the reaction mixture was quenched with 10 mL of brine. The aqueous phase was extracted with ethyl acetate (10 mL x 3), and the combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 24C was purified by silica gel column chromatography.
[0487] MS (ESI) m / z 178.0 (M+H) +
[0488] Step 3: Preparation of 2-hydroxy-2-(2-methylbenzo[d]thiazol-4-yl)acetonitrile (Compound 24D):
[0489] 2-Methyl-1,3-benzothiazole-4-carbaldehyde (110 mg, 620.69 μmol) was dissolved in dichloromethane (3 mL). Trimethylsilyl cyanide (180 mg, 1.82 mmol) and zinc iodide (100 mg, 313.48 μmol) were added at room temperature. The resulting mixture was stirred at room temperature for 2 hours under nitrogen. The reaction mixture was quenched with 10 mL of brine. The aqueous phase was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 24D was obtained by separation and purification on a silica gel column.
[0490] MS (ESI) m / z 205.1 (M+H) +
[0491] Step 4: Preparation of methyl 2-hydroxy-2-(2-methylbenzo[d]thiazol-4-yl)acetate (Compound 24E):
[0492] 2-Hydroxy-2-(2-methyl-1,3-benzothiazol-4-yl)acetonitrile (110 mg, 538.56 μmol) was dissolved in methanol (3 mL), followed by the dropwise addition of concentrated hydrochloric acid (3 mL). The resulting mixture was stirred at 60°C under nitrogen for 2 hours. Upon completion of the reaction, the reaction mixture was concentrated and the pH adjusted to 7-8 with saturated aqueous sodium bicarbonate. The aqueous phase was extracted with ethyl acetate (10 mL x 3), and the combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 24E was obtained by separation and purification on a silica gel column.
[0493] MS (ESI) m / z 238.0 (M+H) +
[0494] Step 5: Preparation of 2-hydroxy-2-(2-methylbenzo[d]thiazol-4-yl)acetic acid (Compound 24F):
[0495] Methyl 2-hydroxy-2-(2-methyl-1,3-benzothiazol-4-yl)acetate (125 mg, 526.82 μmol) was dissolved in a mixture of tetrahydrofuran (3 mL) and water (3 mL). Lithium hydroxide monohydrate (100 mg, 2.44 mmol) was then added, and the resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated, and the pH of the solution was adjusted to 5-6 with 2N dilute hydrochloric acid. The aqueous phase was extracted with ethyl acetate (10 mL x 3), and the combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 24F was obtained by separation and purification on a silica gel column.
[0496] MS (ESI) m / z 224.1 (M+H) +
[0497] In step 4 of Example 6, 2-hydroxy-2-(2-methylbenzo[d]thiazol-4-yl)acetic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as Example 6 was used to obtain Compound 24 of Example 24.
[0498] MS (ESI) m / z 522.1 (M+H) + .
[0499] 1 H-NMR (400MHz, DMSO-d6) δ7.96-7.90(m,3H),7.65-7.29(m,5H),5.88-5.78(m,2H),4.85-4.59(m,2H),4.31-4.23(m,6H),2.77(s,3H).
[0500] Example 25: Preparation of (S)-1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropan-1-one (Compound 25):
[0501] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 25 of Example 25.
[0502] MS (ESI) m / z 474.1 (M+H) + .
[0503] 1 H-NMR (400MHz, DMSO-d6) δ9.69(s,1H),8.82(s,1H),8.35-8.33(d,J=8.0Hz,1H),7.96-7.94(d,J=8.0Hz,1H),7.30-7.27 (m,2H),7.13-7.08(m,2H),4.82(s,1H),4.69-4.66(d,J=12.0Hz,1H),4.35-4.16(m,8H),3.83(s,1H),3.64-3.61(m,1H)
[0504] Example 26: Preparation of 2-(3-chlorophenyl)-1-(1'-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-(methylamino)propan-1-one (Compound 26):
[0505] In step 10 of Example 1, 3-((tert-butyloxycarbonyl)(methyl)amino)-2-(3-chlorophenyl)propanoic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid, and the same preparation method as in Example 6 was used to obtain Compound 26 of Example 26.
[0506] MS (ESI) m / z 504.1 (M+H) + .
[0507] 1H-NMR(400MHz,DMSO-d6)δ7.36-7.24(m,6H),7.07-7.05(d,J=26.1,1H),4.40 -4.30(m,4H),4.02-3.92(m,8H),3.34(s,5H),3.07-3.05(m,1H),1.23(s,1H)
[0508] Example 27: Preparation of (S)-1-(1'-((3-fluoro-4-(oxazol-2-yl)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 27):
[0509] Step 1: Preparation of 4-bromo-N-(2,2-dimethoxyethyl)-2-fluorobenzamide (Compound 27B):
[0510] 4-Bromo-2-fluoro-benzoic acid (3 g, 13.70 mmol) was dissolved in dichloromethane (40 mL), followed by the addition of N,N-diisopropylethylamine (3.53 g, 27.40 mmol) and N,N-carbonyldiimidazole (2.17 g, 15.07 mmol). The reaction was stirred at 25°C for 30 minutes. 2,2-Dimethoxyethylamine (1.58 g, 15.07 mmol) was then added to the mixture, which was stirred at 25°C for an additional 4 hours. After the reaction was complete, the product was purified by silica gel column chromatography to obtain compound 27B.
[0511] MS (ESI) m / z 306.1 (M+H) +
[0512] Step 2: Preparation of 2-(4-bromo-2-fluorophenyl)oxazole (Compound 27C):
[0513] 4-Bromo-N-(2,2-dimethoxyethyl)-2-fluoro-benzamide (2.1 g, 6.86 mmol) was added to polyphosphoric acid (20 mL) and reacted at 90°C for 5 hours. After the reaction was complete, compound 27C was obtained by separation and purification on a silica gel column.
[0514] MS (ESI) m / z 243.0 (M+H) +
[0515] Step 3: Preparation of 2-(4-(benzylthio)-2-fluorophenyl)oxazole (Compound 27D):
[0516] To a solution of 2-(4-bromo-2-fluorophenyl)oxazole (0.8 g, 3.31 mmol) in 1,4-oxane (10 mL) were added benzylmercaptan (410.51 mg, 3.31 mmol), N,N-diisopropylethylamine (1.07 g, 8.26 mmol), tris(dibenzylideneacetone)dipalladium (342.09 mg, 330.52 μmol), and 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (382.74 mg, 661.04 μmol). The mixture was stirred at 90°C under nitrogen for 3 hours. After completion of the reaction, the product was separated and purified by silica gel column chromatography to obtain compound 27D.
[0517] MS (ESI) m / z 286.3 (M+H) +
[0518] Step 4: Preparation of 3-fluoro-4-(oxazol-2-yl)benzenesulfonyl chloride (Compound 27E):
[0519] 2-(4-Benzylsulfanyl-2-fluoro-phenyl)oxazole (0.7 g, 2.45 mmol) was dissolved in a mixture of dichloromethane (10 mL), water (176.63 mg, 9.81 mmol), and glacial acetic acid (735.98 mg, 12.27 mmol). Sulfuryl chloride (1.32 g, 9.81 mmol) was then added dropwise at 0°C. The resulting mixture was stirred at 20°C for 5 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain Compound 27E.
[0520] MS (ESI) m / z 262.0 (M+H) +
[0521] In step 8 of Example 1, 3-fluoro-4-(oxazol-2-yl)benzenesulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 27 of Example 27.
[0522] MS (ESI) m / z 484.1 (M+H) +
[0523] 1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.37-8.35(m,1H),8.02-8.01(m,1H),7.74-7.73(m,1H),7.53(s,1H),7.27-7.21(m,5H),4.8 1-4.79(t,J=0.8Hz,1H),4.71-4.68(d,J=1.2Hz,1H),4.35-4.21(m,7H),3.88-3.87(m,1H),3.62-3.58(m,1H),3.48-3.42(m,1H).
[0524] Example 28: Preparation of 2-(3-chloro-4-fluoro-2-methoxyphenyl)-1-(1'-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-(methylamino)propan-1-one (Compound 28):
[0525] Step 1: Preparation of methyl 2-(4-fluoro-2-methoxyphenyl)acetate (Compound 28B):
[0526] 2-(4-Fluoro-2-methoxyphenyl)acetic acid (1.0 g, 5.43 mmol) was dissolved in anhydrous methanol (100 mL), followed by the slow addition of thionyl chloride (1.29 g, 10.8 mmol). The reaction mixture was incubated at 70°C for 3 hours. After completion of the reaction, the product was purified by silica gel column chromatography to obtain compound 28B.
[0527] MS (ESI) m / z 199.1 (M+H) +
[0528] Step 2: Preparation of methyl 2-(4-fluoro-2-methoxyphenyl)acrylate (Compound 28C):
[0529] Methyl 2-(4-fluoro-2-methoxyphenyl)acetate (900.0 mg, 4.54 mmol) was dissolved in N,N-dimethylformamide (100.0 mL). Potassium carbonate (1.57 g, 11.4 mmol), paraformaldehyde (518.3 mg, 5.76 mmol), and tetrabutylammonium bromide (167.7 mg, 0.45 mmol) were then added. The reaction mixture was stirred at 60°C for 1 hour. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 28C.
[0530] MS (ESI) m / z 211.1 (M+H) +
[0531] Step 3: Preparation of methyl 2-(4-fluoro-2-methoxyphenyl)-3-(methylamino)propanoate (Compound 28D):
[0532] Methyl 2-(4-fluoro-2-methoxyphenyl)acrylate (515.0 mg, 2.45 mmol) was dissolved in a solution of methylamine in tetrahydrofuran (20 mL), and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 28D.
[0533] MS (ESI) m / z 242.1 (M+H) +
[0534] Step 4: Preparation of methyl 3-(tert-butoxycarbonyl)(methyl)amino)-2-(4-fluoro-2-methoxyphenyl)propanoate (Compound 28E):
[0535] Methyl 2-(4-fluoro-2-methoxyphenyl)-3-(methylamino)propanoate (406 mg, 1.68 mmol) was dissolved in dichloromethane (50 mL), followed by the addition of triethylamine (340 mg, 3.37 mmol). The reaction system was cooled to 0°C, and di-tert-butyl dicarbonate (440 mg, 2.02 mmol) was slowly added. The reaction solution was stirred at room temperature for 16 hours. After the reaction was complete, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 28E was obtained by separation and purification on a silica gel column.
[0536] MS (ESI) m / z 342.1 (M+H) +
[0537] Step 5: Preparation of methyl 3-(tert-butoxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluoro-2-methoxyphenyl)propanoate (Compound 28F):
[0538] Methyl 3-((tert-butoxycarbonyl)(methyl)amino)-2-(4-fluoro-2-methoxyphenyl)propanoate (393 mg, 1.15 mmol) was dissolved in N,N-dimethylformamide (100.0 mL), followed by the addition of N-chlorosuccinimide (461.3 mg, 3.45 mmol). The reaction mixture was allowed to react at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 28F was obtained by separation and purification on a silica gel column.
[0539] MS (ESI) m / z 376.1 (M+H) +
[0540] Step 6: Preparation of 3-((tert-Butyloxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluoro-2-methoxyphenyl)propanoic acid (Compound 28G):
[0541] Methyl 3-((tert-butoxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluoro-2-methoxyphenyl)propanoate (302 mg, 0.81 mmol) was dissolved in tetrahydrofuran (50 mL) and water (50 mL), followed by the addition of lithium hydroxide (38.6 g, 1.61 mmol). The reaction mixture was allowed to react at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 28G was obtained by separation and purification on a silica gel column.
[0542] MS (ESI) m / z 362.1 (M+H) +
[0543] In step 8 of Example 1, 2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxin[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-((tert-butoxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluoro-2-methoxyphenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain compound 28 of Example 28.
[0544] MS (ESI) m / z 552.1 (M+H) +
[0545] 1 H-NMR (400MHz, DMSO-d6) δ7.25-7.21(m,3H),7.13-7.10(d,J=8.0Hz,1H),7.04-7.02(d,J=8.0Hz,1H),4 .45-4.15(m,6H),3.98(s,6H),3.78(s,3H),2.96-2.94(d,J=8.0Hz,1H),2.20(s,2H),1.41-0.82(m,4H)
[0546] Example 29: Preparation of (1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)(4-phenyltetrahydro-2H-pyran-4-yl)methanone (Compound 29):
[0547] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 4-phenyltetrahydro-2H-pyran-4-carboxylic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 29 of Example 29.
[0548] MS (ESI) m / z 496.2 (M+H)+
[0549] 1 H-NMR (400MHz, DMSO-d6) δ9.68(s,1H),8.78-8.75(d,J=1.9Hz,1H),8.32-8.29(d,J=8.5Hz,1H),7.92-7.87(m,1H),7.37-7.31(m,2H) ,7.28-7.19(m,3H),4.31-4.16(m,6H),3.97-3.87(m,2H),3.71-3.67(m,2H),3.56-3.44(m,2H),2.17-2.07(m,2H),1.83-1.76(m,2H).
[0550] Example 30: Preparation of (S)-1-(1'-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropan-1-one (Compound 30):
[0551] In step 8 of Example 1, 2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxin[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, (S)-2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 30 of Example 30.
[0552] MS (ESI) m / z 475.1 (M+H) + .
[0553] 1 H NMR (400MHz, DMSO-d6) δ7.34-7.24(m,4H),7.14-7.10(m,2H),7.06(d,J=8.4Hz, 1H),4.83-4.81(m,1H),4.31-4.30(m,5H),4.00-3.85(m,8H),3.52-3.39(m,2H).
[0554] Example 31: Preparation of (R)-1-(1'-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropan-1-one (Compound 31):
[0555] In step 8 of Example 1, 2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxin[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, (R)-2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 31 of Example 31.
[0556] MS (ESI) m / z 475.1 (M+H) + .
[0557] 1 H NMR (400MHz, DMSO-d6) δ7.34-7.24(m,4H),7.14-7.10(m,2H),7.06(d,J=8.4Hz, 1H),4.83-4.81(m,1H),4.31-4.30(m,5H),4.00-3.85(m,8H),3.52-3.39(m,2H).
[0558] Example 32: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-(naphthalen-2-yl)propan-1-one (Compound 32):
[0559] Step 1: Preparation of methyl 3-hydroxy-2-(naphthalen-2-yl)propanoate (Compound 32B):
[0560] Methyl 2-(naphthalen-2-yl)acetate (1.0 g, 4.99 mmol) and paraformaldehyde (449.9 mg, 4.99 mmol) were dissolved in dimethyl sulfoxide (40.0 mL), followed by the addition of sodium methoxide (27.0 mg, 0.50 mmol). The reaction mixture was allowed to react at room temperature for 4 hours. After the reaction was complete, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 32B was obtained by separation and purification on a silica gel column.
[0561] MS (ESI) m / z 231.1 (M+H) +
[0562] Step 2: Preparation of 3-hydroxy-2-(naphthalen-2-yl)propanoic acid (Compound 32C):
[0563] Methyl 3-hydroxy-2-(naphthalen-2-yl)propanoate (260.0 mg, 1.13 mmol) was dissolved in a mixture of tetrahydrofuran (60.0 mL) and water (40.0 mL). Sodium hydroxide (45.2 mg, 1.13 mmol) was then added, and the reaction mixture was stirred at room temperature for 5 hours. After completion of the reaction, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After concentration, the mixture was used directly in the next reaction.
[0564] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(naphthalen-2-yl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 32 of Example 32.
[0565] MS (ESI) m / z 506.1 (M+H) +
[0566] 1H-NMR (400MHz, DMSO-d6) δ9.64 (s, 1H), 8.78-8.77 (d, J = 4.0Hz, 1H), 8.31-8. 29(d,J=8.0Hz,1H),7.92-7.90(m,1H),7.85-7.80(m,3H),7.72(s,1H),7.47 -7.44(m,2H),7.40-7.33(m,1H),4.80-4.78(m,1H),4.72(s,1H),4.34-4.26 (m,6H),4.19(s,1H),3.95-3.92(m,1H),3.77-3.74(m,1H),3.57-3.53(m,1H)
[0567] Example 33: Preparation of 1-(1'-(benzo[d]thiazol-6-ylsulfonyl(-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)propan-1-one (Compound 33):
[0568] Step 1: Preparation of methyl 2-(3-(4-methylpiperazin-1-yl)phenyl)acetate (Compound 33B)
[0569] Methyl 2-(3-bromophenyl)acetate (5.0 g, 21.83 mmol), 1-methylpiperazine (3.3 g, 32.74 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.3 g, 2.18 mmol), and cesium carbonate (10.7 g, 32.74 mmol) were dissolved in toluene (100.0 mL). Tris(dibenzylideneacetone)dipalladium (399.8 mg, 0.44 mmol) was then added. After the addition was complete, the reaction system was placed under a nitrogen atmosphere and heated to 110°C with stirring for 16 hours. After the reaction was complete, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (150.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 33B was obtained by separation and purification on a silica gel column.
[0570] MS (ESI) m / z 249.2 (M+H) +
[0571] Step 2: Preparation of methyl 3-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)propanoate (Compound 33C)
[0572] Methyl 2-(3-(4-methylpiperazin-1-yl)phenyl)acetate (1.8 g, 7.25 mmol) and paraformaldehyde (685.6 mg, 7.61 mmol) were dissolved in dimethyl sulfoxide (90.0 mL), followed by the addition of sodium methoxide (39.2 mg, 0.72 mmol). The reaction mixture was incubated at 50°C for 4 hours. The reaction mixture was diluted with water, and the aqueous phase was extracted with dichloromethane (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 33C was obtained by separation and purification on a silica gel column.
[0573] MS (ESI) m / z 279.2 (M+H) +
[0574] Step 2: Preparation of 3-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)propanoic acid (Compound 33D)
[0575] Methyl 3-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)propanoate (90.0 mg, 0.32 mmol) was dissolved in methanol (2.5 mL) and water (2.5 mL). Sodium hydroxide (25.9 mg, 0.64 mmol) was then added, and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid, concentrated, and used directly in the next reaction.
[0576] MS (ESI) m / z 265.2 (M+H) +
[0577] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain compound 33 of Example 33.
[0578] MS (ESI) m / z 554.2 (M+H) + .
[0579] 1H NMR(400MHz, DMSO-d6)δ9.68(s,1H),8.81-8.80(d,J=1.7Hz,1H),8.33-8.31(d,J =8.6Hz,1H),7.5-7.94(m,1H),7.11-7.07(m,1H),6.78-6.76(m,2H),6.64-6.62( d,J=7.6Hz,1H),4.71-4.63(m,2H),4.42-4.11(m,7H),3.88-3.81(m,1H),3.54-3 .49(m,1H),3.44-3.38(m,1H),3.17-2.97(m,4H),2.47-2.38(m,4H),2.21(s,3H).
[0580] Example 34: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propan-1-one (Compound 34):
[0581] Step 1: Preparation of methyl 2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)acetate (Compound 34B)
[0582] Methyl 2-(4-bromophenyl)acetate (1.0 g, 4.37 mmol), (1-methyl-1H-pyrazol-4-yl)boronic acid (604.7 mg, 4.80 mmol), and potassium carbonate (1.2 g, 8.74 mmol) were dissolved in a mixture of dioxane and water (4:1, 20.0 mL). Tetrakis(triphenylphosphine)palladium (504.5 mg, 0.44 mmol) was then added. After the addition was complete, the reaction system was placed under a nitrogen atmosphere and heated to 80°C with stirring for 16 hours. After the reaction was complete, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (50.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 34B was obtained by separation and purification on a silica gel column.
[0583] MS (ESI) m / z 231.2 (M+H) +
[0584] Step 2: Preparation of methyl 3-hydroxy-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoate (Compound 34C)
[0585] Methyl 2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)acetate (800.0 mg, 3.47 mmol) and paraformaldehyde (313.0 mg, 3.47 mmol) were dissolved in dimethyl sulfoxide (50.0 mL), followed by the addition of sodium methoxide (62.6 mg, 0.35 mmol). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 34C was obtained by separation and purification on a silica gel column.
[0586] MS (ESI) m / z 261.2 (M+H) +
[0587] Step 3: Preparation of 3-hydroxy-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoic acid (Compound 34D)
[0588] Methyl 3-hydroxy-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoate (200.0 mg, 0.77 mmol) was dissolved in a mixture of methanol (6.0 mL) and water (4.0 mL). Sodium hydroxide (61.5 mg, 1.54 mmol) was then added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid, concentrated, and used directly in the next reaction.
[0589] MS (ESI) m / z 267.1 (M+H) +
[0590] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain compound 34 of Example 34.
[0591] MS (ESI) m / z 536.1 (M+H) +
[0592] 1H NMR(400MHz, DMSO-d6)δ9.67(s,1H),8.81-8.80(d,J=1.6Hz,1H),8.32-8.31(d,J =8.6Hz,1H),8.06(s,1H),7.95-7.92(d,J=8.6,1H),7.79(s,1H),7.45-7.43(d,J= 8.2Hz,2H),7.20-7.18(d,J=8.2Hz,2H),4.77-4.74(t,J=5.3Hz,1H),4.68-4.65(m ,1H),4.44-4.12(m,7H),3.90-3.81(m,4H),3.60-3.54(m,1H),3.49-3.40(m,1H).
[0593] Example 35: Preparation of (S)-3-hydroxy-1-(1'-((2-methylbenzo[d]thiazol-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 35):
[0594] Step 1: Preparation of 6-(benzylthio)-2-methylbenzo[d]thiazole (Compound 35B)
[0595] 6-Bromo-2-methylbenzo[d]thiazole (2.0 g, 8.77 mmol), benzyl mercaptan (1.3 g, 10.52 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.5 g, 0.88 mmol), and N,N-diisopropylethylamine (3.4 g, 26.30 mmol) were dissolved in 1,4-dioxane (50.0 mL). Tris(dibenzylideneacetone)dipalladium (401.4 mg, 0.44 mmol) was then added. After the addition, the reaction system was heated to 100°C under a nitrogen atmosphere and stirred for 16 hours. After the reaction was complete, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (150.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 35B was obtained by separation and purification on a silica gel column.
[0596] MS (ESI) m / z 272.1 (M+H) +
[0597] Step 2: Preparation of 2-methylbenzo[d]thiazole-6-sulfonyl chloride (Compound 35C)
[0598] 6-(Benzylthio)-2-methylbenzo[d]thiazole (1.0 g, 3.68 mmol) was dissolved in a mixture of acetonitrile (40.0 mL), acetic acid (1.5 mL), and water (1.0 mL). Dichlorobenzene (1.5 g, 7.37 mmol) was then added to the reaction system at 0°C. The reaction mixture was allowed to react at room temperature for 4 hours. After the reaction was complete, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 35C was obtained by separation and purification on a silica gel column.
[0599] MS (ESI) m / z 248.0 (M+H) +
[0600] In step 8 of Example 1, 2-methylbenzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 35 of Example 35.
[0601] MS (ESI) m / z 470.1 (M+H) +
[0602] 1 H NMR (400MHz, DMSO-d6) δ8.66-8.65(d,J=1.6Hz,1H),8.15-8.13(d,J=8.5Hz,1H),7.89-7.86(d,J=8.5,1H),7.29-7.19(m,5H),4.79 -4.76(t,J=5.2Hz,1H),4.69-4.65(m,1H),4.33-4.15(m,7H),3.90-3.84(m,1H),3.61-3.57(m,1H),3.47-3.42(m,1H),2.87(s,3H)
[0603] Example 36: Preparation of 1-(1'-((2,2-difluorobenzo[d][1,3]dioxolane-5-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropane-1-one (Compound 36):
[0604] Step 1: Preparation of 5-(benzylthio)-2,2-difluorobenzo[d][1,3]dioxolane (Compound 36B)
[0605] 5-Bromo-2,2-difluoro-1,3-benzodioxolane (400 mg, 1.69 mmol) and benzylmercaptan (280 mg, 2.25 mmol) were dissolved in dioxane (10 mL). Sodium tert-butoxide (400.00 mg, 4.16 mmol), palladium acetate (40.00 mg, 178.57 μmol), and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (100 mg, 160.60 μmol) were then added. The reaction system was stirred at 100°C under a nitrogen atmosphere for 16 hours. After cooling to room temperature, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (30.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 36B was obtained by separation and purification on a silica gel column.
[0606] MS (ESI) m / z 280.1 (M+H) +
[0607] Step 2: Preparation of 2,2-difluorobenzo[d][1,3]dioxolane-5-sulfonyl chloride (Compound 36C)
[0608] 2,2-Difluoro-5-phenylthio-1,3-benzodioxolane (270 mg, 963.29 μmol) was dissolved in acetonitrile (20 mL), acetic acid (0.75 mL), and water (0.5 mL). 5-Dimethylimidazolidine-2,4-dione (380 mg, 1.93 mmol) was added at 0°C. After addition, the reaction system was placed under a nitrogen atmosphere and stirred at room temperature for 2 hours. After completion of the reaction, the reaction solution was concentrated and the pH was adjusted to 6-7 with saturated sodium bicarbonate aqueous solution. The aqueous phase was extracted with ethyl acetate (30.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 36C was obtained by separation and purification on a silica gel column.
[0609] MS (ESI) m / z 257.0 (M+H) +
[0610] In step 8 of Example 1, 2,2-difluorobenzo[d][1,3]dioxolane-5-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 36 of Example 36.
[0611] MS (ESI) m / z 497.1 (M+H) + .
[0612] 1H-NMR (400MHz, DMSO-d6) δ7.92 (s, 1H), 7.74-7.68 (m, 2H), 7.31-7.28 (m, 2H), 7.11 (t, J = 8.8Hz, 2H), 4.83-4. 80(m,1H),4.70(d,J=12.4Hz,1H),4.38-4.19(m,7H),3.87-3.81(m,1H),3.66-3.63(m,1H),3.47-3.42(m,1H)
[0613] Example 37: Preparation of (1'-((4-(difluoromethoxy)phenyl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)(3-phenyltetrahydrofuran-3-yl)methanone (Compound 37):
[0614] Step 1: Preparation of 4-phenyl-3,6-dihydro-2H-pyran (Compound 37B)
[0615] Arylmagnesium bromide solution (2.8N, 12.86 mL, 36 mmol) was slowly added to a solution of tetrahydro-4H-pyran-4-one (3.0 g, 29.97 mmol) in tetrahydrofuran (300 mL) at -78°C. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. Compound 37B was obtained by separation and purification on a silica gel column.
[0616] MS (ESI) m / z 161.1 (M+H) + .
[0617] Step 2: Preparation of 3-phenyltetrahydrofuran-3-carbaldehyde (Compound 37C)
[0618] 4-Phenyl-3,6-dihydro-2H-pyran (1 g, 6.24 mmol) and sodium carbonate (1.7 g, 16.04 mmol) were dissolved in dichloromethane (150 mL). m-Chloroperbenzoic acid (2.4 g, 13.95 mmol) was added at 0°C, and the mixture was stirred for 3 hours at room temperature under a nitrogen atmosphere. After the reaction was complete, a saturated aqueous sodium carbonate solution (50 mL) was added to the system, followed by ethyl acetate (50 mL x 3) until the reaction mixture and the organic layer were separated. The organic extract was dried over anhydrous magnesium sulfate. Compound 37C was purified by silica gel column chromatography.
[0619] MS (ESI) m / z 177.1 (M+H) + .
[0620] Step 3: Preparation of 3-phenyltetrahydrofuran-3-carboxylic acid (Compound 37D)
[0621] 3-Phenyltetrahydrofuran-3-carbaldehyde (250 mg, 1.42 mmol) and 2-methylbut-2-ene (2.25 mL) were dissolved in n-butanol (45 mL) and 2-methylbut-2-ene (2.25 mL). Sodium chlorite (520 mg, 4.62 mmol) and potassium dihydrogen phosphate (440 mg, 3.24 mmol) were added at room temperature. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 0.5 hour. After the reaction was complete, the mixture was extracted with ethyl acetate (10 mL x 3), and the organic phases were combined. Compound 37D was obtained by separation and purification on a silica gel column.
[0622] MS (ESI) m / z 193.1 (M+H) + .
[0623] In step 4 of Example 6, 3-phenyltetrahydrofuran-3-carboxylic acid was used instead of 3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid, and the same preparation method as in Example 6 was used to obtain Compound 37 of Example 37.
[0624] MS (ESI) m / z 491.1 (M+H) +
[0625] 1 H-NMR(400MHz,DMSO-d6)δ7.88-7.84(m,2H),7.63-7.21(m,8H),4.27-4.17( m,7H),3.99(s,2H),3.83-3.77(m,3H),2.60-2.55(m,1H),2.23-2.16(m,1H)
[0626] Example 38: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(3-chloro-4-fluorophenyl)-3-(methylamino)propan-1-one (Compound 38):
[0627] Step 1: Preparation of methyl 2-(3-chloro-4-fluorophenyl)acrylate (Compound 38B)
[0628] (3-Chloro-4-fluorophenyl)boronic acid (1.0 g, 5.74 mmol), methyl 2-bromoacrylate (860.2 mg, 32.74 mmol), and potassium phosphate (2.2 g, 10.43 mmol) were dissolved in a 4:1 mixture of dioxane and water (25.0 mL). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (378.5 mg, 0.52 mmol) was then added. After the addition was complete, the reaction system was placed under a nitrogen atmosphere and heated to 80°C with stirring for 16 hours. After the reaction was complete, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (150.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 38B was obtained by separation and purification on a silica gel column.
[0629] MS (ESI) m / z 215.2 (M+H) +
[0630] Step 2: Preparation of methyl 2-(3-chloro-4-fluorophenyl)-3-(methylamino)propanoate (Compound 38C)
[0631] Methyl 2-(3-chloro-4-fluorophenyl)acrylate (395.0 mg, 1.84 mmol) was dissolved in methylamine in tetrahydrofuran (8.0 mL). The reaction mixture was allowed to react at room temperature for 16 hours. After the reaction was complete, the product was separated and purified on a silica gel column to obtain compound 38C.
[0632] MS (ESI) m / z 246.1 (M+H) +
[0633] Step 3: Preparation of methyl 3-(tert-butoxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluorophenyl)propanoate (Compound 38D)
[0634] 2-(3-chloro-4-fluorophenyl)-3-(methylamino)propanoate (276.0 mg, 1.12 mmol), N,N-dimethylaminopyridine (13.7 mg, 0.11 mmol), and triethylamine (227.4 mg, 2.25 mmol) were dissolved in dichloromethane (5 mL). Di-tert-butyl dicarbonate (244.9 mg, 1.12 mmol) was then added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified on a silica gel column to obtain compound 38D.
[0635] MS (ESI) m / z 346.1 (M+H) +
[0636] Step 4: Preparation of 3-((tert-Butyloxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluorophenyl)propanoic acid (Compound 38E)
[0637] Methyl 3-(tert-butoxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluorophenyl)propanoate (245.0 mg, 0.71 mmol) was dissolved in a mixture of methanol (5.0 mL) and water (5.0 mL), followed by the addition of lithium hydroxide monohydrate (59.5 mg, 1.42 mmol). The reaction mixture was stirred at room temperature for 3 hours. After completion, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The resulting white solid was concentrated and used directly in the next reaction.
[0638] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-((tert-butoxycarbonyl)(methyl)amino)-2-(3-chloro-4-fluorophenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain compound 38 of Example 38.
[0639] MS (ESI) m / z 521.1 (M+H) +
[0640] 1 H NMR(400MHz, DMSO-d6)δ9.69(s,1H),8.82(s,1H),8.37-8.31(d,J=8.5Hz,1H),7.98-7.91(d,J=8.5Hz,1H),7.49-7.42(d,J=8.5Hz,1H), 7.37-7.21(m,2H),4.70-4.61(m,1H),4.43-4.13(m,7H),3.73-3.64(t,J=7.0Hz,1H),3.00-2.89(m,1H),2.64-2.55(m,2H),2.21(s,3H).
[0641] Example 39: Preparation of (S)-3-hydroxy-1-(1'-((4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 39):
[0642] Step 1: Preparation of 6-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (Compound 39B)
[0643] 6-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.5 g, 2.34 mmol), paraformaldehyde (140.3 mg, 4.67 mmol), and sodium cyanoborohydride (234.8 mg, 3.74 mmol) were dissolved in acetonitrile (30 mL). After addition, the reaction system was stirred at room temperature for 0.5 hour, followed by the addition of glacial acetic acid (0.5 mL). After completion of the reaction, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 39B was obtained by separation and purification on a silica gel column.
[0644] MS (ESI) m / z 228.0 (M+H) +
[0645] Step 2: Preparation of 6-(benzylthio)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (Compound 39C)
[0646] 6-Bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.45 g, 1.77 mmol), benzyl mercaptan (0.26 g, 3.54 mmol), tris(dibenzylideneacetone)dipalladium (0.09 g, 0.09 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.1 g, 0.18 mmol), and N,N-diisopropylethylamine (686 mg, 5.31 mmol) were dissolved in a mixture of methanol (7.0 mL) and water (3.0 mL). The reaction system was stirred at room temperature overnight. After the reaction was complete, compound 39C was obtained by separation and purification on a silica gel column.
[0647] MS (ESI) m / z 272.3 (M+H) +
[0648] Step 3: Preparation of 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-sulfonyl chloride (Compound 39D)
[0649] 6-(Benzylthio)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (375 mg, 1.38 mmol) was added to a mixed solvent (acetonitrile:acetic acid:water = 40:1.5:1) (25 mL). 1,3-Dichloro-5,5-dimethylhydantoin (545 mg, 2.76 mmol) was added with stirring at 0°C. The mixture was then stirred at room temperature for 3 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 39D.
[0650] In step 8 of Example 1, 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 39 of Example 39.
[0651] MS (ESI) m / z 470.2 (M+H) +
[0652] 1 H NMR (400MHz, DMSO-d6) δ7.29-7.21(m,5H),7.01-6.99(m,1H),6.92-6.87(m,2H),4.79-4.76(t,J=10.8Hz,1H),4.73-4.70 (t,J=13.2Hz,1H),4.31-4.24(m,9H),3.89-3.88(m,1H),3.62-3.60(m,1H),3.48-3.47(m,1H),3.28(s,2H),2.89(s,3H).
[0653] Example 40: Preparation of (S)-6-((1'-(3-hydroxy-2-phenylpropionyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)sulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 40):
[0654] In step 8 of Example 1, 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 40 of Example 40.
[0655] MS (ESI) m / z 470.1 (M+H) +
[0656] 1 H NMR(400MHz,DMSO-d6)δ10.92(s,1H),7.38-7.17(m,8H),4.81-4.79(m,1H),4.78-4.7 0(m,3H),4.29-4.26(m,7H),3.91-3.87(m,1H),3.63-3.61(m,1H),3.46-3.42(m,1H).
[0657] Example 41: Preparation of (S)-6-((1'-(3-hydroxy-2-phenylpropionyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)sulfonyl)-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 41):
[0658] In step 8 of Example 1, 4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 41 of Example 41.
[0659] MS (ESI) m / z 484.2 (M+H) +
[0660] 1 H-NMR(400MHz,DMSO-d6)δ7.48-7.46(d,2H),7.39(s,1H),7.30-7.23(m,6H),4.81-4. 70(m,4H),4.31-4.19(m,8H),3.91-3.85(m,1H),3.63-3.60(m,1H),3.51-3.43(m,2H).
[0661] Example 42: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(3-chloro-4-fluorophenyl)-3-(dimethylamino)propan-1-one (Compound 42):
[0662] Step 1: Preparation of ethyl 3-amino-2-(3-chloro-4-fluorophenyl)propanoate (Compound 42B)
[0663] Ethyl 3-(tert-butoxycarbonylamino)-2-(3-chloro-4-fluorophenyl)propionate (1 g, 2.89 mmol) was dissolved in hydrochloric acid-1,4-dioxane (200 mL). The reaction system was then placed in a nitrogen atmosphere and stirred at room temperature for 6 hours. After the reaction was complete, the mixture was separated and purified by silica gel column to obtain compound 42B.
[0664] MS (ESI) m / z 246.1 (M+H) +
[0665] Step 2: Preparation of ethyl 2-(3-chloro-4-fluorophenyl)-3-(dimethylamino)propanoate (Compound 42C)
[0666] Ethyl 3-amino-2-(3-chloro-4-fluoro-phenyl)propionate (801 mg, 3.26 mmol) was dissolved in methanol (30 mL). N,N-diisopropylethylamine (842.74 mg, 6.52 mmol) and paraformaldehyde (587.39 mg, 6.52 mmol) were added at room temperature. After the addition, the reaction system was placed in a nitrogen atmosphere and stirred at 25°C for 6 hours. After the reaction, the mixture was separated and purified by silica gel column chromatography to obtain compound 42C.
[0667] MS (ESI) m / z 274.1 (M+H) +
[0668] Step 3: Preparation of 2-(3-chloro-4-fluorophenyl)-3-(dimethylamino)propanoic acid (Compound 42D)
[0669] Ethyl 2-(3-chloro-4-fluoro-phenyl)-3-(dimethylamino)propanoate (391 mg, 1.43 mmol) was dissolved in ethanol (7 mL) and water (7 mL). Lithium hydroxide (119.99 mg, 2.86 mmol) was added at room temperature. After the addition was completed, the reaction system was placed in a nitrogen atmosphere at 50°C and stirred for 16 hours. After the reaction was completed, the product was separated and purified by silica gel column chromatography to obtain compound 42D.
[0670] MS (ESI) m / z 246.2 (M+H) +
[0671] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(3-chloro-4-fluorophenyl)-3-(dimethylamino)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 42 of Example 42.
[0672] MS (ESI) m / z 535.1 (M+H) +
[0673] 1H-NMR (400MHz, DMSO-d6) δ9.68(s,1H),8.82(s,1H),8.35-8.33(d,J=8.5Hz,1H),7.96-7.94(d,J=8.5Hz,1H),7.49-7.47(d,J=7.1Hz,1H) ,7.33-7.29(m,2H),4.68-4.65(d,J=13.2Hz,1H),4.48-4.15(m,7H),3.74-3.71(m,1H),2.78-2.67(m,1H),2.37-2.33(m,1H),2.09(s,6H)
[0674] Example 43: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)ethan-1-one (Compound 43):
[0675] Step 1: Preparation of 2-(3-bromophenyl)-2-hydroxyacetic acid (Compound 43B)
[0676] 3-Bromobenzaldehyde (1.85 g, 10.0 mmol) was added to tetrahydrofuran (40 mL). Trimethylsilyl cyanide (1.1 g, 11.0 mmol) was added to the solution, and one drop of 1N tetrabutylammonium fluoride in tetrahydrofuran was added dropwise. The reaction mixture was stirred at room temperature for 1 hour, and the solvent was removed by rotary evaporation under reduced pressure. 6N aqueous hydrochloric acid (10 mL) was added to the residual oil, and the mixture was heated under reflux for 3 hours. The reaction mixture was cooled to 0°C and 10N sodium hydroxide solution was added dropwise to adjust the pH to 1. After the reaction was complete, the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 43B was obtained by separation and purification on a silica gel column.
[0677] MS (ESI) m / z 230.1 (MH) +
[0678] Step 2: Preparation of methyl 2-(3-bromophenyl)-2-hydroxyacetate (Compound 43C)
[0679] (3-Bromophenyl)hydroxyacetic acid (500 mg, 2.16 mmol) was added to methanol (10 mL). Thionyl chloride (773 mg, 6.49 mmol) was added dropwise to the reaction mixture at room temperature. After the addition was complete, the reaction system was stirred at 60°C for 3 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 43C.
[0680] MS (ESI) m / z 268.1 (M+Na) +
[0681] Step 3: Preparation of methyl 2-(3-bromophenyl)-2-((tert-butyldiphenylsilyl)oxy)acetate (Compound 43D)
[0682] Methyl 2-(3-bromophenyl)-2-hydroxyacetate (400 mg, 1.63 mmol), tert-butylchlorodiphenylsilane (539 mg, 1.96 mmol), and imidazole (278 mg, 4.08 mmol) were added to tetrahydrofuran (8 mL) and stirred at 40°C for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 43D.
[0683] MS (ESI) m / z 507.2 (M+Na) +
[0684] Step 4: Preparation of methyl 2-((tert-butyldiphenylsilyl)oxy)-2-(3-(4-methylpiperazin-1-yl)phenyl)acetate (Compound 43E)
[0685] Methyl 2-(3-bromophenyl)-2-((tert-butyldiphenylsilyl)oxy)acetate (400 mg, 0.83 mmol), 1-methylpiperazine (124 mg, 1.24 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (48 mg, 0.08 mmol), tris(dibenzylideneacetone)dipalladium (43 mg, 0.04 mmol), and cesium carbonate (540 mg, 1.65 mmol) were added to 1,4-dioxane (10 mL). After nitrogen was replaced three times, the mixture was stirred at 100°C overnight. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain compound 43E.
[0686] MS (ESI) m / z 542.6 (M+Na) +
[0687] Step 5: Preparation of methyl 2-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)acetate (Compound 43F)
[0688] Methyl 2-((tert-butyldiphenylsilyl)oxy)-2-(3-(4-methylpiperazin-1-yl)phenyl)acetate (350 mg, 0.74 mmol) was dissolved in tetrahydrofuran (10 mL), tetrabutylammonium fluoride (386 mg, 1.48 mmol) was added, and the reaction system was stirred at 50°C overnight. After completion of the reaction, the mixture was diluted with 50 mL of water and extracted with ethyl acetate (50 mL x 3) and water. The combined organic phases were dried over anhydrous sodium sulfate and purified by silica gel column chromatography to obtain compound 43F.
[0689] MS (ESI) m / z 256.3 (M+H)+
[0690] Step 6: Preparation of 2-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)acetic acid (Compound 43G)
[0691] Methyl 2-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)acetate (150 mg, 0.56 mmol) and sodium hydroxide (45 mg, 1.12 mmol) were dissolved in a mixture of methanol (3 mL) and water (3 mL). The reaction system was stirred at 25°C for 3 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain Compound 43G.
[0692] MS (ESI) m / z 249.2 (MH) +
[0693] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-hydroxy-2-(3-(4-methylpiperazin-1-yl)phenyl)acetic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain compound 43 of Example 43.
[0694] MS (ESI) m / z 540.2 (M+H) +
[0695] 1H NMR (400MHz, DMSO-d6) δ9.68 (s, 1H), 8.80-8.79 (d, J = 1.6Hz, 1H), 8.34-8.32 (d,J=8.4Hz,1H),7.95-7.92(m,1H),7.14-7.10(t,J=15.6Hz,1H),6.86-6.69 (m,3H),5.69-5.67(d,J=5.2Hz,1H),4.93-4.92(d,J=5.6Hz,1H),4.62-4.22 (m,8H),3.09-3.06(t,J=10Hz,4H),2.43-2.41(t,J=9.6Hz,4H),2.21(s,3H).
[0696] Example 44: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-(4-methoxyphenyl)propan-1-one (Compound 44):
[0697] Step 1: Preparation of methyl 3-hydroxy-2-(4-methoxyphenyl)propanoate (Compound 44B)
[0698] Methyl 2-(4-methoxyphenyl)acetate (1.0 g, 5.55 mmol), paraformaldehyde (524.4 mg, 5.83 mmol), and sodium methoxide (15 mg, 0.28 mmol) were dissolved in dimethyl sulfoxide (10 mL). After addition, the reaction system was stirred at room temperature for 3 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 44B.
[0699] MS (ESI) m / z 211.0 (M+H) +
[0700] Step 2: Preparation of 3-hydroxy-2-(4-methoxyphenyl)propionic acid (Compound 44C)
[0701] Methyl 3-hydroxy-2-(4-methoxyphenyl)propanoate (0.49 g, 2.33 mmol) and lithium hydroxide monohydrate (0.2 g, 4.66 mmol) were dissolved in a mixture of methanol (7.0 mL) and water (3.0 mL). After addition, the reaction system was stirred at room temperature overnight. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 44C.
[0702] MS (ESI) m / z 197.0 (M+H) +
[0703] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(4-methoxyphenyl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 44 of Example 44.
[0704] MS (ESI) m / z 486.1 (M+H) +
[0705] 1 H NMR (400MHz, DMSO-d6) δ9.67 (s, 1H), 8.81-8.80 (d, J = 2Hz, 1H), 8.34-8.32 (d, J = 8.8Hz, 1H), 7.95-7.92 (m, 1H), 7.14-7.12 (d, J = 8.8Hz, 2H) ,6.83-6.81(d,J=8.8Hz,2H),4.73-4.63(m,2H),4.34-4.23(m,6H),3.83-3.80(m,1H),3.69(s,3H),3.54-3.50(m,1H),3.41-3.37(m,2H).
[0706] Example 45: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-(p-tolyl)propan-1-one (Compound 45):
[0707] Step 1: Preparation of methyl 3-hydroxy-2-(p-tolyl)propionate (Compound 45B)
[0708] Methyl 2-(p-tolyl)acetate (0.5 g, 3.05 mmol) and paraformaldehyde (287.8 mg, 3.20 mmol) were dissolved in dimethyl sulfoxide (2.0 mL), followed by the addition of sodium methoxide (8.2 mg, 0.31 mmol). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the product was separated and purified on a silica gel column to yield compound 45B.
[0709] MS (ESI) m / z 195.1 (M+H) +
[0710] Step 2: Preparation of 3-hydroxy-2-(p-tolyl)propanoic acid (Compound 45C)
[0711] Methyl 2-(p-tolyl)acetate (380.0 mg, 1.96 mmol) was dissolved in a mixture of methanol (9.0 mL) and water (6.0 mL). Sodium hydroxide (156.5 mg, 3.91 mmol) was then added, and the reaction mixture was stirred at 25°C for 16 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The product was concentrated and used directly in the next reaction.
[0712] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(p-tolyl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 45 of Example 45.
[0713] MS (ESI) m / z 470.1 (M+H) +
[0714] 1 H NMR (400MHz, DMSO-d6) δ9.68(s,1H),8.81(s,1H),8.34-8.32(d,J=9.1Hz,1H),7.95-7.93(d,J=8.4Hz,1H),7.09-7.08(m,4H),4.73 -4.60(m,2H),4.34-4.07(m,7H),3.85-3.84(m,1H),3.54-3.52(m,1H),3.40-3.38(m,1H),2.23(s,3H).
[0715] Example 46: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(3-fluorophenyl)-3-hydroxypropane-1-one (Compound 46):
[0716] Step 1: Preparation of methyl 2-(3-fluorophenyl)-3-hydroxypropionate (Compound 46B)
[0717] Methyl 2-(3-fluorophenyl)acetate (1.0 g, 5.95 mmol) was dissolved in dimethyl sulfoxide (10 mL). Sodium methoxide (100 mg, 1.85 mmol) and paraformaldehyde (535 mg, 5.94 mmol) were then added at room temperature. After addition, the reaction system was stirred at room temperature under a nitrogen atmosphere for 3 hours. The reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (10.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 46B was obtained by separation and purification on a silica gel column.
[0718] MS (ESI) m / z 199.2 (M+H) +
[0719] Step 2: Preparation of 2-(3-fluorophenyl)-3-hydroxypropanoic acid (Compound 46C)
[0720] Methyl 2-(3-fluorophenyl)-3-hydroxypropanoate (610 mg, 3.08 mmol) was dissolved in methanol (6 mL) and water (6 mL). Lithium hydroxide (650 mg, 27.14 mmol) was added at room temperature. After addition, the reaction system was stirred at 60°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, the reaction solution was concentrated and the pH was adjusted to 3-4 with 1N hydrochloric acid. The aqueous phase was extracted with ethyl acetate (10.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 46C was obtained by separation and purification on a silica gel column.
[0721] MS (ESI) m / z 183.1 (MH) -
[0722] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(3-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 46 of Example 46.
[0723] MS (ESI) m / z 474.1 (M+H) +
[0724] 1H-NMR(400MHz,DMSO-d6)δ9.68(s,1H),8.81-8.80(m,1H),8.34-8.32(m,1H),7.95-7.93(m,1H),7.34-7. 28(m,1H),7.09-7.03(m,3H),4.38-4.16(m,8H),3.86-3.81(m,1H),3.66-3.58(m,2H),3.51-3.44(m,1H)
[0725] Example 47: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylethan-1-one (Compound 47):
[0726] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, phenylacetic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 47 of Example 47.
[0727] MS (ESI) m / z 426.1 (M+H) +
[0728] 1H NMR (400MHz, DMSO-d6) δ9.69 (s, 1H), 8.82 (s, 1H), 8.35-8.33 (d, J = 8.0Hz, 1H), 7.96-7.94(d,J=8.0Hz,1H),7.27-7.15(m,5H),4.54-4.22(m,8H),3.44(s,2H).
[0729] Example 48: Preparation of 1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-(pyridin-3-yl)propan-1-one (Compound 48):
[0730] Step 1: Preparation of methyl 3-hydroxy-2-(pyridin-3-yl)propanoate (Compound 48B)
[0731] Methyl 2-(3-pyridyl)acetate (1.0 g, 6.62 mmol) was dissolved in dimethyl sulfoxide (10 mL). Sodium methoxide (120 mg, 666.67 μmol) and paraformaldehyde (600 mg, 6.67 mmol) were then added at room temperature. After addition, the reaction system was stirred at room temperature under a nitrogen atmosphere for 3 hours. The reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (30.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 48B was obtained by separation and purification on a silica gel column.
[0732] MS (ESI) m / z 182.1 (M+H) +
[0733] Step 2: Preparation of 3-hydroxy-2-(pyridin-3-yl)propanoic acid (Compound 48C)
[0734] Methyl 3-hydroxy-2-(2-pyridyl)propionate (140 mg, 772.68 μmol) was dissolved in a mixture of methanol (2 mL), water (2 mL), and tetrahydrofuran (2 mL). Lithium hydroxide (350 mg, 8.33 mmol) was added at room temperature. After addition, the reaction system was stirred at 60°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, the reaction solution was concentrated and the pH was adjusted to 3-4 with 1N hydrochloric acid. The aqueous phase was extracted with ethyl acetate (10.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 48C was obtained by separation and purification on a silica gel column.
[0735] MS (ESI) m / z 168.1 (M+H) +
[0736] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(pyridin-3-yl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 48 of Example 48.
[0737] MS (ESI) m / z 457.1 (M+H) +
[0738] 1H-NMR(400MHz,DMSO-d6)δ9.67(s,1H),8.81-8.79(m,1H),8.43-8.42(m,2H),8.37-8.32(m,1H),7.96-7.93(m,1H),7.68 -7.66(m,1H),7.32-7.28(m,1H),4.91-4.88(m,1H),4.75-4.67(m,1H),4 .44-4.17(m,7H),3.88-3.82(m,1H),3.68-3.64(m,1H),3.53-3.48(m,1H)
[0739] Example 49: Preparation of (S)-1-(1'-((2,3-dihydro-[1,4]dioxo[2,3-b]pyridin-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 49):
[0740] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-6-sulfonyl chloride (synthesized by the same method as in Example 20D) was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain compound 49 of Example 49.
[0741] MS (ESI) m / z 458.1 (M+H) +
[0742] 1 H NMR(400MHz, DMSO-d6)δ7.54-7.50(t,J=1.6Hz,2H),7.32-7.21(m,5H),4.50-4.46(m,1H ),4.37-4.30(m,11H),3.91-3.86(t,J=1.0Hz,1H),3.64-3.61(m,2H),3.48-3.44(m,1H).
[0743] Example 50: Preparation of (S)-1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropane-1-one (Compound 50):
[0744] Step 1: Preparation of methyl 2-(4-fluorophenyl)-3-hydroxypropionate (Compound 50B)
[0745] Methyl 2-(4-fluorophenyl)acetate (2.0 g, 11.89 mmol) was dissolved in dimethyl sulfoxide (20.0 mL), followed by the addition of paraformaldehyde (1.2 g, 12.49 mmol), followed by the slow addition of sodium methoxide solution (32.1 mg, 594.66 μmol). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (50.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 50B was obtained by separation and purification on a silica gel column.
[0746] MS (ESI) m / z 199.0 (M+H) +
[0747] Step 2: Preparation of 2-(4-fluorophenyl)-3-hydroxypropanoic acid (Compound 50C)
[0748] Methyl 2-(4-fluorophenyl)-3-hydroxypropanoate (1.5 g, 7.47 mmol) was dissolved in a mixture of methanol (15.0 mL) and water (10.0 mL), followed by the addition of sodium hydroxide (597.4 mg, 14.94 mmol). The reaction mixture was incubated at 50°C for 3 hours. TLC indicated the reaction was complete. The pH of the reaction mixture was adjusted to acidic with 1N hydrochloric acid. The aqueous phase was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography to obtain compound 50C.
[0749] MS (ESI) m / z 185.0 (M+H) +
[0750] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used and chiral separation was performed to obtain compound 50 of Example 50.
[0751] MS (ESI) m / z 474.1 (M+H) +
[0752] 1H NMR(400MHz, DMSO-d6)δ9.68(s,1H),8.81-8.80(d,J=4.0Hz,1H),8.34-8.32(d,J=8.0Hz,1H),7.95-7.92(m,1H),7.29-7.2 5(m,2H),7.11-7.07(m,2H),4.68-4.65(m,1H),4.34-4.25(m,7H),3.82-3.79(m,1H),3.62-3.60(m,1H),3.44-3.40(m,2H).
[0753] Example 51: Preparation of (R)-1-(1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-fluorophenyl)-3-hydroxypropane-1-one (Compound 51):
[0754] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used and chiral separation was performed to obtain compound 51 of Example 51.
[0755] MS (ESI) m / z 474.1 (M+H) +
[0756] 1 H NMR(400MHz, DMSO-d6)δ9.68(s,1H),8.81-8.80(d,J=4.0Hz,1H),8.34-8.32(d,J=8.0Hz,1H),7.95-7.92(m,1H),7.29-7.2 5(m,2H),7.11-7.07(m,2H),4.68-4.65(m,1H),4.34-4.25(m,7H),3.82-3.79(m,1H),3.62-3.60(m,1H),3.44-3.40(m,2H).
[0757] Example 52: Preparation of (1'-(Benzo[d]thiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)(1H-indol-3-yl)methanone (Compound 52):
[0758] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 1H-indole-3-carboxylic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 52 of Example 52.
[0759] MS (ESI) m / z 451.1 (M+H) +
[0760] 1 H NMR (400MHz, DMSO-d6) δ11.68(s,1H),9.73-9.63(t,J=4Hz,1H),8.85-8.84(d,J=0.4Hz,1H),8.36-8.34(d,J=0.8Hz,1H),8.05-8.0 3(d,J=0.8Hz,1H),7.99-7.96(m,1H),7.69-7.68(d,J=0.4Hz,1H),7.42-7.40(d,J=0.8Hz,1H),7.16-7.06(m,2H),59-4.40(m,8H).
[0761] Example 53: Preparation of 3-hydroxy-2-(4-methoxyphenyl)-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 53):
[0762] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(4-methoxyphenyl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 53 of Example 53.
[0763] MS (ESI) m / z 430.1 (M+H) +
[0764] 1H-NMR (400MHz, DMSO-d6) δ8.81-8.79(m,1H),8.17-8.13(m,1H),7.99-7.97(d,J=8.0Hz,1H),7.76-7.73(m,1H),7.18-7.15(m,2H),6.87 -6.83(m,2H),4.76-4.68(m,2H),4.53(s,4H),4.35-4.18(m,3H),3.89-3.81(m,1H),3.71(s,3H),3.57-3.53(m,1H),3.42-3.37(m,1H).
[0765] Example 54: Preparation of (S)-2-(4-fluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 54):
[0766] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride was replaced with pyridine-2-sulfonyl chloride, and in step 10, (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid was replaced with 2-(4-fluorophenyl)-3-hydroxypropionic acid. The same preparation method as in Example 1 was used, followed by chiral separation to give Compound 54 of Example 54.
[0767] MS (ESI) m / z 418.1 (M+H) +
[0768] 1 H-NMR (400MHz, DMSO-d6) δ8.81-8.80(d,J=4.7Hz,1H),8.17-8.13(m,1H),7.99-7.97(d,J=7.7Hz,1H),7.77-7.73(m,1H),7.32- 7.29(m,2H),7.14-7.09(m,2H),4.83-4.70(m,2H),4.54-4.19(m,7H),3.87-3.82(m,1H),3.66-3.63(m,1H),3.46-3.42(m,1H).
[0769] Example 55: Preparation of (R)-2-(4-fluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 55):
[0770] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride was replaced with pyridine-2-sulfonyl chloride, and in step 10, (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid was replaced with 2-(4-fluorophenyl)-3-hydroxypropionic acid. The same preparation method as in Example 1 was used, followed by chiral separation to obtain compound 55 of Example 55.
[0771] MS (ESI) m / z 418.1 (M+H) +
[0772] 1 H-NMR (400MHz, DMSO-d6) δ8.81-8.80(d,J=4.7Hz,1H),8.17-8.13(m,1H),7.99-7.97(d,J=7.7Hz,1H),7.77-7.73(m,1H),7.32- 7.29(m,2H),7.14-7.09(m,2H),4.83-4.70(m,2H),4.54-4.19(m,7H),3.87-3.82(m,1H),3.66-3.63(m,1H),3.46-3.42(m,1H).
[0773] Example 56: Preparation of (1H-indol-3-yl)(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)methanone (Compound 56):
[0774] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 1H-indole-3-carboxylic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 56 of Example 56.
[0775] MS (ESI) m / z 395.1 (M+H) +
[0776] 1H NMR (400MHz, DMSO-d6) δ11.71(s,1H),8.84(s,1H),8.19-8.16(t,J=1.2Hz,1H),8.08-8.06(d,J=0.8Hz,1H),8.02 -8.00(d,J=0.8Hz,1H),7.77-7.73(d,J=1.6Hz,2H),7.43-7.41(d,J=0.8Hz,1H),7.17-7.08(m,2H),4.60(s,8H).
[0777] Example 57: Preparation of 3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(p-tolyl)propan-1-one (Compound 57):
[0778] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(p-tolyl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 57 of Example 57.
[0779] MS (ESI) m / z 414.1 (M+H) +
[0780] 1 H-NMR(400MHz,DMSO-d6)δ8.80-8.79(m,1H),8.17-8.13(m,1H),7.99-7.96(m,1H),7.76-7.73(m,1H),7.14-7.08(m,4H), 4.77-4.68(m,2H),4.53(s,4H),4.35-4.18(m,3H),3.89-3.83(m,1H),3.58-3.55(m,1H),3.44-3.39(m,1H),2.25(s,3H).
[0781] Example 58: Preparation of (4-phenyltetrahydro-2H-pyran-4-yl)(1'-(pyridin-2-ylsulfonyl-(1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)methanone (Compound 58):
[0782] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 4-phenyltetrahydro-2H-pyran-4-carboxylic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 58 of Example 58.
[0783] MS (ESI) m / z 440.2 (M+H) +
[0784] 1 H-NMR (400MHz, DMSO-d6) δ8.78-8.76(m,1H),8.16-8.11(m,1H),7.95-7.93(d,J=8.0Hz,1H),7.76-7.73(m,1H),7.40- 7.25(m,5H),4.46-3.99(m,8H),3.73-3.70(m,2H),3.56-3.51(m,2H),2.18-2.15(d,J=13.5Hz,2H),1.85-1.78(m,2H).
[0785] Example 59: Preparation of 2-(3-chloro-4-fluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 59):
[0786] Step 1: Preparation of methyl 2-(3-chloro-4-fluorophenyl)-3-hydroxypropanoate (Compound 59B)
[0787] Methyl 2-(3-chloro-4-fluorophenyl)acetate (2.2 g, 10.61 mmol) and paraformaldehyde (477.9 mg, 5.31 mmol) were dissolved in dimethyl sulfoxide (40.0 mL), followed by the addition of sodium methoxide (191.1 mg, 1.06 mmol, 30%). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 59B.
[0788] MS (ESI) m / z 233.0 (M+H) +
[0789] Step 2: Preparation of 2-(3-chloro-4-fluorophenyl)-3-hydroxypropanoic acid (Compound 59C)
[0790] Methyl 2-(3-chloro-4-fluorophenyl)-3-hydroxypropanoate (2.0 g, 8.60 mmol) was dissolved in tetrahydrofuran (60.0 mL) and water (40.0 mL). Sodium hydroxide (687.8 mg, 17.19 mmol) was then added and the reaction mixture was stirred at room temperature for 5 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The resulting yellow oil was concentrated and used directly in the next reaction.
[0791] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(3-chloro-4-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 59 of Example 59.
[0792] MS (ESI) m / z 452.1 (M+H) +
[0793] 1 H NMR(400MHz,DMSO-d6)δ8.82-8.81(m,1H),8.19-8.14(m,1H),8.00-7.97(m,1H),7.78-7.74(m,1H),7.51-7.49(m,1H ),7.37-7.31(m,2H),4.94-4.87(m,1H),4.78-4.40(m,6H),4.38-4.19(m,2H),3.87-3.77(m,2H),3.55-3.43(m,1H).
[0794] Example 60: Preparation of 3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(pyridin-3-yl)propan-1-one (Compound 60):
[0795] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(pyridin-3-yl)propionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 60 of Example 60.
[0796] MS (ESI) m / z 401.1 (M+H) +
[0797] 1 H-NMR (400MHz, DMSO-d6) δ8.81-8.79(m,1H),8.47-8.44(m,2H),8.18-8.13(m,1H),7.99-7.97(d,J=8.0Hz,1H),7.77-7.69(m,2H),7.34-7.31( m,1H),4.94-4.92(m,1H),4.76-4.73(d,J=12.6Hz,1H),4.55-4.46(m,5 H),4.35-4.21(m,2H),3.91-3.85(m,1H),3.70(m,1H),3.55-3.50(m,1H)
[0798] Example 61: Preparation of 2-(3,4-difluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 61):
[0799] Step 1: Preparation of methyl 2-(3,4-difluorophenyl)-3-hydroxypropionate (Compound 61B)
[0800] Methyl 2-(3,4-difluorophenyl)acetate (0.5 g, 2.69 mmol) and paraformaldehyde (241.9 mg, 2.69 mmol) were dissolved in dimethyl sulfoxide (10.0 mL), followed by the addition of sodium methoxide (48.4 mg, 0.27 mmol, 30%). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the product was separated and purified by silica gel column chromatography to obtain compound 50C.
[0801] MS (ESI) m / z 217.2 (M+H) +
[0802] Step 2: Preparation of 2-(3,4-difluorophenyl)-3-hydroxypropanoic acid (Compound 61C)
[0803] Methyl 2-(3,4-difluorophenyl)-3-hydroxypropanoate (320.0 mg, 1.48 mmol) was dissolved in methanol (15.0 mL) and water (10.0 mL). Sodium hydroxide (118.4 mg, 2.96 mmol) was then added, and the reaction mixture was stirred at 50°C for 3 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After concentration, the mixture was used directly in the next reaction.
[0804] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(3,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 61 of Example 61.
[0805] MS (ESI) m / z 436.1 (M+H) +
[0806] 1 H NMR(400MHz,DMSO-d6)δ8.82-8.78(m,1H),8.18-8.14(m,1H),8.00-7.95(m,1H),7.79-7.74(m,1H),7.39-7.32(m,2H),7.15-7.11(m,1H) ),4.90-4.87(m,1H),4.73-4.69(m,1H),4.55-4.44(m,5H),4.34-4.21(m,2H),3.85-3.80(m,1H),3.69-3.65(m,1H),3.50-3.45(m,1H).
[0807] Example 62: Preparation of 3-hydroxy-3-methyl-2-phenyl-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)butan-1-one (Compound 62):
[0808] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride was replaced with pyridine-2-sulfonyl chloride, and in step 10, (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid was replaced with 3-hydroxy-3-methyl-2-phenylbutyric acid. The same preparation method as in Example 1 was used to obtain compound 62 of Example 62.
[0809] MS (ESI) m / z 428.2 (M+H) +
[0810] 1H NMR (400MHz, DMSO-d6) δ8.79-8.77(m,1H),8.17-8.12(m,1H),7.98-7.96(d,J=7.7Hz,1H),7.75-7.72(m,1H),7.38-7.22 (m,5H),4.89(brs,1H),4.77-4.73(m,1H),4.60-4.45(m,4H),4.35-4.19(m,3H),3.51(s,1H),1.15(s,3H),0.98(s,3H).
[0811] Example 63: Preparation of (S)-3-hydroxy-1-(1'-((1-methyl-1H-benzimidazol-6-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 63):
[0812] Step 1: Preparation of 6-(benzylthio)-1-methyl-1H-benzo[d]imidazole (Compound 63B)
[0813] 6-Bromo-1-methyl-1H-benzo[d]imidazole (1 g, 4.74 mmol) was dissolved in 1,4-dioxane, followed by benzyl mercaptan (588 mg, 4.74 mmol), DIPEA (1.22 g, 9.48 mmol), Pd(dba)CHCl (485 mg, 0.47 mmol), and xantphos (548 mg, 0.95 mmol). After the additions were complete, the reaction mixture was purged three times under nitrogen atmosphere, then heated to 80°C and stirred for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain compound 63B.
[0814] MS (ESI) m / z 255.1 (M+H) +
[0815] Step 2: Preparation of 1-methyl-1H-benzo[d]imidazole-6-sulfonyl chloride (Compound 63C)
[0816] 6-(Benzylthio)-1-methyl-1H-benzo[d]imidazole (560 mg, 2.20 mmol) was dissolved in acetonitrile. Acetic acid (661 mg, 11.01 mmol), water (397 mg, 22.02 mmol), and 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (868 mg, 4.40 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 63C.
[0817] MS (ESI) m / z 231.0 (M+H) +
[0818] In step 8 of Example 1, 1-methyl-1H-benzo[d]imidazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 63 of Example 63.
[0819] MS (ESI) m / z 453.2 (M+H) +
[0820] 1 H NMR(400MHz,DMSO-d6)δ8.48(s,1H),8.17–8.04(m,1H),7.90(d,J=8.5Hz,1H),7 .70–7.59(m,1H),7.25(dt,J=13.8,7.2Hz,5H),4.77(t,J=5.2Hz,1H),4.67(d,J =12.5Hz,1H),4.28(d,J=21.7Hz,6H),4.17(d,J=14.6Hz,1H),3.96(s,3H),3.86 (td,J=9.4,5.5Hz,1H),3.59(dd,J=8.8,5.3Hz,1H),3.45(dd,J=9.8,4.9Hz,1H).
[0821] Example 64: Preparation of (1'-(Benzothiazol-6-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)(isoindolin-1-yl)methanone (Compound 64):
[0822] In step 8 of Example 1, benzo[d]thiazole-6-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(tert-butoxycarbonyl)isoindoline-1-carboxylic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 64 of Example 64.
[0823] MS (ESI) m / z 453.1 (M+H) +
[0824] 1H NMR (400MHz, DMSO-d6) δ9.69(s,1H),8.82(d,J=1.8Hz,1H),8.35(d,J=8.6Hz,1H),7.96(dd,J= 8.6,1.9Hz,1H),7.27–7.17(m,4H),4.82(m,2H),4.49(m,1H),4.32(m,7H),4.20–4.04(m,2H).
[0825] Example 65: Preparation of (S)-4-(1'-(3-hydroxy-2-phenylpropionyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-ylsulfonyl)benzonitrile (Compound 65):
[0826] In step 8 of Example 1, 4-cyanobenzenesulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 65 of Example 65.
[0827] MS (ESI) m / z 424.1 (M+H) +
[0828] 1 H NMR (400MHz, DMSO-d6) δ8.19–8.13(m,2H),8.03–7.98(m,2H),7.32–7.18(m,5H),4.79(t,J=5.3Hz,1H),4.70(d,J= 12.5Hz,1H),4.33(d,J=15.0Hz,6H),4.19(d,J=14.4Hz,1H),3.88(m,1H),3.61(dd,J=8.8,5.5Hz,1H),3.45(m,1H).
[0829] Example 66: Preparation of (S)-1-(1'-(5-chloropyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 66):
[0830] In step 8 of Example 1, 5-chloropyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 66 of Example 66.
[0831] MS (ESI) m / z 434.1 (M+H) +
[0832] 1 H NMR (400MHz, DMSO-d6) δ8.93–8.84(m,1H),8.28(dd,J=8.4,2.4Hz,1H),7.99(dd,J=8.4,0.7Hz,1H),7.31–7.23(m,5H ),4.82–4.67(m,2H),4.54(d,J=2.8Hz,4H),4.39–4.21(m,3H),3.89(m,1H),3.63(dd,J=8.9,5.4Hz,1H),3.46(m,1H).
[0833] Example 67: Preparation of (S)-3-hydroxy-1-(1'-((5-methoxypyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 67):
[0834] Step 1: Preparation of 2-(benzylthio)-5-methoxypyridine (Compound 67B)
[0835] 2-Bromo-5-methoxypyridine (1 g, 5.32 mmol) was dissolved in 1,4-dioxane, followed by benzyl mercaptan (660 mg, 5.32 mmol), DIPEA (1.37 g, 10.64 mmol), Pd2(dba)3CHCl3 (544 mg, 0.53 mmol), and xantphos (615 mg, 1.06 mmol). After the additions were complete, the reaction mixture was purged three times under nitrogen atmosphere, then heated to 80°C and stirred for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain compound 67B.
[0836] MS (ESI) m / z 232.1 (M+H) +
[0837] Step 2: Preparation of 5-methoxypyridine-2-sulfonyl chloride (Compound 67C)
[0838] 2-(Benzylthio)-5-methoxypyridine (1.3 g, 5.62 mmol) was dissolved in acetonitrile. Acetic acid (1.69 g, 28.1 mmol), water (1.01 g, 56.2 mmol), and NCS (1.5 g, 11.24 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain compound 67C.
[0839] MS (ESI) m / z 208.0 (M+H) +
[0840] In step 8 of Example 1, 5-methoxypyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 67 of Example 67.
[0841] MS (ESI) m / z 430.1 (M+H) +
[0842] 1 H NMR (400MHz, DMSO-d6) δ8.48(d,J=2.9Hz,1H),7.94(d,J=8.7Hz,1H),7.65(m,1H),7.33–7.20(m,5H),4.80(t,J=5.3Hz,1H ),4.72(d,J=12.8Hz,1H),4.54–4.42(m,4H),4.41–4.27(m,2H),4.25–4.16(m,1H),3.93(s,4H),3.62(m,1H),3.46(m,1H).
[0843] Example 68: Preparation of (S)-3-hydroxy-2-phenyl-1-(1'-(pyridin-3-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 68):
[0844] In step 8 of Example 1, pyridine-3-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 68 of Example 68.
[0845] MS (ESI) m / z 400.1 (M+H) +
[0846] 1H NMR (400MHz, DMSO-d6) δ8.99(d,J=2.3Hz,1H),8.92(dd,J=4.8,1.6Hz,1H),8.26(m,1H),7.72(dd,J=8.0,4.9Hz,1H),7.33–7.18(m,5H),4.7 6–4.64(m,1H),4.44–4.25(m,6H),4.19(d,J=13.4Hz,1H),3.88(t,J=9.5Hz,1H),3.61(dd,J=8.8,5.5Hz,1H),3.45(dd,J=10.1,5.5Hz,2H).
[0847] Example 69: Preparation of (S)-3-hydroxy-2-phenyl-1-(1'-(quinolin-8-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 69):
[0848] In step 8 of Example 1, quinoline-8-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 69 of Example 69.
[0849] MS (ESI) m / z 450.1 (M+H) +
[0850] 1 H NMR (400MHz, DMSO-d6) δ9.08(dd,J=4.2,1.8Hz,1H),8.56(dd,J=8.4,1.8Hz,1H),8.35(m,2H),7.78(t,J=7.8Hz,1H),7.71(dd,J=8.3,4.2Hz,1H),7. 33–7.19(m,5H),4.92–4.59(m,6H),4.40–4.28(m,2H),4.22(m,1H),3.89( t,J=9.5Hz,1H),3.62(dd,J=8.8,5.5Hz,1H),3.46(dd,J=10.1,5.5Hz,1H).
[0851] Example 70: Preparation of (S)-6-((1'-(3-hydroxy-2-phenylpropionyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)sulfonyl)nicotinonitrile (Compound 70):
[0852] Step 1: Preparation of 6-(benzylthio)nicotinonitrile (Compound 70B)
[0853] 2-Bromo-5-cyanopyridine (2 g, 14.44 mmol) was dissolved in DMF, followed by the addition of benzyl mercaptan (1.79 g, 14.44 mmol) and cesium carbonate (5.65 g, 17.33 mmol). After the addition was complete, the reaction mixture was heated to 60°C and stirred for 6 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 70B.
[0854] MS (ESI) m / z 227.1 (M+H) +
[0855] Step 2: Preparation of 5-cyanopyridine-2-sulfonyl chloride (Compound 70C)
[0856] Dissolve 6-(Benzylthio)nicotinonitrile (1 g, 4.42 mmol) in a mixture of dichloromethane and water. Cool the reaction system to 0°C and slowly add concentrated hydrochloric acid dropwise. After the addition is complete, stir the reaction at 0°C for 10 minutes, then slowly add aqueous sodium hypochlorite dropwise. After the addition is complete, stir the reaction system at 0°C for 10 minutes before quickly separating the liquids. The organic phase proceeds directly to the next reaction.
[0857] In step 8 of Example 1, 5-cyanopyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as in Example 1 was used to obtain Compound 70 of Example 70.
[0858] MS (ESI) m / z 425.1 (M+H) +
[0859] 1 H NMR (400MHz, DMSO-d6) δ9.25(dd,J=2.1,0.9Hz,1H),8.67(dd,J=8.2,2.1Hz,1H),8.14(dd,J=8.1,0.9Hz,1H),7.33–7.20(m,5H),4.80(t,J=5.3 Hz,1H),4.73(m,1H),4.63–4.52(m,4H),4.34(dd,J=21.7,8.2Hz,2H),4 .27–4.18(m,1H),3.90(m,1H),3.63(dd,J=8.9,5.5Hz,1H),3.47(m,1H).
[0860] Example 71: Preparation of 2-(4-(difluoromethyl)phenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 71):
[0861] Step 1: Preparation of methyl 2-(4-(difluoromethyl)phenyl)acetate (Compound 71B)
[0862] To a solution of methyl 2-(4-formylphenyl)acetate (2.0 g, 11.22 mmol) in dichloromethane (10.0 mL) was added diethylaminosulfur trifluoride (3.62 g, 22.45 mmol), and the mixture was stirred at 50°C under nitrogen for 3 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 71B.
[0863] MS (ESI) m / z 201.0 (M+H) +
[0864] Step 2: Preparation of methyl 2-(4-(difluoromethyl)phenyl)-3-hydroxypropanoate (Compound 71C)
[0865] Methyl 2-(4-(difluoromethyl)phenyl)acetate (1.5 g, 7.49 mmol) was dissolved in dimethyl sulfoxide (10.0 mL), followed by the addition of paraformaldehyde (681.13 mg, 7.57 mmol), followed by the slow addition of sodium methoxide solution (136.23 mg, 756.81 μmol, 30% purity). The reaction mixture was allowed to react at room temperature for 3 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 71C.
[0866] MS (ESI) m / z 231.0 (M+H) +
[0867] Step 3: Preparation of 2-(4-(difluoromethyl)phenyl)-3-hydroxypropanoic acid (Compound 71D)
[0868] Methyl 2-[4-(difluoromethyl)phenyl]-3-hydroxypropanoate (300 mg, 1.30 mmol) was dissolved in a mixture of water (3.0 mL), methanol (3.0 mL), and tetrahydrofuran (3.0 mL), followed by the addition of lithium hydroxide (156.05 mg, 6.52 mmol). The mixture was stirred at 50°C for 3 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain Compound 71D.
[0869] MS (ESI) m / z 217.0 (M+H) +
[0870] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-(difluoromethyl)phenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 71 of Example 71.
[0871] MS (ESI) m / z 450.0 (M+H) +
[0872] 1 H NMR(400MHz, DMSO-d6)δ8.80(s,1H),8.17-8.13(t,1H),7.98-7.97(m,1H),7.76-7.72(m,1H),7.51-7.49(d,J=6.8Hz,2H),7.42-7.40(m,J=6.8 Hz,2H),7.113-6.85(t,1H),4.87(s,1H),4.75-4.72(d,J=12.0Hz,1H), 4.54(s,4H),4.40-4.19(m,3H),3.88(s,1H),3.71(s,1H),3.49(s,1H).
[0873] Example 72: Preparation of (S)-1-(1'-((5-ethoxypyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 72):
[0874] Step 1: Preparation of 2-(benzylthio)-5-ethoxypyridine (Compound 72B)
[0875] 2-Bromo-5-ethoxypyridine (2 g, 9.9 mmol) was dissolved in 1,4-dioxane, followed by the addition of benzyl mercaptan (1.23 g, 9.9 mmol), DIPEA (3.28 ml, 19.8 mmol), Pd2(dba)3CHCl3 (1.02 g, 0.99 mmol), and xantphos (1.15 g, 1.98 mmol). After the addition was complete, the reaction mixture was purged with nitrogen three times, then heated to 80°C and stirred for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 72B.
[0876] MS (ESI) m / z 246.1 (M+H) +
[0877] Step 2: Preparation of 5-ethoxypyridine-2-sulfonyl chloride (Compound 72C)
[0878] 2-(Benzylthio)-5-ethoxypyridine (2.3 g, 9.37 mmol) was dissolved in acetonitrile. Acetic acid (2.81 g, 46.85 mmol), water (1.69 g, 93.7 mmol), and 1,3-dichloroimidazolidine-2,4-dione (3.69 g, 18.74 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain Compound 72C.
[0879] MS (ESI) m / z 221.9 (M+H) +
[0880] In step 8 of Example 1, 5-ethoxypyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 72 of Example 72.
[0881] MS (ESI) m / z 444.1 (M+H) +
[0882] 1 H NMR (400MHz, DMSO-d6) δ8.46(d,J=2.8Hz,1H),7.92(d,J=8.7Hz,1H),7.63(dd,J=8.8,2.9Hz,1H),7.39–7.11(m,5H),4.80(t,J=5.3Hz,1H),4.72(d, J=13.4Hz,1H),4.47(s,4H),4.40–4.26(m,2H),4.22(q,J=7.0Hz,3H),3.8 9(m,1H),3.62(dd,J=8.9,5.5Hz,1H),3.46(m,1H),1.37(t,J=6.9Hz,3H).
[0883] Example 73: Preparation of 3-fluoro-2-phenyl-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 73):
[0884] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-fluoro-2-phenylpropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 73 of Example 73.
[0885] MS (ESI) m / z 402.1 (M+H) +
[0886] 1 H-NMR (400MHz, DMSO-d6) δ8.79-8.78(d,J=8.0Hz,1H),8.17-8.12(m,1H),7.98-7.96(d,J=8.0Hz,1H),7.76-7.72(m, 1H),7.37-7.33(m,2H),7.31-7.23(m,3H),4.89-4.72(m,2H),4.56-4.52(m,4H),4.44-4.21(m,4H),4.06-3.99(m,1H)
[0887] Example 74: Preparation of 2-(2,4-difluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 74):
[0888] Step 1: Preparation of methyl 2-(2,4-difluorophenyl)-3-hydroxypropionate (Compound 74B)
[0889] Methyl 2-(2,4-difluorophenyl)acetate (0.8 g, 4.30 mmol) and paraformaldehyde (387.1 mg, 4.30 mmol) were dissolved in dimethyl sulfoxide (5.0 mL), followed by the addition of sodium methoxide (77.4 mg, 0.43 mmol, 30%). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 74B.
[0890] MS (ESI) m / z 217.2 (M+H) +
[0891] Step 2: Preparation of 2-(2,4-difluorophenyl)-3-hydroxypropanoic acid (Compound 74C)
[0892] Methyl 2-(2,4-difluorophenyl)-3-hydroxypropanoate (440.0 mg, 2.04 mmol) was dissolved in methanol (15.0 mL) and water (10.0 mL). Sodium hydroxide (162.8 mg, 4.07 mmol) was then added, and the reaction mixture was stirred at 50°C for 3 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After concentration, the mixture was used directly in the next reaction.
[0893] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(2,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 74 of Example 74.
[0894] MS (ESI) m / z 436.1 (M+H) +
[0895] 1 H NMR(400MHz, DMSO-d6)δ8.81-8.80(d,J=3.8Hz,1H),8.18-8.13(t,J=7.7Hz,1H),7.99-7 .97(d,J=7.7Hz,1H),7.77-7.74(t,J=5.9Hz,1H),7.45-7.39(q,J=7.7Hz,1H),7.23-7.17 (t,J=9.8Hz,1H),7.07-7.02(t,J=8.4Hz,1H),4.92-4.89(m,1H),4.74-4.71(m, 1H),4.60-4.48(m,4H),4.40-4.19(m,3H),3.92-3.82(m,2H),3.55-3.48(m,1H)
[0896] Example 75: Preparation of 2-(4-chlorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 75):
[0897] Step 1: Preparation of methyl 2-(4-chlorophenyl)-3-hydroxypropionate (Compound 75B)
[0898] Methyl 2-(4-chlorophenyl)acetate (2.0 g, 10.83 mmol) and paraformaldehyde (975.9 mg, 10.83 mmol) were dissolved in dimethyl sulfoxide (50.0 mL), followed by the addition of sodium methoxide (195.1 mg, 1.08 mmol, 30%). The reaction mixture was allowed to react at room temperature for 4 hours. After completion, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 75B.
[0899] MS (ESI) m / z 215.1 (M+H) +
[0900] Step 2: Preparation of 2-(4-chlorophenyl)-3-hydroxypropanoic acid (Compound 75C)
[0901] Methyl 2-(4-chlorophenyl)-3-hydroxypropanoate (1.3 g, 6.06 mmol) was dissolved in methanol (45.0 mL) and water (30.0 mL). Sodium hydroxide (484.5 mg, 12.11 mmol) was then added and the reaction mixture was stirred at 50°C for 3 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After concentration, the mixture was used directly in the next reaction.
[0902] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-chlorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain compound 75 of Example 75.
[0903] MS (ESI) m / z 434.1 (M+H) +
[0904] 1 H NMR (400MHz, DMSO-d6) δ8.81-8.80(m,1H),8.17-8.12(m,1H),7.99-7.97(d,J=7.7Hz,1H),7.77-7.73(m,1H),7.38-7.32(m,2 H),7.32-7.27(m,2H),4.86-4.83(t,J=5.2Hz,1H),4.73-4.20(m,8H),3.88-3.82(m,1H),3.67-3.63(m,1H),3.49-3.44(m,1H)
[0905] Example 76: Preparation of (R)-2-(3-chloro-4-fluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 76):
[0906] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride was replaced with pyridine-2-sulfonyl chloride, and in step 10, (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid was replaced with 2-(3-chloro-4-fluorophenyl)-3-hydroxypropionic acid. The same preparation method as in Example 1 was used, followed by chiral separation to obtain compound 76 of Example 76.
[0907] MS (ESI) m / z 452.1 (M+H) +
[0908] 1 H NMR(400MHz,DMSO-d6)δ8.82-8.81(m,1H),8.19-8.14(m,1H),8.00-7.97(m,1H),7.78-7.74(m,1H),7.51-7.49(m,1H ),7.37-7.31(m,2H),4.94-4.87(m,1H),4.78-4.40(m,6H),4.38-4.19(m,2H),3.87-3.77(m,2H),3.55-3.43(m,1H).
[0909] Example 77: Preparation of (S)-2-(3-chloro-4-fluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 77):
[0910] In step 8 of Example 1, 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride was replaced with pyridine-2-sulfonyl chloride, and in step 10, (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid was replaced with 2-(3-chloro-4-fluorophenyl)-3-hydroxypropionic acid. The same preparation method as in Example 1 was used, followed by chiral separation to give Compound 77 of Example 77.
[0911] MS (ESI) m / z 452.1 (M+H) +
[0912] 1H NMR(400MHz,DMSO-d6)δ8.82-8.81(m,1H),8.19-8.14(m,1H),8.00-7.97(m,1H),7.78-7.74(m,1H),7.51-7.49(m,1H ),7.37-7.31(m,2H),4.94-4.87(m,1H),4.78-4.40(m,6H),4.38-4.19(m,2H),3.87-3.77(m,2H),3.55-3.43(m,1H).
[0913] Example 78: Preparation of 3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-(4-(trifluoromethyl)phenyl)propan-1-one (Compound 78):
[0914] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-hydroxy-2-(4-(trifluoromethyl)phenyl)propanoic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropanoic acid. The same preparation method as in Example 1 was used to obtain compound 78 of Example 78.
[0915] MS (ESI) m / z 468.1 (M+H) +
[0916] 1 H-NMR (400MHz, DMSO-d6) δ8.81-8.79(d,J=4.7Hz,1H),8.18-8.13(m,1H),7.99-7.97(d,J=8.0Hz,1 H),7.76-7.73(m,1H),7.67-7.65(d,J=8.2Hz,2H),7.52-7.50(d,J=8.2Hz,2H),4.76-4.73(d,J=12 .4Hz,1H),4.54(s,4H),4.43-4.39(d,J=13.2Hz,1H),4.34-4.31(d,J=13.7Hz,1H),4.24-4.21(d,J =12.9Hz,1H),3.91-3.87(m,1H),3.78-3.75(m,1H),3.54-3.50(m,1H),2.67-2.65(d,J=7.4Hz,1H)
[0917] Example 79: Preparation of 2-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 79):
[0918] Step 1: Preparation of methyl 2-(4-hydroxy-3-nitrophenyl)acetate (Compound 79B)
[0919] 2-(4-Hydroxy-3-nitrophenyl)acetic acid (5.0 g, 25.36 mmol) was dissolved in anhydrous methanol (100 mL), followed by the slow addition of thionyl chloride (6.03 g, 50.72 mmol). The reaction mixture was allowed to react at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 79B was obtained by separation and purification on a silica gel column.
[0920] MS (ESI) m / z 212.1 (M+H) +
[0921] Step 2: Preparation of methyl 2-(3-amino-4-hydroxyphenyl)acetate (Compound 79C)
[0922] Methyl 2-(4-hydroxy-3-nitrophenyl)acetate (4.7 g, 22.3 mmol) was dissolved in anhydrous ethanol (100.0 mL), followed by the addition of palladium on carbon (470 mg, 2.23 mmol). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 79C was obtained by separation and purification on a silica gel column.
[0923] MS (ESI) m / z 182.1 (M+H) +
[0924] Step 3: Preparation of methyl 2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acetate (Compound 79D)
[0925] Methyl 2-(4-fluoro-2-methoxyphenyl)acrylate (3.5 g, 19.3 mmol) was dissolved in ethyl acetate (100 mL) and water (100 mL). Sodium carbonate (4.19 g, 38.6 mmol) and 2-chloroacetyl chloride (2.16 g, 19.3 mmol) were then added. The reaction mixture was stirred at room temperature for 4 hours. After the reaction was complete, the mixture was extracted three times with ethyl acetate (200 mL). The combined organic phases were separated and purified on a silica gel column to obtain compound 79D.
[0926] MS (ESI) m / z 222.1 (M+H) +
[0927] Step 4: Preparation of methyl 2-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acetate (Compound 79E)
[0928] Methyl 2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acetate (2.4 g, 10.9 mmol) was dissolved in tetrahydrofuran (100.0 mL), followed by the addition of a solution of borane in tetrahydrofuran (1.87 g, 21.7 mmol). The reaction mixture was stirred at 60°C for 12 hours. After the reaction was complete, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 79E was obtained by separation and purification on a silica gel column.
[0929] MS (ESI) m / z 208.1 (M+H) +
[0930] Step 5: Preparation of tert-butyl 6-(2-methoxy-2-oxoethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 79F)
[0931] Methyl 2-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acetate (1.2 g, 5.45 mmol) was dissolved in dichloromethane (100 mL). Triethylamine (1.18 g, 10.9 mmol) and 4-dimethylaminopyridine (662.7 mg, 5.45 mmol) were then added. The reaction system was cooled to 0°C, and di-tert-butyl dicarbonate (1.77 g, 8.14 mmol) was slowly added. The reaction solution was stirred at room temperature for 16 hours. After the reaction was complete, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 79F was obtained by separation and purification on a silica gel column.
[0932] MS (ESI) m / z 308.1 (M+H) +
[0933] Step 6: Preparation of tert-butyl 6-(3-hydroxy-1-methoxy-1-oxopropan-2-yl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate (Compound 79G)
[0934] Tert-butyl 6-(2-methoxy-2-oxoethyl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate (576 mg, 1.87 mmol) and paraformaldehyde (168.9 mg, 1.87 mmol) were dissolved in dimethyl sulfoxide (50.0 mL), followed by the addition of sodium methoxide (10.1 mg, 0.19 mmol). The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the reaction mixture was diluted with water, and the aqueous phase was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 79F was obtained by separation and purification on a silica gel column.
[0935] MS (ESI) m / z 338.4 (M+H) +
[0936] Step 7: Preparation of 2-(4-(tert-Butyloxycarbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-3-hydroxypropanoic acid (Compound 79H)
[0937] Methyl 3-hydroxy-2-(naphthalen-2-yl)propanoate (235.0 mg, 0.69 mmol) was dissolved in anhydrous methanol (60.0 mL) and water (40.0 mL). Sodium hydroxide (27.8 mg, 0.69 mmol) was then added, and the reaction mixture was stirred at room temperature for 5 hours. After the reaction was complete, the pH was adjusted to 2 with 1N hydrochloric acid and extracted with dichloromethane (100 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The resulting yellow oil was concentrated and used directly in the next reaction.
[0938] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-(tert-butoxycarbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to obtain Compound 79 of Example 79.
[0939] MS (ESI) m / z 457.2 (M+H) +
[0940] 1 H-NMR (400MHz, DMSO-d6) δ8.82-8.81(m,1H),8.17-8.14(m,1H),8.00-7.98(d,J=8.0Hz,1H),7.78-7.74(m,1H),6.55-6.31(m,3H),5 .75(s,1H),4.70-4.67(m,2H),4.55(s,4H),4.33-4.20(m,3H),4.08-4.06(m,2H),3.87-3.80(m,1H),3.41-3.38(m,2H),3.24(s,2H)
[0941] Example 80: Preparation of (S)-1-(1'-((5-(difluoromethoxy)pyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 80):
[0942] Step 1: Preparation of 2-(benzylthio)-5-(difluoromethoxy)pyridine (Compound 80B)
[0943] 2-Bromo-5-difluoromethoxypyridine (2 g, 8.93 mmol) was dissolved in 1,4-dioxane, followed by benzyl mercaptan (1.11 g, 8.93 mmol), DIPEA (2.31 g, 17.86 mmol), Pd2(dba)3CHCl3 (913 mg, 0.89 mmol), and xantphos (1.03 g, 1.79 mmol). After the additions were complete, the reaction mixture was purged three times under nitrogen atmosphere, then heated to 80°C and stirred for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain Compound 80B.
[0944] MS (ESI) m / z 268.1 (M+H) +
[0945] Step 2: Preparation of 5-(difluoromethoxy)pyridine-2-sulfonyl chloride (Compound 80C)
[0946] 2-(Benzylthio)-5-difluoromethoxypyridine (1.0 g, 3.74 mmol) was dissolved in acetonitrile. Acetic acid (1.12 g, 18.71 mmol), water (674 mg, 37.41 mmol), and 1,3-dichloro-5,5-dimethylhydantoin (1.47 g, 7.48 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain Compound 80C.
[0947] MS (ESI) m / z 244.0 (M+H)+
[0948] In step 8 of Example 1, 5-(difluoromethoxy)pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 80 of Example 80.
[0949] MS (ESI) m / z 466.1 (M+H) +
[0950] 1 H NMR (400MHz, DMSO-d6) δ8.71(d,J=2.7Hz,1H),8.07(d,J=8.7Hz,1H),7.95(dd,J=8.7,2.7Hz,1H),7.50(s,1H),7.34–7.19(m,5H),4.80(t,J=5. 3Hz,1H),4.73(d,J=13.3Hz,1H),4.53(s,4H),4.42–4.27(m,2H),4.22( d,J=15.0Hz,1H),3.89(m,1H),3.63(dd,J=8.8,5.5Hz,1H),3.46(m,1H).
[0951] Example 81: Preparation of (S)-3-hydroxy-1-(1'-((5-isopropoxypyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 81):
[0952] Step 1: Preparation of 2-(benzylthio)-5-isopropoxypyridine (Compound 81B)
[0953] 2-Bromo-5-isopropoxypyridine (2 g, 9.26 mmol) was dissolved in 1,4-dioxane, followed by benzyl mercaptan (1.15 g, 9.26 mmol), DIPEA (2.39 g, 18.51 mmol), Pd2(dba)3CHCl3 (947 mg, 0.93 mmol), and xantphos (1.07 g, 1.85 mmol). After the additions were complete, the reaction mixture was purged three times under nitrogen atmosphere, then heated to 80°C and stirred for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain compound 81B.
[0954] MS (ESI) m / z 260.1 (M+H) +
[0955] Step 2: Preparation of 5-isopropoxypyridine-2-sulfonyl chloride (Compound 81C)
[0956] 2-(Benzylthio)-5-isopropoxypyridine (1.0 g, 3.86 mmol) was dissolved in acetonitrile. Acetic acid (1.16 g, 19.28 mmol), water (695 mg, 38.56 mmol), and 1,3-dichloro-5,5-dimethylhydantoin (1.52 g, 7.71 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 81C.
[0957] MS (ESI) m / z 236.0 (M+H) +
[0958] In step 8 of Example 1, 5-isopropoxypyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 81 of Example 81.
[0959] MS (ESI) m / z 458.2 (M+H) +
[0960] 1H NMR (400MHz, DMSO-d6) δ8.42(d,J=2.8Hz,1H),7.90(d,J=8.8Hz,1H),7.64(dd,J=8.8,2.8Hz,1H),7.26(m,5H),4.82(m,2H),4.72(d,J=13.3H z,1H),4.47(s,4H),4.42–4.26(m,2H),4.21(d,J=14.6Hz,1H),3.89(m,1H),3.62(dd,J=8.9,5.5Hz,1H),3.46(m,1H),1.32(d,J=6.0Hz,6H).
[0961] Example 82: Preparation of (S)-1-(1'-((5-cyclopropyloxypyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-3-hydroxy-2-phenylpropane-1-one (Compound 82):
[0962] Step 1: Preparation of 2-(benzylthio)-5-cyclopropyloxypyridine (Compound 82B)
[0963] 2-Bromo-5-cyclopropyloxypyridine (3.98 g, 18.59 mmol) was dissolved in 1,4-dioxane, followed by benzyl mercaptan (2.31 g, 18.59 mmol), DIPEA (7.21 g, 55.77 mmol), Pd2(dba)3CHCl3 (1.92 g, 1.86 mmol), and xantphos (2.15 g, 3.72 mmol). After the addition was complete, the reaction mixture was purged three times with nitrogen and then heated to 80°C with stirring for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain compound 82B.
[0964] MS (ESI) m / z 258.1 (M+H) +
[0965] Step 2: Preparation of 5-cyclopropyloxypyridine-2-sulfonyl chloride (Compound 82C)
[0966] 2-(Benzylthio)-5-cyclopropyloxypyridine (2.0 g, 7.78 mmol) was dissolved in acetonitrile. Acetic acid (2.33 g, 38.9 mmol), water (1.40 g, 77.8 mmol), and 1,3-dichloroimidazolidine-2,4-dione (3.06 g, 15.56 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the mixture was separated and purified by silica gel column chromatography to obtain Compound 82C.
[0967] MS (ESI) m / z 233.9 (M+H) +
[0968] In step 8 of Example 1, 5-cyclopropyloxypyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to obtain Compound 82 of Example 82.
[0969] MS (ESI) m / z 456.2 (M+H) +
[0970] 1 H NMR(400MHz,Chloroform-d)δ8.46(d,J=2.8Hz,1H),7.93(d,J=8.7Hz,1H),7.53(dd,J=8.6,2.9Hz,1H),7.38–7.28(m,3H),7.25–7.19(m,2H),4. 50(d,J=29.8Hz,7H),4.19–3.92(m,2H),3.86(m,J=6.4,2.9Hz,1H),3.71 (dd,J=11.2,4.4Hz,1H),3.65(dd,J=8.8,4.4Hz,1H),0.97–0.79(m,4H).
[0971] Example 83: Preparation of (S)-2-(2,4-difluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 83):
[0972] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(2,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used for separation and chiral separation to obtain compound 83 of Example 83.
[0973] MS (ESI) m / z 436.1 (M+H) +
[0974] 1H NMR(400MHz, DMSO-d6)δ8.81-8.80(d,J=3.8Hz,1H),8.18-8.13(t,J=7.7Hz,1H),7. 99-7.97(d,J=7.7Hz,1H),7.77-7.74(t,J=5.9Hz,1H),7.45-7.39(q,J=7.7Hz,1H),7 .23-7.17(t,J=9.8Hz,1H),7.07-7.02(t,J=8.4Hz,1H),4.92-4.89(m,1H),4.74-4.7 1(m,1H),4.60-4.48(m,4H),4.40-4.19(m,3H),3.92-3.82(m,2H),3.55-3.48(m,1H)
[0975] Example 84: Preparation of (R)-2-(2,4-difluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 84):
[0976] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(2,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used for separation and chiral separation to obtain compound 84 of Example 84.
[0977] MS (ESI) m / z 436.1 (M+H) +
[0978] 1 H NMR(400MHz, DMSO-d6)δ8.81-8.80(d,J=3.8Hz,1H),8.18-8.13(t,J=7.7Hz,1H),7. 99-7.97(d,J=7.7Hz,1H),7.77-7.74(t,J=5.9Hz,1H),7.45-7.39(q,J=7.7Hz,1H),7 .23-7.17(t,J=9.8Hz,1H),7.07-7.02(t,J=8.4Hz,1H),4.92-4.89(m,1H),4.74-4.7 1(m,1H),4.60-4.48(m,4H),4.40-4.19(m,3H),3.92-3.82(m,2H),3.55-3.48(m,1H)
[0979] Example 85: Preparation of 4-(3-hydroxy-1-oxo-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-2-yl)benzonitrile (Compound 85):
[0980] Step 1: Preparation of methyl 2-(4-cyanophenyl)-3-hydroxypropionate (Compound 85B)
[0981] Methyl 2-(4-cyanophenyl)acetate (1.0 g, 5.71 mmol), paraformaldehyde (257 mg, 2.85 mmol), and sodium bicarbonate (14 mg, 0.17 mmol) were dissolved in dimethyl sulfoxide (10 mL). After addition, the reaction system was stirred at room temperature for 3 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain Compound 85B.
[0982] MS (ESI) m / z 206.1 (M+H) +
[0983] Step 2: Preparation of 2-(4-cyanophenyl)-3-hydroxypropionic acid (Compound 85C)
[0984] Methyl 3-hydroxy-2-(4-cyanophenyl)propanoate (0.2 g, 0.97 mmol) and lithium hydroxide monohydrate (82 mg, 1.95 mmol) were dissolved in a mixture of methanol (3.0 mL) and water (1 mL). The reaction system was stirred at room temperature overnight. After the reaction was complete, the mixture was separated and purified on a silica gel column to obtain compound 85C.
[0985] MS (ESI) m / z 192.2 (M+H) +
[0986] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(4-cyanophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to isolate compound 85 of Example 85.
[0987] MS (ESI) m / z 425.1 (M+H) +
[0988] 1H NMR (400MHz, DMSO-d6) δ8.82-8.81(m,1H),8.17-8.14(t,J=1.2Hz,1H),8.00-7.98(d,J=0.8Hz,1H),7.79-7.77(m,3H),7.51-7.48(d,J=1.2Hz,2H ),4.94-4.92(d,J=0.8Hz,1H),4.75-4.72(d,J=1.2Hz,1H),4.55-4.25(m ,6H),3.91-3.81(m,1H),3.79-3.77(t,J=0.8Hz,1H),3.56-3.38(m,2H).
[0989] Example 86: Preparation of 2-(3-chloro-5-fluorophenyl)-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 86):
[0990] Step 1: Preparation of methyl 2-(3-chloro-5-fluorophenyl)acetate (Compound 86B)
[0991] 2-(3-chloro-5-fluorophenyl)acetic acid (1 g, 5.30 mmol) was dissolved in methanol (10 mL), followed by the addition of thionyl chloride (1.25 g, 10.59 mmol) at 0°C. After addition, the reaction system was stirred at 60°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, compound 86B was obtained by separation and purification on a silica gel column.
[0992] MS (ESI) m / z 201.2 (MH) -
[0993] Step 2: Preparation of methyl 2-(3-chloro-5-fluorophenyl)-3-hydroxypropanoate (Compound 86C)
[0994] Methyl 2-(3-chloro-5-fluorophenyl)acetate (1.01 g, 4.98 mmol) was dissolved in dimethyl sulfoxide (10 mL). Sodium methoxide (90 mg, 500.00 μmol) and paraformaldehyde (220 mg, 2.44 mmol) were then added at room temperature. After addition, the reaction system was stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (10.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After completion of the reaction, the product was purified by silica gel column chromatography to obtain compound 86C.
[0995] MS (ESI) m / z 233.1 (M+H) +
[0996] Step 3: Preparation of 2-(3-chloro-5-fluorophenyl)-3-hydroxypropanoic acid (Compound 86D)
[0997] Methyl 2-(3-chloro-5-fluorophenyl)-3-hydroxypropanoate (200 mg, 859.71 μmol) was dissolved in tetrahydrofuran (3 mL) and water (3 mL). Lithium hydroxide (72 mg, 1.71 mmol) was added at room temperature. After addition, the reaction system was placed under a nitrogen atmosphere and stirred at room temperature for 2 hours. After completion of the reaction, the reaction solution was concentrated and the pH was adjusted to 3-4 with 1N hydrochloric acid. The aqueous phase was extracted with ethyl acetate (10.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 86D.
[0998] MS (ESI) m / z 217.1 (MH) -
[0999] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(3-chloro-5-fluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to isolate compound 86 of Example 86.
[1000] MS (ESI) m / z 452.1 (M+H) +
[1001] 1 H-NMR(400MHz,DMSO-d6)δ8.82-8.81(m,1H),8.16-8.14(m,1H),8.00-7. 98(m,1H),7.77-7.74(m,1H),7.34-7.30(m,1H),7.24(s,1H),7.17-7.14 (m,1H),4.94(t,J=5.2Hz,1H),4.74-4.70(m,1H),4.55-4.50(m,5H),4.3 5-4.23(m,2H),3.86-3.80(m,1H),3.73-3.70(m,1H),3.54-3.49(m,1H).
[1002] Example 87: Preparation of (S)-2-(2,4-difluorophenyl)-3-hydroxy-1-(1'-((5-methoxypyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 87):
[1003] Step 1: Preparation of methyl 2-(2,4-difluorophenyl)-3-hydroxypropionate (Compound 87B)
[1004] Methyl 2-(2,4-difluorophenyl)acetate (820 mg, 4.40 mmol) was dissolved in dimethyl sulfoxide (8 mL). Sodium methoxide (80 mg, 444.44 μmol, 30% purity) and paraformaldehyde (200 mg, 2.22 mmol) were then added at room temperature. After addition, the reaction system was stirred at room temperature under a nitrogen atmosphere for 3 hours. After completion of the reaction, the reaction solution was diluted with water, and the aqueous phase was extracted with ethyl acetate (30.0 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. Compound 87B was obtained by separation and purification on a silica gel column.
[1005] MS (ESI) m / z 217.1 (M+H) +
[1006] Step 2: Preparation of 2-(2,4-difluorophenyl)-3-hydroxypropanoic acid (Compound 87C)
[1007] Methyl 2-(2,4-difluorophenyl)-3-hydroxypropionate (260 mg, 1.20 mmol) was dissolved in water (3 mL) and tetrahydrofuran (3 mL), and lithium hydroxide (100 mg, 2.38 mmol) was added at room temperature. After the addition was complete, the reaction system was placed in a nitrogen atmosphere and stirred at 25°C for 2 hours. After the reaction was complete, compound 87C was obtained by separation and purification on a silica gel column.
[1008] MS (ESI) m / z 201.0 (MH) -
[1009] In step 8 of Example 1, 5-methoxypyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(2,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used to isolate compound 87 of Example 87.
[1010] MS (ESI) m / z 466.1 (M+H)+
[1011] 1 H-NMR (400MHz, DMSO-d6) δ8.49-8.48(d,J=2.7Hz,1H),7.96-7.34(d,J=8.8Hz,1H),7.67-7.64(m,1H),7.43-7.41(m,1H),7.22-7.17(m,1 H),7.07-7.04(m,1H),4.74-4.4.71(d,J=12.9Hz,1H),4.48(s,4H),4.36-4.21(m,3H),3.94(s,3H),3.89-3.83(m,2H),3.55-3.48(m,1H).
[1012] Example 88: Preparation of (R)-2-(2,4-difluorophenyl)-3-hydroxy-1-(1'-((5-methoxypyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 88):
[1013] In step 8 of Example 1, 5-methoxypyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 2-(2,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used for separation and chiral separation to obtain compound 88 of Example 88.
[1014] MS (ESI) m / z 466.1 (M+H) +
[1015] 1 H-NMR (400MHz, DMSO-d6) δ8.49-8.48(d,J=2.7Hz,1H),7.96-7.34(d,J=8.8Hz,1H),7.67-7.64(m,1H),7.43-7.41(m,1H),7.22-7.17(m,1 H),7.07-7.04(m,1H),4.74-4.4.71(d,J=12.9Hz,1H),4.48(s,4H),4.36-4.21(m,3H),3.94(s,3H),3.89-3.83(m,2H),3.55-3.48(m,1H).
[1016] Example 89: Preparation of (3-phenyloxetane-3-yl)(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)methanone (Compound 89):
[1017] Step 1: Preparation of ethyl 2-(3-phenyloxetan-3-yl)acetate (Compound 89B)
[1018] Ethyl 2-(oxetane-3-ylidene)acetate (5 g, 35.17 mmol) was dissolved in 1,4-dioxane, followed by an aqueous solution of potassium hydroxide (2.57 g, 1.5 N, 45.72 mmol), phenylboronic acid (6.43 g, 52.76 mmol), and (1,5-cyclooctadiene)chlororhodium(I) dimer (1.73 g, 3.52 mmol). After the addition was complete, the reaction was stirred at room temperature for 16 hours. After completion of the reaction, the product was separated and purified by silica gel column chromatography to obtain compound 89B.
[1019] MS (ESI) m / z 221.1 (M+H) +
[1020] Step 2: Preparation of 2-(3-phenyloxetane-3-yl)ethan-1-ol (Compound 89C)
[1021] Ethyl 2-(3-phenyloxetane-3-yl)acetate (3 g, 13.62 mmol) was dissolved in tetrahydrofuran. The reaction system was cooled to 0°C, and lithium aluminum tetrahydride (0.52 g, 13.62 mmol) was slowly added. After the addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 2 hours. After the reaction was complete, the product was separated and purified on a silica gel column to obtain Compound 89C.
[1022] MS (ESI) m / z 179.1 (M+H) +
[1023] Step 3: Preparation of 2-(3-phenyloxetan-3-yl)ethyl methanesulfonate (Compound 89D)
[1024] Dissolve 2-(3-phenyloxetane-3-yl)ethan-1-ol (2.43 g, 13.63 mmol) in dichloromethane. Cool the reaction system to 0°C, then add triethylamine (2.48 g, 24.54 mmol), followed by the slow dropwise addition of methylsulfonyl chloride (2.81 g, 24.54 mmol). After addition, allow the reaction to warm to room temperature and stir for 2 hours. After completion of the reaction, separate and purify the product on a silica gel column to obtain Compound 89D.
[1025] Step 4: Preparation of 3-phenyl-3-vinyloxetane (Compound 89E)
[1026] 2-(3-phenyloxetane-3-yl)ethyl methanesulfonate (3.4 g, 13.26 mmol) was dissolved in dimethyl sulfoxide. Potassium tert-butoxide (1.64 g, 14.59 mmol) was then added portionwise. After addition, the reaction system was stirred at room temperature for 16 hours. After the reaction was complete, saturated aqueous sodium bicarbonate was added to the reaction system and extracted with ethyl acetate (200 mL x 3). The combined organic phases were separated and purified on a silica gel column to obtain Compound 89E.
[1027] MS (ESI) m / z 161.1 (M+H) +
[1028] Step 5: Preparation of 3-phenyloxetane-3-carboxylic acid (Compound 89F)
[1029] 3-Phenyl-3-vinyloxetane (1.4 g, 8.74 mmol) was dissolved in a mixture of ethyl acetate, acetonitrile, and water. The reaction system was cooled to 0°C and ruthenium trichloride (91 mg, 0.43 mmol) was added. After the addition was complete, the reaction was stirred at 0°C for 10 minutes, followed by the slow addition of sodium periodate (7.17 g, 33.21 mmol) in portions. The reaction was maintained at 0°C and stirred for 30 minutes. After the reaction was complete, the reaction system was filtered through celite, and the aqueous phase was extracted with ethyl acetate (200 mL x 3). The combined organic phases were concentrated, saturated sodium bicarbonate solution was added, and the mixture was extracted once with ethyl acetate. 1N hydrochloric acid was slowly added dropwise to the aqueous phase to adjust the pH to 1, and the mixture was spin-dried to obtain Compound 89F.
[1030] In step 8 of Example 1, pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and in step 10, 3-phenyloxetane-3-carboxylic acid was used instead of (S)-3-((tert-butyldiphenylsilyl)oxy)-2-phenylpropionic acid. The same preparation method as in Example 1 was used for separation and chiral separation to obtain Compound 89 of Example 89.
[1031] MS (ESI) m / z 412.1 (M+H) +
[1032] 1H NMR (400MHz, DMSO-d6) δ8.79(m,1H),8.14(m,1H),7.96(dd,J=7.9,1.2Hz,1H),7.75(m,1H),7.43(dd,J=8.2,6.8Hz ,2H),7.35(m,3H),5.09(d,J=6.2Hz,2H),4.69(d,J=6.2Hz,2H),4.48(m,4H),4.41–4.33(m,2H),4.12–4.03(m,2H).
[1033] Example 90: Preparation of 2-cyclohexyl-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 90):
[1034] Step 1: Preparation of dimethyl 2-cyclohexylmalonate (Compound 90B)
[1035] Sodium (1.6 g, 71.41 mmol) was slowly added portionwise to anhydrous methanol (100.0 mL) under an ice bath. After the sodium filaments were completely dissolved, dimethyl malonate (6.3 g, 47.61 mmol) and iodocyclohexane (10.0 g, 47.61 mmol) were added. The reaction mixture was allowed to react at 70°C for 18 hours. After completion of the reaction, the product was separated and purified on a silica gel column to obtain compound 90B.
[1036] MS (ESI) m / z 215.3 (M+H) +
[1037] Step 2: Preparation of 2-cyclohexyl-3-methoxy-3-oxopropanoic acid (Compound 90C)
[1038] Dimethyl 2-cyclohexylmalonate (100.0 mg, 0.47 mmol) was dissolved in methanol (3.0 mL) and water (1.0 mL). A solution of potassium hydroxide (26.2 mg, 0.47 mmol) in water (1.0 mL) was then added. The reaction mixture was stirred at room temperature for 3 hours. LCMS indicated that the reaction was nearly complete. The pH of the reaction mixture was adjusted to 5 with 1N hydrochloric acid and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The resulting yellow oil was concentrated and used directly in the next step.
[1039] Step 3: Preparation of methyl 2-cyclohexyl-3-oxo-3-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propanoate (Compound 90D)
[1040] 2-Cyclohexyl-3-methoxy-3-oxopropanoic acid (93.4 mg, 0.46 mmol), 1-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-3,3'-diazetidinylidene (94.78 mg, 0.26 mmol), HATU (197.3 mg, 0.52 mmol), and N,N-diisopropylethylamine (134.1 mg, 1.04 mmol) were dissolved in N,N-dimethylformamide (5.0 mL). The reaction solution was stirred at room temperature for 3 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain Compound 90D.
[1041] MS (ESI) m / z 434.2 (M+H) +
[1042] Step 4: Preparation of 2-cyclohexyl-3-hydroxy-1-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propan-1-one (Compound 90)
[1043] Methyl 2-cyclohexyl-3-oxo-3-(1'-(pyridin-2-ylsulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)propanoate (60.0 mg, 0.14 mmol) was dissolved in methanol (6.0 mL) and tetrahydrofuran (6.0 mL). Sodium borohydride (52.4 mg, 1.38 mmol) was then added, and the reaction mixture was stirred at 80°C for 72 hours. After completion of the reaction, compound 90 was obtained by preparative separation and purification using reverse-phase high-pressure liquid chromatography.
[1044] MS (ESI) m / z 406.2 (M+H) +
[1045] 1H NMR (400MHz, DMSO-d6) δ8.83-8.82(d,J=4.4Hz,1H),8.19-8.17(m,1H),8.00-7.98(d,J=8.0Hz,1H),7.78-7.75(m,1H),4.63-4.46(m,8 H),4.30-4.25(m,2H),3.52-3.36(m,2H),2.16-2.14(m,1H),1.65-1.58(m,4H),1.52-1.32(m,2H),1.10-1.03(m,2H),1.00-0.81(m,2H)
[1046] Example 91: Preparation of (S)-3-hydroxy-1-(1'-((5-(methoxy-d3)pyridin-2-yl)sulfonyl)-1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)-2-phenylpropan-1-one (Compound 91):
[1047] Step 1: Preparation of 2-bromo-5-(methoxy-d3)pyridine (Compound 91B)
[1048] 2-Bromo-5-hydroxypyridine (3 g, 17.24 mmol) was dissolved in 1,4-dioxane, followed by the addition of deuterated methanol (3.11 g, 86.20 mmol), triphenylphosphine (4.97 g, 18.96 mmol), and DIAD (3.83 g, 18.96 mmol). After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 91B.
[1049] MS (ESI) m / z 191.0 (M+H) +
[1050] Step 2: Preparation of 2-(benzylthio)-5-(methoxy-d3)pyridine (Compound 91C)
[1051] 2-Bromo-5-(methoxy-d3)pyridine (2.53 g, 13.24 mmol) was dissolved in 1,4-dioxane, followed by benzyl mercaptan (1.64 g, 13.24 mmol), DIPEA (3.42 g, 26.49 mmol), Pd2(dba)3CHCl3 (1.35 g, 1.32 mmol), and xantphos (1.53 g, 2.65 mmol). After the addition was complete, the reaction mixture was purged three times under nitrogen atmosphere, then heated to 80°C and stirred for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 91C.
[1052] MS (ESI) m / z 235.1 (M+H) +
[1053] Step 3: Preparation of 5-(methoxy-d3)pyridine-2-sulfonyl chloride (Compound 91D)
[1054] 2-(Benzylthio)-5-(methoxy-d3)pyridine (1.1 g, 4.69 mmol) was dissolved in acetonitrile. Acetic acid (1.41 g, 23.47 mmol), water (846 mg, 46.94 mmol), and 1,3-dichloro-5,5-dimethylhydantoin (1.85 g, 9.39 mmol) were then added in sequence. After the addition was complete, the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the product was separated and purified by silica gel column chromatography to obtain compound 91D.
[1055] MS (ESI) m / z 211.0 (M+H) +
[1056] In step 8 of Example 1, 5-(methoxy-d3)pyridine-2-sulfonyl chloride was used instead of 2,3-dihydro-[1,4]dioxo[2,3-b]pyridine-7-sulfonyl chloride, and the same preparation method as Example 1 was used to isolate Compound 91 of Example 91.
[1057] MS (ESI) m / z 433.2 (M+H) +
[1058] 1 H NMR (400MHz, DMSO-d6) δ8.48(d,J=2.9Hz,1H),7.94(d,J=8.8Hz,1H),7.64(dd,J=8.8,3.0Hz,1H),7.27(m,5H),4.80(t,J=5.2Hz,1H), 4.72(d,J=13.4Hz,1H),4.48(s,4H),4.41–4.27(m,2H),4.21(d,J=14.7Hz,1H),3.89(m,1H),3.62(dd,J=8.9,5.4Hz,1H),3.46(m,1H).
[1059] Example 92: Preparation of (S)-4-((1'-(2-(2,4-difluorophenyl)-3-hydroxypropyl)-1'-,4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-yl)sulfonyl)benzonitrile (Compound 92):
[1060] In step 3 of Example 35, 4-cyanobenzenesulfonyl chloride was used instead of 2-methylbenzo[d]thiazole-6-sulfonyl chloride, and in step 5, (S)-2-(2,4-difluorophenyl)-3-hydroxypropionic acid was used instead of (S)-3-hydroxy-2-phenylpropionic acid. The same preparation method as in Example 35 was used to isolate compound 92 of Example 92.
[1061] MS (ESI) m / z 460.1 (M+H) +
[1062] 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=8.2Hz,2H),8.01(d,J=8.2Hz,2H),7.41(m,1H),7.20(m,1H),7.04(m,1H),4.91(t,J= 5.0Hz,1H),4.70(d,J=12.5Hz,1H),4.40–4.27(m,6H),4.21(d,J=13.4Hz,1H),3.85(d,J=5.3Hz,2H),3.61–3.46(m,1H).
[1063] Biological test data
[1064] Unless otherwise specified, the test materials, reagents, operations and methods used in the following active examples can be obtained from commercial channels or can be easily known or prepared based on existing technologies.
[1065] Test Example 1: Pyruvate kinase (PKR) activity test
[1066] 1. Purpose of the experiment
[1067] The compounds of the present invention were tested for their activation effects on recombinant human PKR enzyme.
[1068] 2. Experimental Materials and Instruments
[1069] Reagents and consumables:
[1070] instrument:
[1071] 3. Test steps:
[1072] 3.1 Prepare recombinant human PKR enzyme solution at a concentration of 60 ng / well (20 μL reaction system) and add 5 μL to each well of a black transparent bottom 384-well plate.
[1073] 3.2 Prepare compound solutions of different concentrations to a final concentration of 1000 / 300 / 100 nM (containing 1% DMSO), add 5 μL of compound to the well plate prepared in step 3.1, mix well, and incubate at room temperature for 10 min.
[1074] 3.3 Prepare the reaction system according to the kit instructions (as shown in the table below), add 10 μL to each well of a 384-well plate, and mix with the solution in step 3.2.
[1075] 3.4 Place the 384-well plate on a microplate reader to measure fluorescence at 540 / 590 nm, reading the value every 2 minutes for 1 hour.
[1076] 3.5 Calculate the Slope value during the measurement time, using the 1% DMSO well as the control well to calculate the compound activation rate. Activation rate % = (Slope of compound well / Slope of control well) × 100%
[1077] 3.6 Fitting the dose-effect curve
[1078] The log value of compound concentration was used as the X-axis and the percentage activation rate was used as the Y-axis. The log (agonist) vs. response-variable slope (Variable slope) analysis software GraphPad Prism5 was used to fit the dose-effect curve to obtain the AC value of each compound on PKR activity. 50 value.
[1079] Calculation formula: Y = min + (max - min) / (1 + 10^((LogAC 50 -X)×Hillslope)).
[1080] 4. Test results:
[1081] The PKR enzyme activation effect of the compounds of the present invention was determined by the above test, and the AC 50 The values are as follows (A represents 0 to 100 nM, B represents 101 to 300 nM, and C represents 300 to 1000 nM).
[1082] Experimental Example 2: Ex vivo pyruvate kinase (PKR) activity assay
[1083] 1. Purpose of the study
[1084] The compounds of the present invention were tested for their activation effects on PKR in isolated erythrocytes of healthy individuals / thalassemia patients.
[1085] 2. Test materials and instruments
[1086] Main reagents and consumables
[1087] instrument
[1088] 3. Experimental steps
[1089] a) Preparation of AGAM medium
[1090] i. Weigh 5 g of glucose, 85 mg of adenine, and 2.625 g of mannitol into a 50 mL centrifuge tube and dissolve in 40 mL of PBS (ultrasonicate for 30 min until completely dissolved). Filter through a 0.22 μm filter, add to 460 mL of sterile PBS, and mix.
[1091] b) Isolation, purification and storage of red blood cells
[1092] i. Collect fresh human peripheral blood, use K2EDTA as the anticoagulant, mix 1 part anticoagulant + 9 parts blood, centrifuge at 500g for 10 minutes at room temperature, and remove the plasma.
[1093] ii. Packed red blood cells: Add 1.5 volumes of PBS and centrifuge at 2000 × g for 5 min at room temperature. Remove the supernatant and repeat this step twice.
[1094] iii. Dilute the red blood cells: Add 1.5 times the volume of PBS to the packed red blood cells, resuspend and mix.
[1095] iv. Slowly add the diluted red blood cells to 0.5 volumes of 70% isotonic solution (e.g., 7.5 mL of diluted red blood cells + 3 mL of Percoll 70% isotonic solution) and centrifuge at 4000 × g for 20 min at 4°C.
[1096] v. Remove the supernatant and elute the Percolloid particles from the lower layer of red blood cells with 4-5 mL of PBS once. Centrifuge at 2000 × g for 5 minutes at room temperature.
[1097] vi. Remove the supernatant, count the red blood cells in the lower layer, and dilute to a density of 2×10 with AGAM medium containing 10% FBS. 8 / mL, stored at 4℃.
[1098] c) Agonist activity test
[1099] i. Red blood cells were seeded in a 96-well plate at a density of 1×10 7Cells were diluted at 100 μL / well. Test compounds (dissolved in DMSO) were diluted and added to the cell culture medium to final concentrations of 3000 / 1000 / 300 / 100 / 10 / 3 / 1 nM (1% DMSO). Cells and compounds were incubated at 37°C, 5% CO2 for 3 hours, centrifuged at 2000 g for 20 minutes, and the supernatant discarded. 100 μL of red blood cell lysis buffer was added to the cell pellet, vortexed for 20 minutes, and centrifuged at 4000 g for 5 minutes. The supernatant was collected for analysis.
[1100] ii. Prepare the reaction system according to the kit instructions (see the table below), add 10 μL to each well of a 384-well plate, and mix 10 μL of red blood cell lysis buffer (20 μL reaction system).
[1101] iii. Place a black, transparent-bottomed 384-well plate in a microplate reader to measure fluorescence at 540 / 590 nm. Read the fluorescence every 2 minutes for 1 hour.
[1102] d) Data analysis
[1103] i. Calculate the Slope value during the measurement time, using the 1% DMSO well as the control well to calculate the compound activation rate. Activation rate % = (Slope of compound well / Slope of control well) × 100%
[1104] ii. The log value of compound concentration was used as the X-axis and the percentage activation rate was used as the Y-axis. The log (agonist) vs. response-variable slope (Variable slope) analysis software GraphPad Prism 5 was used to fit the dose-effect curve to obtain the AC value of each compound on PKR activity. 50 value.
[1105] Calculation formula: Y = min + (max - min) / (1 + 10^((LogAC50 - X) × Hillslope)).
[1106] The PKR stimulating effect of the compounds of the present invention on the isolated erythrocytes of healthy subjects / thalassemia patients was determined by the above test. 50 The values are as follows (A represents 0 to 100 nM, B represents 101 to 300 nM, and C represents 300 to 1000 nM):
[1107] AC measured from isolated red blood cells of patients with thalassemia 50 The values are as follows:
[1108] The experimental data show that the compounds of the present invention have agonistic activity on PKR in isolated erythrocytes of healthy individuals and thalassemia patients.
[1109] Test Example 3: In vivo efficacy test in wild-type mice
[1110] 1. Purpose of the study
[1111] The effects of the compounds on wild-type mice were evaluated by detecting the concentrations of HGB, ATP, and 2,3-DPG in the whole blood of mice.
[1112] 2. Experimental Animals
[1113] 3. Experimental steps
[1114] a) Drug preparation
[1115] i. On the day of administration, weigh the compound and add the solvent to prepare the dosing solution:
[1116] Solvent: 5% DMSO+10% Solutol+85% saline
[1117] b) Grouping and Dosing
[1118] i. Wild-type mice were randomly divided into groups based on body weight, with 8 mice in each group. The drugs were administered according to the following schedule.
[1119] c) Determination of HGB content in mice
[1120] i. Whole blood was collected from the experimental animals 2-3 hours after the last administration for HGB detection.
[1121] d) Determination of ATP and 2,3-DPG levels in mouse whole blood
[1122] i. Establish an LC-MS / MS method and collect whole blood from experimental animals 2-3 hours after the last administration to determine the ATP and 2,3-DPG levels.
[1123] The compounds of the present invention were tested by the above test, and the concentrations of hemoglobin ATP and 2,3-DPG in wild-type mice after administration were measured and are shown in the table below.
[1124] The results showed that the compound of the present invention could increase the ATP concentration and decrease the 2,3-DPG concentration in the whole blood of wild-type mice.
[1125] Test Example 4: Pharmacokinetic properties test in mice, rats, and dogs
[1126] 1. Purpose of the study
[1127] The pharmacokinetic properties of the compound of the present invention in different animal species were studied by measuring the plasma drug concentrations after intravenous and oral administration to mice, rats and dogs.
[1128] 2. Experimental Animals
[1129] 3. Experimental steps
[1130] a) Drug preparation and administration
[1131] i. After weighing the compound, add the solvent 5% DMSO + 10% Solutol + 85% saline to prepare the dosing solution.
[1132] ii. One day before the experiment, animals in the oral administration group were fasted overnight (10-14 h) before administration and fed 4 h after administration.
[1133] iii. On the day of the experiment, administer the drugs according to the schedule in the table below. At each time point after dosing, approximately 30 μL of venous blood was collected from an appropriate location in each group of animals and placed in a sodium heparin anticoagulant tube. After collection, the blood samples were placed on ice and centrifuged within 1 hour to separate the plasma (centrifugation conditions: 6800g, 6 minutes, 2-8°C). Plasma samples were stored at -80°C until analysis.
[1134] b) Establish an LC-MS / MS analytical method for determining the concentration of the compound in the plasma of mice, rats, and dogs, and use it to determine the concentration of the compound in the biological samples obtained in this study.
[1135] c) Data analysis
[1136] The pharmacokinetic parameters were calculated using Phoenix WinNonlin7.0 based on the plasma drug concentration data at different time points.
[1137] The compounds of the present invention were tested through the above tests, and the pharmacokinetic parameters of different animal species were shown in the table below.
[1138] The results showed that the compound of the present invention was well absorbed orally in rats, mice and dogs.
[1139] The present invention is not limited to the above optional embodiments. Anyone can derive various other forms of products based on the teachings of the present invention. The above specific embodiments should not be construed as limiting the scope of protection of the present invention. The scope of protection of the present invention shall be based on the scope defined in the claims, and the description can be used to interpret the claims.
Claims
1. Use of a pharmaceutical composition in the preparation of a drug for preventing or treating anemia-related diseases, the pharmaceutical composition comprising an active ingredient and a pharmaceutically acceptable excipient, the active ingredient being a compound of the following formula I or II or an isomer, a pharmaceutically acceptable salt or a solvate thereof, and the content of the active ingredient in the pharmaceutical composition being 0.05 mg to 1000 mg: in: R 1 , R 2 and R 3 independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b 、-SR b 、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f or-C(O)OR g , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -R a 、-OR b 、-SR b 、-NO2、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f and -C(O)OR g ; Or, R 1 and R 2 , R 1 and R 3 or R 2 and R 3 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, -(C5-C8)spirocyclyl, 5 to 8 membered spiroheterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S; R 4 is -NH2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b 、-SR b 、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f 、-C(O)OR g or -NR c (CR h R i ) t -R a , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -R a 、-OR b 、-SR b 、-NO2、-NR c R d 、-S(O)2R e 、-S(O)2NR c R d 、-S(O)R e 、-S(O)NR c R d 、-NR c S(O)2R e 、-NR c S(O)R e 、-C(O)R f and -C(O)OR g ; t is 0, 1, 2, or 3; R a , R b , R c , R d , R e , R f , R g , R h and R i is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O) 2OH, -NHS(O)OH, -C(O)H or -C(O)OH, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of: =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H, -C(O)OH, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, and 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S; Or, any two selected from R on adjacent atoms a , R b , R c , R d , R e , R f , R g , R h and R i The groups together with the atoms to which they are attached may optionally be combined to form a group optionally separated by one or more R a Substituted C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, (C3-C8) cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S; In Formula II: Each R j independently -H, halogen, -OH, -NH2, -CN, =O, -NO2, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH, -NHS(O)OH, -C(O)H or -C(O)OH, wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, The aryl, heteroaryl or fused cyclic radical is optionally substituted by one or more substituents selected from the group consisting of -H, =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH, -NHS(O)OH, -C(O)H, -C(O)OH, a 3-14 membered heterocyclic radical containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S; m is independently selected from 0, 1, 2, 3, 4, 5 or 6; v is 0 or 1; Ring B is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 The invention further comprises an aryl group, a 5- to 14-membered heteroaryl group containing 1 to 4 heteroatoms independently selected from O, N and S, or a 7- to 14-membered fused cyclic group containing 0 to 4 heteroatoms independently selected from O, N and S.
2. The use according to claim 1, wherein the anemia-related disease is pyruvate kinase deficiency (PKD).
3. The use according to claim 1, wherein the anemia-related diseases include myelodysplastic syndrome (MDS), hemoglobinopathy, sickle cell anemia (SCD), β-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia or anemia of chronic disease.
4. The use according to claim 1, wherein the anemia-related disease is sickle cell anemia (SCD), β-thalassemia or low-risk myelodysplastic syndrome (LR-MDS).
5. The use according to claim 1, wherein the unit dose of the pharmaceutical composition contains 0.05 mg to 1000 mg of active ingredient.
6. The use according to claim 1, wherein the compound of formula I has the structure shown in formula I-1 or I-2:
7. The use according to claim 1, wherein: R 1 and R 2 independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b or -NR c R d , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ; Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S; R a , R b , R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or 7-14 membered fused cyclic radical containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic radical, aryl, heteroaryl or fused cyclic radical is optionally substituted by one or more substituents selected from the following: =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl and 3-14 membered heterocyclic radical containing 1-4 heteroatoms independently selected from O, N and S.
8. The use according to claim 7, wherein: R 1 and R 2 independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl group, a 5-8 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, N and S, a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -OR b or -NR c R d , wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted by one or more substituents selected from the group consisting of: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ; Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S; R a , R b , R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, C6-C8 aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl and a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S.
9. The use according to claim 8, wherein: R 1 and R 2 independently -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6) straight chain alkyl, -(C1-C6) branched chain alkyl, -(C3-C6) cycloalkyl, a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, C6-C8 aryl, a 7-14 membered bicyclic or tricyclic fused ring group containing 0-4 heteroatoms independently selected from O, N and S, -OR b or -NR c R d , wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted by one or more substituents selected from the group consisting of: -F, -Cl, -Br, -CN, -R a 、-OR b 、-NR c R d ; Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S; R a , R b , R c and R d is independently at each occurrence -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl, or a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2 and -(C1-C6)alkyl.
10. The use according to claim 9, wherein: R 1 and R 2 independently -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6) straight chain alkyl, -(C1-C6) branched chain alkyl, -(C3-C6) cycloalkyl, or a 3-6 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from the following: -F, -Cl, -Br, -CN, -R a 、-OR b 、-NR c R d ; Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form -(C3-C8)cycloalkyl or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S; R a , R b , R c and R d is independently at each occurrence -H, -F, -Cl, -Br, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2 and -(C1-C6)alkyl.
11. The use according to claim 10, wherein: R 2 is -H, -F, -Cl or -Br; R 1 -H, -F, -Cl, -Br, -OH, -NH2, -(CH2) q CH3, -(CH2) q OH, -CH(OH)(CH2) q CH3, -C(OH)((CH2) q CH3)2. -(CH2) q NH2, -(CH2) q NH(CH2) q CH3, -(CH2) q N((CH2) q CH3)2, 3-6 membered heterocycloalkyl containing 1 N atom, -(C1-C6)alkyl substituted by 3-6 membered heterocycloalkyl containing 1 N atom; q is 0, 1, 2, 3, or 4 independently at each occurrence; Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, tetrahydrofuran, tetrahydropyran, morpholine, dioxane, a 2,3-dihydrobenzofuran ring or tetrahydro-2H-pyran.
12. The use according to claim 9, wherein: R 2 is -H, -F, -Cl or -Br; R 1 is -H, -F, -Cl, -Br, -OH, -NH2, -CH3, -CH(OH)CH3, -(CH2) q CH3, -(CH2) q OH, -CH(OH)(CH2) q CH3, -C(OH)((CH2) q CH3)2, -C(OH)(CH2) q CH3)(CH3), -C(OH)(CH3)2, -CH2F、-CHF2、-(CH2) q CH2F、-(CH2) q CHF2、-CH2Cl、-CHCl2、-(CH2) q CH2Cl、-(CH2) q CHCl2、-(CH2) q NH2、-NHCH3、-NH(CH2) q CH3、-(CH2) q NHCH3、- (CH2) q NH(CH2) q CH3, -N(CH3)2, -N((CH2) q CH3)2, -(CH2) q N(CH3)((CH2) q CH3)、-(CH2) q N(CH3)2, -(CH2) q N((CH2) q CH3)2, 3-6 membered heterocycloalkyl containing 1 N atom, -(C1-C6)alkyl substituted by 3-6 membered heterocycloalkyl containing 1 N atom; q is 1, 2, 3, or 4 independently at each occurrence; Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, an oxetane, a tetrahydrofuran, a tetrahydropyran, a morpholine, a dioxane, a 2,3-dihydrobenzofuran ring or a tetrahydro-2H-pyran.
13. The use according to claim 7, wherein: R 2 is -H, -F, -Cl or -Br; R 1 -H, -F, -Cl, -Br, -OH, -NH2, Or, R 1 and R 2 Together with the atoms to which they are attached, they may optionally combine to form 14. The use according to any one of claims 1 to 13, wherein: R 3 is -H, halogen, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or 7-14 membered fused cyclic radical containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl or fused cyclic radical is optionally substituted by one or more substituents selected from the following: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ; R a , R b , R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or 7-14 membered fused cyclic radical containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic radical, aryl, heteroaryl or fused cyclic radical is optionally substituted by one or more substituents selected from the following: =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl and 3-14 membered heterocyclic radical containing 1-4 heteroatoms independently selected from O, N and S.
15. The use according to claim 14, wherein: R 3 is -H, halogen, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered bicyclic or tricyclic fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is optionally substituted by one or more substituents selected from the following: =O, halogen, -CN, -R a 、-OR b 、-NO2、-NR c R d ; R a , R b , R c and R d is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C8 aryl, a 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused cyclic group is independently selected from The group is optionally substituted by one or more substituents selected from the following: =O, halogen, -CN, -OH, -NO2, -NH2, -(C1-C6)alkyl, -(C3-C6)cycloalkyl and a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S.
16. The use according to claim 15, wherein R 3 is -H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, C6-C8aryl, or a 7-14 membered bicyclic fused ring group containing 0-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl, aryl or fused ring group is optionally substituted by one or more substituents selected from the following: -F, -Cl, -Br, -CN, -R a AND-OR b ; R a and R b is independently at each occurrence -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C3-C8)cycloalkyl, or a 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, wherein each alkyl, cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -OH, -NO2, -NH2 and -(C1-C6)alkyl.
17. The use according to claim 14, wherein R 3 is -H, -F, -Cl, -Br, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, pyridyl, phenyl, naphthyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl or Among them, pyridyl, phenyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl, Optionally substituted with one or more substituents selected from the group consisting of -F, -Cl, -Br, -CN, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -(C1-C6)haloalkyl, -(C3-C6)halocycloalkyl, -O-(C1-C6)haloalkyl, -O-(C3-C6)halocycloalkyl, pyrazolyl, pyrazolyl substituted with any number of halogen or -(C1-C6)alkyl, piperazinyl, piperazinyl substituted with any number of halogen or -(C1-C6)alkyl; ring is a 3-6 membered saturated or unsaturated N-containing heterocyclic group linked via a N atom, and the heterocyclic group optionally contains 1-2 heteroatoms independently selected from O, N and S in addition to the N atom.
18. The use according to claim 14, wherein R 3 -H, -F, -Cl, -Br, -CH3, -CH2CH3, 19. The use according to any one of claims 1 to 18, wherein: R 4 for X is a chemical bond, -(CR h R i ) t -、-NR c (CR h R i ) t -or-O-; represents a single bond or a double bond; Y 1 is N, C or CH; Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all are N; Each R j independently -H, halogen, -OH, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -O-(C3-C6)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, a 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, a 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH, -NHS(O)OH, -C(O)H or -C(O)OH, wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, The aryl, heteroaryl or fused cyclic radical is optionally substituted by one or more substituents selected from the group consisting of -H, =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH, -NHS(O)OH, -C(O)H, -C(O)OH, a 3-14 membered heterocyclic radical containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S; m is selected from 0, 1, 2, 3, 4, 5 or 6; n is 0, 1, or 2, R c , R h , R i and t is as defined in any one of claims 1-18.
20. The use according to claim 19, wherein X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-; represents a single bond or a double bond; Y 1 is N, C or CH; Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all are N; Each R j Each of them is independently -H, halogen, -OH, -NH2, -CN, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -(C1-C6)alkoxy, -O-(C3-C6)cycloalkyl, -(C1-C6)alkyl substituted with any number of halogens, -(C1-C6)alkyl substituted with any number of halogens C6) alkoxy, -(C3-C6) cycloalkyl substituted with any number of halogens, -O-(C3-C6) cycloalkyl substituted with any number of halogens, oxazolyl, thiazolyl and triazolyl; m is selected from 0, 1, 2, 3, 4, 5 or 6; n is 0, 1 or 2.
21. The use according to any one of claims 1 to 18, wherein: R 4 for X is a chemical bond, -(CR h R i ) t -、-NR c (CR h R i ) t -or-O-; represents a single bond or a double bond; Y 1 is N, C or CH; Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all are N; Each R j independently -H, halogen, -OH, =O, -NH2, -CN, -NO2, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C4-C8)cycloalkenyl, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S, -SH, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -S(O)2OH, -S(O)OH, -NHS(O)2OH, -NHS(O)OH, -C(O)H or -C(O)OH, wherein each alkyl, alkane The oxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused cyclic radical is optionally substituted by one or more substituents selected from the group consisting of: =O, halogen, -CN, -OH, -SH, -NO2, -NH2, -S(O)2H, -S(O)2NH2, -S(O)H, -S(O)NH2, -NHS(O)2H, -NHS(O)H, -C(O)H, -C(O)OH, a 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 Aryl or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S; m and p are independently selected from 0, 1, 2, 3, 4, 5 or 6; n is 0, 1 or 2; Ring A is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from O, N and S, or 7-14 membered fused cyclic group containing 0-4 heteroatoms independently selected from O, N and S; R c , R h , R i and t is as defined in any one of claims 1-18.
22. The use according to claim 21, wherein X is a chemical bond, -CH2-, -CH2CH2-, -NHCH2-, -NHCH2CH2- or -O-; represents a single bond or a double bond; Y 1 is N, C or CH; Y 2 and Y 3 Each independently represents N, CH2 or CH, Y 2 and Y 3 Not all are N; Each R j Each is independently -H, halogen, -OH, -NH2, -CN, =O, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C1-C6)alkyl substituted with any number of halogens, -(C1-C6)alkoxy substituted with any number of halogens, oxazolyl, thiazolyl or triazolyl; m and p are independently selected from 0, 1, 2, 3, 4, 5 or 6; n is 0, 1 or 2; Ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxacyclohexane, piperazine, pyrazine, triazine, 4,5-dihydro-1H-imidazole or 1,3-dioxolane.
23. The use according to claim 1, wherein R 4 for 24. The use according to claim 1, wherein: Each R j are independently -H, halogen, -OH, -NH2, -CN, =O, -(C1-C6)alkyl, -(C1-C6)alkoxy, -(C1-C6)alkyl substituted with any number of halogens, -(C1-C6)alkoxy substituted with any number of halogens, oxazolyl, thiazolyl or triazolyl; Ring B is (C3-C8) cycloalkyl, a 3-14 membered heterocyclic group containing 1-4 heteroatoms independently selected from O, N and S, a C6-C 14 The invention further comprises an aryl group, a 5-14 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, N and S, or a 7-14 membered bicyclic or tricyclic fused ring group containing 0-4 heteroatoms independently selected from O, N and S.
25. The use according to claim 24, wherein: Ring B is a 3- to 7-membered oxacycloalkyl group or an 8- to 10-membered azabicyclic condensed heteroaryl group.
26. The use according to claim 25, wherein: Ring B is oxepane, oxhexane, tetrahydrofuran, oxetane, oxirane, 1H-indole or isoindoline.
27. The use according to claim 26, wherein: Ring B is 28. The use according to any one of claims 1 to 27, wherein: Any one or more H in the compound of formula I or II is replaced by D.
29. The use according to claim 28, wherein: The structure of the compound of formula I or II Any one or more H in is replaced by D, or R 4 Any one or more H in is replaced by D.
30. The use according to claim 29, wherein: The structure of the compound of formula I or II All H in are replaced by D.
31. The use according to claim 28, wherein: R 1 , R 2 or R 3 When H is selected, it is independently optionally substituted by D.
32. The use according to claim 1, wherein The compound is selected from:
33. The use according to any one of claims 1 to 32, wherein the pharmaceutical composition is in the form of tablets, capsules, granules, pills, pastes, powders, tinctures, films, patches, paints, implants, injections, lozenges, drops, sprays, aerosols, nebulized inhalers, gels, suppositories, or ointments.
34. The use according to any one of claims 1 to 32, wherein the pharmaceutical composition is administered by oral, intravenous, rectal, parenteral, topical, transdermal, ocular, nasal, buccal or pulmonary (inhalation) administration.
35. The use according to claim 34, wherein the pharmaceutical composition is administered by oral administration.
36. A method for treating or preventing anemia-related diseases, comprising administering 0.05 mg to 1000 mg of an active ingredient, wherein the active ingredient is the active ingredient in any use of claims 1 to 32, and the anemia-related disease is the disease described in any use of claims 1 to 4.
Citation Information
Patent Citations
Therapeutic compounds and compositions
WO2011002817A1
Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (PMK2) modulators
WO2012083246A1
Therapeutic compounds and compositions
WO2012092442A1
Therapeutic compounds and compositions
WO2014139325A1
Pyrrolidine-pyrazoles as pyruvate kinase activators
WO2021202796A1
